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Tissue Distribution of Hantavirus Antigen in Naturally Infected Humans and
Deer Mice
W. Green, R. Feddersen, O. Yousef, M. Behr, K. Smith,* Department of Pathology, University of New Mexico School of
Medicine, and New Mexico Veterinary Diagnostic Services, New MexicoJ. Nestler, S. Jenison,* T. Yamada,* and B. Hjelle
Department of Agriculture, Albuquerque, New Mexico; Department of
Biology, Walla Walla College, College Place, Washington
The Sin Nombre virus (SNV) is the etiologic agent of hantavirus pulmonary syndrome in humans
but does not cause disease in chronically infected deer mice (Peromyscus maniculatus), the natural
host. In this study, murine antiserum raised against recombinant SNV nucleocapsid protein was
utilized to localize viral antigen immunohistochemically in tissues from both humans (n  20; 11
positive, 9 negative) and deer mice (n 6; 4 positive, 2 negative). Viral infection status was confirmed
by Western blot or reverse transcriptase–polymerase chain reaction. SNV antigen was detected in
pulmonary and cardiac endothelium in both species, but positive cells in deer mice were rare. Other
deer mouse tissues, including kidney, were negative; in contrast, vascular elements of several tissues
from infected humans were positive, with strong staining of renal endothelium. The paucity of
positive cells in chronically infected mice suggests a low virus burden compared with that of acutely
infected humans.
Hantaviruses, which constitute a genus of the Bunyaviridae mouse (Peromyscus maniculatus) in western North America
and is the predominant agent of HPS in North Americafamily, are primarily harbored by rodents. Hantaviruses do not
appear to cause disease in their rodent hosts but are considered [2, 3]. Reliable diagnostic assays for SNV antibodies and ge-
netic materials are available. The assays (Western blot, stripthe etiologic agents of two distinct disease syndromes in humans:
hemorrhagic fever with renal syndrome (HFRS) and hantavirus immunoblot assay, and reverse transcriptase–polymerase chain
reaction [RT-PCR]) require laboratory personnel to handle po-pulmonary syndrome (HPS). Of these, HFRS is associated with
hantaviruses carried by murid rodents of Old World origin, tentially infectious material (patient serum, blood, or tissue),
but they have very high sensitivity and specificity for acutewhereas HPS is caused by hantavirus species carried by sigmo-
dontine rodents indigenous to the Americas [1]. SNV infection [4–6]. An immunohistochemical assay utilizing
antibody directed against the SNV nucleocapsid (N) protein ofHPS was first identified in the spring of 1993, when a cluster
of cases in the Four Corners area of Arizona, Colorado, New a related hantavirus has been used to detect viral antigen in
formalin-fixed tissues from HPS patients for retrospective diag-Mexico, and Utah brought attention to the disease. As of July
1997, there have been 167 cases of HPS reported, with 47% nosis of HPS and to further elucidate the pathogenesis of this
disease [7, 8].mortality. Sin Nombre virus (SNV) is endemic in the deer
The purpose of this study was to demonstrate SNV tissue
localization in human patients and in seropositive deer mice,
using an antibody directed against an SNV protein. This study
Received 5 September 1997; revised 9 December 1997. differs from previous studies in the immunogen used for anti-
Presented in part: annual meeting of the American College of Veterinary body development. Ultimately, we hope to contribute to thePathologists, Seattle, December 1996 (abstract 189).
understanding of the mechanisms of SNV transmission, theInformed consent was obtained. Human experimentation guidelines of the
US Department of Health and Human Services and the University of New pathogenesis of HPS in humans, and the absence of clinical
Mexico Institutional Review Board were followed in the conduct of this re- disease in rodent carriers.search.
Grant support: Department of Health and Human Resources (AI-36336).
Reprints or correspondence: Dr. Brian Hjelle, Dept. of Pathology, University
of New Mexico School of Medicine, Albuquerque, NM 87131 (Brian Hjelle@ Materials and Methods
somasf.unm.edu).
* Current affiliation: HIV/AIDS/STD Bureau, Santa Fe, New Mexico (S.J.); Patient samples. Formalin-fixed autopsy tissue from 11 pa-
Emory Clinic, Division of Hematology and Oncology, Emory University, At- tients who died of HPS during the spring and summer of 1993
lanta (K.S.); Department of Obstetrics and Gynecology, Hokkaido University
were obtained through the New Mexico Office of the MedicalSchool of Medicine, Sapporo, Japan (T.Y.).
Investigator and the University of New Mexico Department of
The Journal of Infectious Diseases 1998;177:1696–700
Pathology. In all cases, infection with SNV was confirmed by theq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0034$02.00 characteristic history, progression, and pathologic findings associ-
/ 9d46$$ju46 05-11-98 10:41:02 jinfa UC: J Infect
1697JID 1998;177 (June) Concise Communications
ated with the disease, as well as by positive IgM and IgG antibody control for possible effects of this blocking agent on specific detec-
tion of SNV antigen, a subset of the human tissues was stainedreactivity to recombinant SNV-N protein and SNV G1 glycopro-
tein by Western blot assay. The presence of SNV RNA was con- with and without the prestaining block: no significant difference
was noted (data not shown).firmed by RT-PCR in all cases for which appropriate tissue or
blood samples could be obtained (6/11 cases). All 11 cases are Immune mouse serum was applied at 1:2000, 1:4000, and
1:16,000 dilutions. Next a biotinylated goat-anti mouse secondaryrecognized as HPS patients by the US Public Health Service. Tis-
sues from an additional 9 patients with nonhantaviral pulmonary antibody was applied, followed by a horseradish peroxidase–avi-
din conjugate. Positive staining was visualized utilizing an amino–disease were chosen as negative controls. These patients died of
non-AIDS–related pneumonia (n  5), AIDS-related pneumonia ethyl carbazole chromogen. Stained slides were counterstained
with hematoxylin, mounted with aqueous mounting media, and(n  2), or interstitial pulmonary fibrosis (n  2).
Peromyscus maniculatus samples. Serum samples from an es- viewed at 1100–1000.
tablished colony of wild-caught P. maniculatus were screened by
Western blot for antibody reactivity to recombinant SNV-N pro-
teins. Of 80 animals screened, 8 were seropositive. These animals Results
were culled from the colony and sacrificed. Four of the seropositive
animals were injected intrapleurally and intraperitoneally with a All slides were reviewed by 3 independent readers who
total of 5 mL of 10% neutral-buffered formalin, and tissues were were blinded to the clinical status of each patient. Discrepan-
collected and processed for histochemistry within 48 h. The re-
cies in results were rare and were resolved by the readers
maining seropositive animals were frozen for RT-PCR and viral
by use of a multiheaded microscope. For all slides, cell stain-isolation studies. Nucleotide sequence analysis of amplified viral
ing was graded as negative, focal, multifocal but sparse, orcDNA from 3 specimens confirmed that SNV was the hantavirus
widespread. Results are summarized in table 1. In seroposi-within the colony. There were essentially no differences in the N
tive patients, N-antigen localized to the endothelium in aprotein amino acid sequences for the different mouse and human
samples analyzed (Hjelle B, unpublished results, 1994). The col- dense, granular-to-punctate, dark red staining pattern (figure
ony was rescreened 1 month later, and all animals were seronega- 1A – C.) In the human tissues evaluated, the specific staining
tive. Two animals were sacrificed, injected with formalin, and was readily distinguished from nonspecific staining, which
processed as above as negative controls for immunohistochemical tended to be more orange and globular with indistinct mar-
studies. gins, and from endogenous pigments, such as lipofuscin.
Development of primary antibody. Full-length SNV-N protein Pulmonary endothelium demonstrated the strongest staining
cDNA was cloned into an Escherichia coli expression vector
of the tissues examined, as evidenced by the intensity and
(pMAL-c2; New England BioLabs, Boston, MA), and the N pro-
abundance of signal within individual cells, and by the wide-tein was expressed as a fusion protein with maltose binding protein
spread distribution of positive cells throughout the tissue.and then purified over an amylose resin column (New England
Positive pulmonary endothelial staining was evident in allBioLabs) according to previously described methods [9]. Mature
HPS patients examined for whom lung tissue was availableBALB/c mice were immunized intraperitoneally with 50–100 mg
of SNV-N/pMAL fusion protein in emulsion containing Freund’s (10/11 patients). Viral antigen in other tissues was most
complete adjuvant (Sigma, St. Louis). Immunizations were re- consistently found in the endothelium, but variable staining
peated 3 times at 14-day intervals with 50–100 mg protein in of hepatic Kupffer cells, splenic dendritic cells, circulating
Freund’s incomplete adjuvant. Sera from immunized mice were mononuclear cells, and pulmonary macrophages was also
periodically tested for specific immunoreactivity to SNV-N by observed. Staining of renal glomerular capillary endothelium
ELISA using SNV-N antigen [5]. Serum was collected from 2 was prominent as was staining of myocardial endothelium
strong immunoreactors, and pooled serum was utilized as the pri-
in some patients. The staining patterns that we observed
mary antibody throughout this study.
largely parallel those reported using the heterologous anti-Immunohistochemistry. For all tissues sampled, 4- to 6-mm
body [7].sections were mounted on glass slides, deparaffinized, and stained
In tissues from infected P. maniculatus, viral antigen stainingon an automated processor following antigen retrieval. Antigen
was demonstrated only in pulmonary and cardiac tissues. Inretrieval involved boiling tissue sections for 19 min in 0.5 M citrate
buffer, pH 6.5, after which slides were cooled in citrate buffer for general, viral antigen–positive cells had few dark red punctate
20 min immediately prior to staining. signals, and individual positive cells in these tissues were rare
Since a secondary anti-mouse conjugate was used in our studies, for all animals examined. Unexpectedly, no viral antigen was
we needed to consider possible antigenic cross-reactivity due to detected in the kidney of seropositive animals. We determined
species similarity between Mus musculus and Peromyscus species. that antigen detection was not obscured by the blocking reagent
A prestaining step to block endogenous P. maniculatus immuno-
and attribute the higher background staining in the human tis-
globulin prior to the addition of primary antibody was necessary
sues to species differences or differences in tissue processingto avoid high background reactivity for all P. maniculatus tissues
(mice were formalin-fixed immediately following sacrifice).(Histomouse kit; Zymed, Camarillo, CA, used according to the
Even with the blocking step, there was widespread intravascu-manufacturer’s instructions). Without this blocking step, nonspe-
lar orange-pink background staining of serum in both seroposi-cific staining in all mouse tissues evaluated (both seropositive and
seronegative) precluded meaningful interpretation of results. As a tive and seronegative animals. No positive (punctate) staining
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Table 1. Results of cell staining of various formalin-fixed autopsy tissues from 11 patients who died of hantavirus pulmonary syndrome
(HPS), 9 patients with nonhantaviral pulmonary disease (negative controls), and 6 wild-caught Peromyscus maniculatus.
Age Lung Lymph Salivary
Patient no., sex (years) pathology Immunoblot RT-PCR Lung Heart Kidney Liver Spleen node Pancreas Intestine gland Adrenal Ovary
HPS patients
2257, F 31 HPS / N F F
2717, F 21 HPS / W W W
2718, M 19 HPS / W N N
2823, F 58 HPS / W W F
2891, M 21 HPS / / W
3053, F 22 HPS / / W N N W F N
3188, F 64 HPS / / W F W N F
3226, F 39 HPS / / W F W F
3326, F 42 HPS / W N N
3376, M 34 HPS / / W W F W
3472, M 68 HPS / W N W N N N
Negative controls
2732, F 56 NARP N N
1530, F 81 NARP N
1913, M 35 NARP N N
3029, F 61 NARP N
5074, F 74 IPF N
2736, M 34 ARP N
2332, M 41 ARP N
5374, M 42 DAD N N N
1660, F 51 DAD N
P. maniculatus
H2A / F F/ N N N
H2D / F/ F N N N N
H4B / F F/ N N N N
H4E / F F N N
NN1 0 N N N N N N
NN2 0 N N N N N
NOTE. RT-PCR  reverse transcriptase–polymerase chain reaction. /  positive, N  negative, F  focal, W  widespread, NARP  non-AIDS–related
pneumonia, IPF  interstitial pulmonary fibrosis, DAD  diffuse alveolar disease, F/  multifocal but sparse, 0  negative.
was detected in any of the tissues from negative control ani- into contact with either the tissue blocks or slides before they
were completely processed. In addition, the use of recombinantmals. These data are summarized in table 1. Characteristic
staining of pulmonary and cardiac endothelium, as well as viral protein as an immunogen both defines the targeted antigen
negative renal endothelium from a seropositive animal, are and ensures that immunized animals do not pose an infectious
shown in figure 1D–E. threat to laboratory personnel.
In this study, we have shown that the use of murine poly-
clonal antisera generated against a recombinant full-length
Discussion
SNV-N protein demonstrates promise as a useful indicator of
SNV infection in humans, demonstrating similar specificity toHantavirus-related disease has occurred as early as 1959 in the
that of an assay based upon a monoclonal antibody to a relatedNew World [10]. However, HPS in humans was first recognized
hantavirus (CDC monoclonal antibody GB04-BF07 directedduring an outbreak in the spring of 1993. Sporadic cases of HPS
against Puumala hantavirus nucleoprotein [7]). The human tis-have occurred in the past and have gone unrecognized. The
sues we evaluated had undergone various degrees of autolysisdevelopment of an immunohistochemical assay for retrospective
or processing (or both; e.g., embalming) prior to formalin fixa-diagnosis of such cases is a useful tool for investigating the
tion. Nevertheless, antigen was readily detected at antibodynatural history of HPS in humans [8, 11], as are carefully de-
dilutions of 1:16,000. None of the tissues examined from sero-signed serologic tools with epitope mapping [12, 13].
negative human tissues demonstrated antigen staining.In the development of such an assay, one must consider the
Although only a few seropositive P. maniculatus were exam-potential risks involved in working with live virus or infected
ined in this study, the findings were consistent among theseanimals. We used formalin-fixed tissue in this study to elimi-
nate the risk of virus exposure to all personnel who might come samples. The rodent hosts of SNV manifest few if any of the
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Figure 1. Immunohistochemically stained
tissues from Sin Nombre (SNV) virus–posi-
tive humans and deer mice. A, Human lung:
alveoli with antigen-positive capillary endo-
thelium. B, Human heart: ventricular myo-
cardium with antigen-positive capillary en-
dothelium. C, Human kidney: tubular
epithelium and interstitial vessel with anti-
gen-positive endothelial cell. Note nonspe-
cific staining of renal tubular epithelial cells.
D Peromyscus maniculatus lung: alveolus
with antigen-positive capillary. E, P. man-
iculatus heart: atrial myocardium with anti-
gen-positive endothelium. F, P. maniculatus
kidney: tubule and glomerulus, no antigen
detected. All tissues were stained with poly-
clonal murine serum directed against recom-
binant SNV–nucleocapsid antigen protein.
Arrows indicate positive antigen staining.
11000.
clinical and pathologic findings observed in humans with HPS Patients infected with SNV undergo an acute, rapid dis-
ease course. Their tissues contain abundant viral antigen in[14]. In addition, the lack of seroconversion of any of the
remaining P. maniculatus in the colony would suggest that vascular endothelial cells, especially in the lung. This finding
suggests that at the time of death, they had a relatively highhantavirus infection is not readily or rapidly passed among
cohabitating positive and negative animals [15]. Our finding virus burden. However, there have also been reports of peo-
ple with serum antibody against SNV but only mild disease;that virus-positive animals with serum antibodies to viral pro-
tein have relatively few viral antigen–positive endothelial cells interestingly, it is often more difficult to detect SNV RNA
in the blood of these patients by RT-PCR (Hjelle B, unpub-may reflect a low level of viral replication in these animals.
This is consistent with both the low transmissibility of the virus lished results). Further studies are necessary to determine
the role of virus burden on the clinical expression of HPSin rodent colonies as well as the lack of associated disease in
chronically infected P. maniculatus. and virus tissue localization during acute through chronic
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6. Hjelle B, Spiropoulou CF, Torrez-Martinez N, Morzunov S, Peters CJ,infection and the role of host factors that may contribute to
Nichol ST. Detection of Muerto Canyon virus RNA in peripheral bloodthis process.
mononuclear cells from patients with hantavirus pulmonary syndrome.
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Analysis of the Persistence of Humoral and Cellular Immunity in Children and
Adults Immunized with Varicella Vaccine
Leigh Zerboni, Sonia Nader, Kristan Aoki, Department of Pediatrics, Division of Infectious Diseases, Stanford
University School of Medicine, Stanford, Californiaand Ann M. Arvin
The persistence of humoral and cellular immunity to varicella-zoster virus (VZV) was evaluated
in 60 children and 18 adults immunized with live attenuated VZV vaccine. At a mean of 5 years
after vaccination, 93% of children and 94% of adults had IgG antibodies to VZV as determined by
ELISA. VZV antibody concentrations were significantly higher at 5 years than at 1 year after
immunization in children and adults. Cell-mediated immunity to VZV was detected in 87% of
children and 94% of adults at 5 years. The mean stimulation index was significantly higher at 5
years than at 1 year among children and adults. Cytokine responses to VZV, including interleukin-
2, interferon-g, and interleukin-10 were equivalent between children and adults at 5 years. In
summary, varicella immunization induced long-term humoral and cellular immunity, and initial
differences between cell-mediated responses in children and adults diminished over time.
Immunization with the live attenuated varicella vaccine elic- responses, which are important for the resolution of VZV infec-
tion and maintenance of latency [1]. Natural immunity is char-its protection against varicella-zoster virus (VZV), a human
herpesvirus that causes varicella (chickenpox) and reactivates acterized by the long-term persistence of circulating T cells
that recognize VZV proteins and by the persistence of IgGas herpes zoster (shingles) [1]. The varicella vaccine was devel-
oped and evaluated in clinical trials in Japan in the 1970s [2]. antibodies to VZV.
After natural infection, cellular immunity to VZV, measuredIn the United States, clinical trials were conducted in children
with leukemia and later in healthy children [3]. The varicella as in vitro T cell proliferation, is well-preserved until the fifth
decade of life or later. An age-related decline in cellular immu-vaccine elicits humoral and cellular immunity in children and
adults [4, 5]. Early vaccine studies demonstrated an age-related nity to VZV then occurs, which predisposes to herpes zoster.
VZV-specific T lymphocytes are found in CD4/ and CD8/difference in seroconversion rates, resulting in the recommen-
dation of a two-dose regimen for adolescents and adults [6, subsets. Within the CD4/ subset, T cells that recognize VZV
protein are predominately of the Th1 CD4/ subset, producing7]. Whether the initial administration of the varicella vaccine
induces prolonged immunity or whether revaccination will be interleukin (IL)-2 and interferon (IFN)-g [11]. Cytokine pro-
files of elderly immune persons demonstrate that Th1 typeneeded is an important question.
The vaccine, produced by Merck (West Point, PA), is made CD4/ T cell function declines significantly with age, whereas
Th2 type responses, detected by IL-4 production, do not [11].from the Oka isolate of VZV; it is produced in human diploid
cells and given as a subcutaneous inoculation. Clinical attenua- Thus, induction and preservation of Th1 CD4/ T cell immunity
appears to represent the optimal response to VZV.tion of this vaccine has been shown in pre- and postlicensure
experience [2, 8, 9]. Our analysis of the virologic basis of The purpose of this study was to assess the long-term persis-
tence of cellular immunity compared with that of VZV IgGattenuation demonstrates that it results from impaired replica-
tion in epidermal and dermal cells [10]. antibodies in immunized children and adults and to characterize
the relative preservation of Th1 and Th2 type cytokine re-The host response to primary infection with VZV involves
synchronous induction of humoral and cell-mediated immune sponses.
Patients, Materials, and Methods
Received 26 August 1997; revised 25 November 1997.
Presented in part: Western Society for Pediatric Research, Carmel, CA, Study populations. Studies of the immunogenicity of the Oka-
February 1997. Merck varicella vaccine were done at Stanford University between
Informed consent was obtained from subjects prior to blood sample collec- 1988 and 1992 [4, 5]. The population in the current study consisted
tion. The research conformed to the guidelines established by the Administra-
of vaccinees who seroconverted and did not develop breakthroughtive Panel on Human Subjects in Medical Research at Stanford University, in
varicella.accordance with federal regulations.
Grant support: NIH (AI-20459); Merck and Co., Inc. Two hundred healthy children (ages 2–12 years), who were
Reprints or correspondence: Leigh Zerboni, Dept. of Pediatrics, Stanford vaccinated between 1988 and 1990, received one dose of 1140–
University School of Medicine, Stanford, CA 94305-5208 (zerboni@leland
5850 pfu of infectious virus or two doses of 3315, 3625, or 9000.stanford.edu).
pfu. Sixty (30%) of these vaccinees agreed to be reevaluated [5].
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of vaccine (905–9000 pfu/dose) [5]. Eighteen of these vaccinees Five years after vaccination, seropositivity rates were 93.3%
(45%) agreed to be reevaluated. (56/60) for children and 94.4% (17/18) for adults. An increase
Twenty-six (13%) of 200 children and 1 (2.5%) of 40 adults in antibody concentrations from 1 to 5 years was significant
were excluded due to breakthrough varicella. for both adults and children (P  .05). Antibody levels were
Humoral immunity. Serum was collected at the time of vacci- equivalent between adults and children at 1- and 5-year time
nation, 3 months after vaccination, 1 year after vaccination, and
points (figure 1A).
at follow-up. The presence of anti-VZV IgG antibodies was mea-
VZV-specific T lymphocyte proliferation. One year aftersured by ELISA to unfractionated VZV-infected cell lysates (anti-
vaccination, 89.7% (26/29) of children and 94.1% (16/17) ofgen) and uninfected cell lysates (control) as previously described
adults had cellular immunity to VZV. At 5 years, VZV-specific[12]. Initial sera were retested in parallel with follow-up sera to
T cell proliferation was maintained in 86.7% (52/60) of chil-eliminate assay-to-assay variability.
VZV-specific lymphocyte proliferation assay. Peripheral blood dren and 94.1% (16/17) of adults. The mean SI { SE at 1 year
mononuclear cells (PBMC) were isolated from whole blood and was 12.08 { 2.03 for children and 9.89 { 1.80 for adults,
incubated with unfractionated VZV-infected cell lysates or an un- compared with a mean at 5 years of 22.08 { 2.35 in children
infected cell lysate using methods previously described [5]. T cell and 22.39 { 4.78 in adults. Responses of children and adults
recognition of VZV antigen was determined by the stimulation were equivalent at 1 and 5 years.
index (SI), which is the ratio of mean counts per minute in antigen-
stimulated wells to that in control-stimulated wells. A positive
response was defined as an SI of⁄3.0. The method used to prepare
antigen batches has been standardized to minimize variability be-
tween preparations; the antigenicity of each preparation is evalu-
ated using naturally immune subjects.
Assays for cytokine production. Cytokine release by PBMC
was evaluated by stimulation with VZV antigen or uninfected cell
control; maximum release in supernatants harvested on days 1–
8 was determined. IL-2 was detected using kits from Genzyme
(Cambridge, MA); IL-10 and IFN-g were detected using kits from
Endogen (Cambridge, MA). Cytokine concentrations were deter-
mined using a series of standards and extrapolated from a standard
curve. Sensitivities of detection were defined by reference stan-
dards in each assay.
Exposure surveys. Five (8.3%) of 60 children and 1 (6%) of
18 adults reported a household exposure to VZV since vaccination.
Nine children (15%) and 3 (17%) adults reported a nonhousehold,
close-contact exposure that lasted 4 h.
Statistical analysis. Statistical analyses were done using a
computer software program (Microsoft Excel, version 5.0; Micro-
soft, Redmond, WA). Comparisons were made using Student’s
paired and unpaired t tests.
Results
Study population. 60 children and 18 adults were reevalu-
ated in our follow-up study. Fifteen of 60 children (25%) and
all adults received two doses of vaccine. For children, the mean
interval after vaccination was 6.4 years (range, 2.1–8.4) and
for adults was 4.7 years (range, 3.6–6.2). The mean age at
vaccination was 5 years (range, 2–12) for children and 34
years (range, 23–43) for adults.
Figure 1. A, Persistence of IgG antibodies to varicella-zoster virus
VZV IgG antibody responses. Three-month seropositivity (VZV). There is significant increase in 3-month antibody levels in
rates were 100% for children and adults; 1-year seropositivity children (black bars) and adults (white bars) who received 2 doses
of vaccine, compared with levels in children who received 1 dose (Prates were 97.7% (43/44) for children and 100% (14/14) for
 .05). Difference between responses at 1 year and follow-up isadults. At 3 months, adults and children who received two
significant (P  .05) for children and adults. B, Persistence of T celldoses of vaccine had significantly more VZV antibody than
recognition of VZV. Stimulation indices (SI) 3.0 are considered
children who received one dose of vaccine (optical density { negative. Mean SI responses were increased significantly at follow-
SE: in adults, 1.06 { 0.16; in children after two doses, 1.03 up vs. 1 year in children (black bars) and adults (white bars) (P 
.05). Mos  months.{ 0.15; in children after one dose, 0.55 { 0.11; P  .05).
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The mean SI { SE at day 42 was significantly greater in
children than in adults (15.59 { 3.67 vs. 7.19 { 0.95;
P  .03). The mean SI was equivalent at 3 months, by which
time, all adults had received two doses of vaccine. Responses
diminished in both groups between 3 months and 1 year after
vaccination (P  .13 and .02 for children and adults, respec-
tively). The SIs in individual vaccinees increased significantly
between 1 year and the follow-up specimen (P  .04 for both
children and adults) (figure 1B).
No statistically significant association between the infectious
virus content of the vaccine and the persistence of T cell recog-
nition of VZV antigen was demonstrated.
Cytokine profiles. Cytokine release profiles of proliferating
T cells were evaluated when follow-up blood sampling was
done. The value in picograms per milliliter was calculated as
the difference between the response to the VZV antigen and
Figure 2. Cytokine release from varicella-zoster virus (VZV)–control. Samples were considered positive if the level of detect-
stimulated peripheral blood mononuclear cells. Bars indicate meanable cytokine was above the sensitivity of detection defined by
concentration in VZV antigen–stimulated wells for children (black)reference standards for each assay. Analysis of the kinetics of
and adults (white) and in control-stimulated wells for children (hori-
cytokine release from days 1 through 8 revealed no age-related zontally striped) and adults (vertically striped). IFN  interferon, IL
differences; peak responses for IL-2 occurred at 2–4 days, and  interleukin.
those for IL-10 and IFN-g occurred at 5–7 days. The interval-
to-peak response was equivalent in children and adults.
IL-2 was detected in 71% (36/51) of PBMC cultures from term equivalence of humoral immunity to VZV in adults and
children.children and 50% (8/16) of cultures from adults. The mean IL-
2 concentration in positive cultures was 496.0 { 53.6 in chil- The capacity to elicit cell-mediated responses is an important
factor, accounting for the long-term protective efficacy of livedren and 511.7 { 87.7 in adults. IFN-g was detected in 91%
(43/47) of PBMC cultures from children and 93% (14/15) from attenuated viral vaccines. From 98% to 100% of healthy chil-
dren given the varicella vaccine have T cell recognition ofadults. The mean value for IFN-g in positive cultures was
685.4 { 78.2 in children and 737.7 { 163.6 in adults. IL-10 VZV antigens by 2–6 weeks after immunization with one dose;
however, the initial T cell responses of adult vaccinees arevalues were 214.2 { 38.2 in children and 200.8 { 44.0 in
adults. IL-10 was at detectable levels in supernatants of PBMC lower [5]. In our experience with longer follow-up, cell-medi-
ated immunity was found to increase significantly in childrencultures from 60% (30/50) of children and 38% (6/16) of adults
(figure 2). Background levels (mean concentrations in control- and adults, with the responses of adults becoming equivalent
to those of children with vaccine-induced immunity.stimulated wells) are given in figure 2. The concentrations of
cytokines produced in PBMC cultures for children and adults Consistent with the significant role of the cell-mediated im-
mune response to varicella, VZV infection elicits the prolifera-were equivalent and did not correlate with the SI.
tion of T cells that produce predominantly Th1 type cytokines
[4]. A prominent IFN-g response is characteristic of naturally
Discussion
acquired immunity to VZV [11]. In our follow-up study, the
protection elicited by immunization with live attenuated vari-In our study, antibodies to VZV were well-preserved at a
mean of 5 years following vaccination in adults and children. cella vaccine was characterized by antigen-specific IL-2 and
IFN-g release by activated T cells. No age-related differencesSimilarly high rates of antibody persistence have been observed
in healthy children; surveillance studies have demonstrated that in the cytokine secretion patterns of cultured T cells were
detected with long-term follow-up in children and adults whothe vaccine induces antibody responses that persist for at least
20 years [2, 8]. Lower VZV IgG titers were associated with had vaccine-induced immunity.
Surveillance studies indicate that breakthrough varicella oc-lower cellular immune responses in adult vaccinees [5]. How-
ever, with longer follow-up, VZV-specific IgG antibody con- curs at an incidence of about 2%–3% per year in children and
adults but that the incidence and severity do not increase overcentrations increased significantly in adults and children. The
increase in antibody titers with time after immunization has time [2, 14]. Our finding that immune responses to VZV are
preserved well after varicella vaccination is consistent withbeen observed by others [13]. Our study demonstrated that
even among vaccinees with low initial responses, the antibody these clinical observations.
Whether the immunologic basis for the increase of VZVconcentrations can be expected to increase over time and that
the two-dose vaccine regimen is sufficient to achieve long- immune responses in vaccinees was due to endogenous or ex-
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Spontaneous Loss of Viral Episomes Accompanying Epstein-Barr Virus
Reactivation in a Burkitt’s Lymphoma Cell Line
Shamala K. Srinivas, Jeffery T. Sample, Program in Viral Oncogenesis and Tumor Immunology, St. Jude
Children’s Research Hospital, and Departments of Pathology andand John W. Sixbey
Pediatrics, University of Tennessee College of Medicine,
Memphis, Tennessee
Life-long viral persistence is a hallmark of human herpesvirus infection. In the Epstein-Barr virus
(EBV)–positive Burkitt’s lymphoma (BL) cell line, Mutu, spontaneous loss of all viral episomes
accompanied productive viral DNA replication. The molecular configuration of intracellular EBV
DNA evolved from monoclonal episomes in cells retaining the original tumor phenotype to predomi-
nantly replicating linear DNA and, subsequently, only integrated forms in BL cells that had acquired
the lymphoblastoid cell phenotype. Transient appearance of deleted, rearranged WZhet EBV DNA
capable of disrupting viral latency, along with the integration of viral DNA into human chromo-
somes, indicates a genetic instability in the host cell which, if duplicated in vivo, may affect configu-
ration and persistence of the viral genome in expanding malignant cell clones.
like) (gift of A. B. Rickinson, University of Birmingham, UnitedBurkitt’s lymphoma (BL) is a B cell neoplasm that occurs
Kingdom) [4] were maintained in RPMI 1640 with 10% fetalin children and young adults worldwide. Epstein-Barr virus
bovine serum. Relatedness of each Mutu clone after long-term(EBV) is variably associated with the tumor, being found in
culture was confirmed by analysis of cell karyotype (St. Jude Chil-virtually all cases of African BL, half of South American BL,
dren’s Cancer Center Cytogenetics Facility) and immunoglobulinand 20% of cases in the United States [reviewed in 1]. In
gene rearrangements using a probe derived from a 3.4-kb pair
EBV-linked disease, viral initiation of tumorigenesis is sug-
(kbp) EcoRI/HindIII fragment of the joining region (JH). Stabilitygested by molecular evidence for the presence of EBV DNA of the phenotypic grouping of each clone [4] was assessed by
in a single tumor progenitor cell prior to its malignant conver- standard immunoblotting for EBV protein expression using human
sion [2, 3]. Infection precedes and therefore is likely to contrib- serum from a patient with nasopharyngeal carcinoma and by indi-
ute to clonal expansion. rect immunofluorescent staining of cells using monoclonal antibod-
Within latently infected cells, the EBV genome is maintained ies PE2, CS1-4, and BZ.1 (gift of L. S. Young, University of
in multiple episomal copies. Cultured, EBV-positive BL cell Birmingham, United Kingdom) specific for EBV proteins EBNA2,
LMP1, and BZLF1, respectively.lines generally contain from 10 to as many as 100 episomes
Southern analysis of EBV DNA. The molecular configurationper cell. While varying among cell lines, the viral copy number
of EBV termini (linear, episomal, or integrated) was determinedremains largely constant over time for each individual cell line.
by the method of Raab-Traub and Flynn [2], using 32P-labeledIn the African BL line Mutu [4], we investigated the complete
riboprobes specific for regions of unique EBV DNA (XhoI-a andloss of episomal DNA observed during long-term culture. Such
BamHI-J portion of EcoRI-I; gift of N. Raab-Traub, University ofspontaneous viral DNA loss mimics aspects of unstable mainte-
North Carolina) immediately internal to terminal repeat sequences
nance of EBV DNA in tumors in vivo [5, 6] and may be
at either end of the viral genome. Total cellular DNA from BL cell
relevant to the less than total association of EBV with human lines was digested with BamHI restriction endonuclease, loaded at
malignancies that share clinical, histopathologic, and cytoge- 10 mg of DNA per well, separated by electrophoresis in 0.8%
netic features. agarose gels, and then transferred to nylon membranes for hybrid-
ization.
Fluorescent in situ hybridization. The cosmid cM302-21 [7],Materials and Methods
containing 40 kbp of EBV DNA, was used to create probes
Cell lines and EBV expression. The BL-derived cell line Mutu, labeled by nick-translation with digoxigenin-11-dUTP (Boehringer
clone 59 (group I/Burkitt’s-like) and clone 176 (group III/LCL-
Mannheim, Indianapolis). Probe was hybridized to fixed interphase
or metaphase chromosomes as previously described [8]. Hybrid-
ized probe was detected by fluorescein-conjugated sheep antibod-
Received 20 August 1997; revised 17 December 1997. ies to digoxigenin (Boehringer Mannheim).
Financial support: Public Health Service (CA-67372), Cancer Center Sup-
Detection of WZhet DNA by polymerase chain reaction (PCR).port (CORE grant CA-21765 from the National Cancer Institute), and CA-
56639 (J.T.S.); American Lebanese Syrian Associated Charities. Twenty-five cycles of PCR amplification were performed on 100
Reprints or correspondence: Dr. John W. Sixbey, Depts. of Infectious Dis- ng DNA with Taq polymerase using a DNA thermal cycler (Perkin-
eases and Virology & Molecular Biology, St. Jude Children’s Research Hospi- Elmer Cetus, Norwalk, CT) as per manufacturer’s recommenda-
tal, 332 N. Lauderdale, Memphis, TN 38105-2729 (john.sixbey@stjude.org).
tions. Primers were selected that framed the junction of rearranged
The Journal of Infectious Diseases 1998;177:1705–9 DNA in WZhet EBV (5*-TGGGACGTGCTAAATTTAG-3* andq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0036$02.00 5*-GTCCAGCGCGTTTACGTAAG-3*). Probes specific to both
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of the abnormally juxtaposed W and Z BamHI fragments were were no longer joined as if in the circular configuration but
used to detect the predicted 301-bp PCR product [6]. P3HR1 clone 5 integrated with cellular sequences of varying length, the two
(from G. Miller, Yale University, New Haven, CT), which contains bands identified by each probe representing individual integra-
WZhet DNA, served as positive control. tion events.
To corroborate evidence for viral integration, interphase and
metaphase chromosomes were examined by fluorescent in situResults
hybridization, using as probe EBV DNA from a large cosmid
clone covering approximately a quarter of the viral genomeOn serial passage, BL cells typically drift from the original
biopsy cell phenotype (termed group I: CD10/CD77-positive, [7]. Consistent with the termini analysis, metaphase spreads
from multiple mitoses repeatedly demonstrated symmetricalactivation antigen/adhesion molecule–negative) expressing
only one latent viral nuclear antigen (EBNA1) to a lymphoblas- doublet signals on sister chromatids at two chromosomal sites,
indicating EBV DNA integration (figure 1). On the basis oftoid cell line phenotype (termed group III: CD10/CD77-nega-
tive, activation antigen/adhesion molecule–positive) in which the possibility that the spontaneous changes observed in EBV
DNA configuration in this late-passaged cell population repre-cells express all nine latency-associated EBV proteins and some
enter the EBV lytic cycle [4, 9]. Cell clones of Mutu BL have sented inadvertent contamination of cell lines, we analyzed
both the karyotype and immunoglobulin gene rearrangementsbeen established that grow stably in either the group I or III
phenotype [4]. After 30 months in culture, Mutu group III in Mutu III early and late passages, each of which were identi-
cal for the two cell populations (data not shown).cells yielded a progressively diminished hybridization signal
for EBV DNA on standard Southern analysis (not shown). EBV replication in another BL-derived cell line, P3HR1, has
been directly linked to presence of defective, rearranged EBVBecause group III cells had previously been described as
containing significant numbers of cells in lytic cycle [4], the DNA, termed heterogeneous (or WZhet) DNA [10]. Since EBV
integration may reflect a more pervasive DNA instability thatobserved change in viral DNA content might merely reflect
cessation of EBV replication in that subset of cells. To assess might foster both defective virus and episomal loss, we used
PCR analysis to examine Mutu total cellular DNA for WZhetthis possibility, we analyzed DNA from early and late passages
of Mutu group I and group III culture phenotypes for the con- rearrangements (figure 2). PCR primers that flanked the aber-
rant junction between two EBV DNA fragments, BamHI-Wfiguration of EBV termini (figure 1). BamHI restriction endonu-
clease digestion of viral DNA preserves terminal repeat se- and -Z, contiguous in WZhet DNA but 55 kbp apart in the
standard genome, yielded a product in the same Mutu group Iquences that vary in number for each virion but cleaves
adjacent unique DNA. Fused termini, indicated by a high- and group III populations that by Southern analysis (figure 1)
contained replicating virus. PCR products were somewhatmolecular-weight band that hybridizes to probes specific for
opposite ends of the genome, denote circular forms found in larger from Mutu than from the P3HR1 control, suggesting
variability in the junction between rearranged fragments. How-latently infected cells, whereas an array of smaller unjoined
ends varying in size by the 500 bp in each repeat represents ever, each product hybridized to oligonucleotide probes internal
to primer sequences and specific for either the BamHI Z or Wlinear viral DNA characteristic of replicative infection [2].
As shown in figure 1 (blots A and B), both the early- and fragment (figure 2).
Because the BZLF1 (BamHI-Z leftward open-reading framelate-passage Mutu cells retaining the BL group I phenotype
contained predominantly episomal EBV DNA. Detection of a 1) protein encoded by both standard and defective genomes
initiates the switch from EBV latency to virus replication [10],single high-molecular-weight fragment with probes specific for
unique sequences at either end of the EBV genome confirm late-passage group I and group III clones that differed with
regard to state of viral activation (figure 1, blots B and D) werethat the BL line contained a single clonal population of epi-
somal DNA. A minor component of replicating virus was de- stained by indirect immunofluorescence for BZLF1. Consistent
with DNA analyses that demonstrated the presence of WZhettected in the late passage, as represented by small-molecular-
weight unjoined termini. By contrast, exuberant replication was DNA and viral replication, late-passage group I cells contained
a subset of BZLF1-positive cells in contrast to late-passageseen in the early-passage group III clone in the presence of a
persisting, yet proportionally diminished, episomal DNA popu- group III cells (figure 2), a pattern just the reverse of that
originally described for early Mutu cell passages [4]. The pat-lation (blot C). As was anticipated, late-passage group III cells
now contained no evidence of replicating virus, accounting in tern of viral latent gene expression definitive for group I and
group III cells, however, remained unchanged (not shown).part for the reduction in EBV DNA content observed. Surpris-
ingly, however, the single 20-kb band representing joined EBV
termini in both group I and early-passage group III Mutu cells
Discussion
was also absent (blot D). Instead, the episomal band was re-
placed by two high-molecular-weight bands, the sizes of which The notion that viruses may be responsible for genetic dam-
age, yet fail to persist in the malignant cell, has previouslyvaried when probes to the right versus left end of the EBV
genome were used. These results suggested the EBV termini been advanced in the case of those human herpesviruses (e.g.,
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Figure 1. EBV episomal DNA loss and chro-
mosomal integration associated with viral replica-
tion in Burkitt’s lymphoma cell line, Mutu. South-
ern blot depicts conformation of EBV termini from
early- (blots A and C) and late- (blots B and D)
passaged Mutu group I and III cells. L  probe
to left end (BamHI-J portion of EcoR1-I ) of EBV
genome; R  blot stripped and reprobed for right
end (XhoI-a) of genome; arrowhead  joined ter-
mini in EBV episomal DNA (blots A–C); arrows
(blot D)  integrated terminal EBV fragments;
tick marks (blots B and C)  linear ends of repli-
cating EBV DNA containing variable reiterations
of 500-bp repeat sequence; B95-8  EBV–posi-
tive control cell line with episomal (10-kb band)
and linear EBV DNA. At bottom, fluorescent in
situ hybridization of interphase (left) and meta-
phase (right) chromosomes from Mutu cells ana-
lyzed in blot D above, using EBV DNA as probe.
Symmetrical doublet signal (arrowheads) on 2
chromosomes is representative of all analyzed mi-
toses and indicates 2 integration events.
/ 9d46$$ju46 05-11-98 10:41:02 jinfa UC: J Infect
1708 Concise Communications JID 1998;177 (June)
Figure 2. Rearranged WZhet EBV DNA
in cell populations replicating EBV. Using
total Mutu DNA (early [blots A and C] vs.
late [blots B and D] cell passages), poly-
merase chain reaction products were de-
rived from sequences spanning junction of
abnormally juxtaposed BamHI-W and -Z
EBV DNA fragments. P3HR1 clone 5 
WZhet-positive control; expected product
size is 301 bp. At bottom, late-passage
Mutu cells analyzed in blots B (left) and
D (right) above were stained by indirect
immunofluorescence for EBV immediate-
early (replicative cycle) protein BZLF1
with monoclonal antibody BZ.1.
herpes simplex virus) for which little positive evidence exists episomal DNA loss, EBV DNA integration) closely parallel
findings reported in uncultured sporadic BL tissue biopsies into support an association with human cancer [11]. Conceptu-
ally, such a ‘‘hit-and-run’’ mechanism of viral oncogenesis which presence of only integrated EBV DNA or rearranged
WZhet DNA led to their misclassification as EBV-negativemight be more convincingly argued for EBV, which encodes
known oncoproteins but whose well-documented associations tumors [6]. As indicated in that report, integrated viral DNA
may not contribute to the malignant process but rather attestswith the human malignancies Hodgkin’s lymphoma and BL
are less than complete. Just such a process of viral DNA loss to the overall genomic instability within the cell.
The clearance of viral episomes from a population of cellshas been recently suggested by findings of heterogeneity within
a single BL in the form of EBV-positive and EBV-negative also containing WZhet EBV DNA may be more than coinciden-
tal. The rearrangement of BamHI-W and BamHI-Z EBV frag-cells bearing identical chromosomal abnormalities [5].
Our findings of complete episomal DNA loss, accompanied ments confers unusual biologic properties on the defective
DNA as a result of constitutive expression of the immediate-by viral DNA integration, complement an earlier report of EBV
DNA loss from the BL cell line Akata, where up to half of the early gene BZLF1 [14], transient transfections of which have
been shown to cause partial elimination of EBV episomes fromcells failed to maintain the viral episomes after 2 years in
culture [12]. Although affected Mutu cells retained their group BL cells [15]. Since WZhet DNA itself is not stably associated
with cells [10], both might be effectively lost from an ex-III phenotype, including expression of all latent EBV proteins,
viral integration presumably offered some selective advantage panding cell clone. Unless episomal loss was accompanied by
EBV DNA integration, evidence for past infection of tumorleading to the outgrowth of this subpopulation. Alternatively,
Mutu cell variants with integrated EBV inapparent on initial would be absent.
The consistency with which t(8:14), t(2:8), and t(8:22) trans-DNA blots may have preexisted EBV lytic replication and have
been selected for during cytolysis. Episomal and integrated locations are found in all BL makes the juxtaposition of c-myc
and immunoglobulin gene loci a critical step in lymphomagen-copies of EBV have been known to coexist in some BL cell
lines [13], but marked episomal EBV DNA loss with clonal esis. Agreement on the contribution of virus has been more
problematic due to the only partial association of EBV withemergence of a population containing integrated virus has not
been described. What makes these observations of particular BL, an issue that can be resolved if we accept a priori that
transforming events other than EBV infection can lead to thenote is that the footprints of viral instability described here for
Mutu (EBV reactivation, WZhet EBV DNA rearrangement, same histological and cytogenetic abnormalities. Our data raise
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The stability over time of serum IgG antibody levels to human papillomavirus type 16 (HPV-16)
was determined by comparing the HPV-16 capsid antibody levels in serial serum samples of an age-
stratified random subsample of 1656 primiparous mothers resident in Helsinki who were followed
until their second pregnancy, on average 29.5 months later. The correlation between the first and
second pregnancy HPV-16 serum antibody levels of the same woman was high, even when4 years
had elapsed between pregnancies (r  .822). Between negativity, indeterminate results, or quartiles
of positivity, the predictive values for being classified in the same category on both occasions ranged
between 42% and 91%. Correlation coefficients, predictive values, and k coefficients between serial
samples all were comparable with those of repeat analyses of the same sample, indicating that HPV
capsid antibody levels are generally stable during several years of follow-up.
The oncogenic genital human papillomaviruses (HPVs) are For the capsid-based HPV-16 serology, estimates of sensitiv-
ity for detecting HPV-16 exposure (using detection of HPV-widespread sexually transmitted agents that are established (es-
pecially HPV-16) as a major cause of anogenital cancers [1]. 16 DNA in cervical samples as reference) have ranged from
14% [3] to 80% [4, 5], with most studies reporting 50%Historically, HPV infection has been assayed by detection of
viral DNA in cell samples. However, a single test for the sensitivity [6–9]. Specificity for the sexually transmitted HPV
types seems to be high, since no virginal and few monogamousdetection of HPV DNA, no matter how sensitive, may be inac-
curate because of sampling errors [1, 2]. Also, in follow-up women are seropositive [4, 7]. Seropositivity has not been
associated with number of recent sex partners but associatesstudies of HPV DNA-positive women, a majority have cleared
their HPV DNA within 1–2 years [1]. Thus, the only way to very strongly with the lifetime number of sex partners (linear
increase of seroprevalences with 4%/partner) [7], arguingdetect previous HPV infections, that is, cumulative exposure,
or an infection at a site not accessible to sampling is by de- that seropositivity is rather a measure of lifetime cumulative
exposure than of recent exposure. Seroprevalences have alsotecting an antibody response. HPV seroepidemiology is there-
fore important for the continuing elucidation of the natural not shown any consistent association with age [6, 7, 10, 11],
in spite of the fact that HPV DNA prevalences are stronglyhistory of HPV infection, its role in malignancies, and the
spread of the infection in different populations. age-dependent [1].
Evaluation of the biologic stability of capsid antibody levelsIn general, interpretable seroepidemiology requires knowl-
edge of several indices of antibody responses and assay charac- over time is important for understanding the immunobiology
of HPV infection and for interpreting HPV seroepidemiology.teristics, the most important of which are sensitivity, specificity,
biologic stability of antibodies over time, and assay variability. We took advantage of the population-based Finnish serologic
screening of pregnant women for a large-scale evaluation of
assay consistency and biologic stability of antibody levels in
serial samples taken from the same women.
Received 25 July 1997; revised 8 December 1997.
Presented in part: 15th International Papillomavirus Conference, Brisbane,
Australia, 1996 (abstract 50); 16th International Papillomavirus Conference, Materials and Methods
Siena, Italy, 1997 (abstract 234).
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of 1656 primiparous women, stratified by age at first pregnancy equal number of subjects were defined (table 1). In addition,
(6 strata of 13–17, 18–19, 21, 23, 25, and 30 years of age) among a similarly sized group of women with OD values just below
women who were resident in the Helsinki metropolitan area, had the cutoff level were defined as an indeterminate group. The
been pregnant for the first time during 1983–1984 or 1990–1991, remaining 1169 women constituted the seronegative group.
and had had a second pregnancy during a 5-year follow-up period. As seen in table 1, the predictive values for the probability
The standard direct ELISA method [8] for detecting IgG antibodies
that the antibody levels of the second pregnancy samples ofspecific for HPV-16 by use of baculovirus-expressed capsids compris-
the same women tracked in the same group as at first preg-ing both the L1 and L2 proteins was used, with disrupted capsids
nancy ranged between 91% and 42%. By comparison, a re-of bovine papillomavirus as negative control, as described in detail
peat analysis of 469 serum samples randomly chosen fromelsewhere [12]. The assays included several internal standard samples
the 6 groups found the predictive values to be of the sameon each ELISA plate, both positive controls (pools of serum from
patients with cervical dysplasia or cancer and from healthy women magnitude (ranging between 90% and 45%). The overall k
with cervical HPV-16 DNA) and negative control sera (sera from coefficient between the first and second pregnancy antibody
sexually inexperienced women). The optical density (OD) values level was .585 (z  40.8; P  .0001). The antibody levels
from each plate were normalized relative to the results of the internal tracked well in the seronegative group and the group with
standard sera. The cutoff level was preassigned (OD of 0.100) and the strongest level of positivity. Moderate tracking was ob-
had previously been shown to distinguish HPV-infected from virginal
served for the other 3 quartile groups of positivity, whereaswomen [4]. The intraassay coefficients of variation varied between
the indeterminate group tracked poorly. A similar tracking9.4% and 10.7% in different assay runs, and the interassay coefficients
pattern was observed among the repeated measurements ofof variation varied between 9.9% and 23.9%.
the same sample.The predictive value equals the number of subjects who stay in
The tracking between antibody level categories appeared toa percentile category during follow-up divided by the total number
of subjects in that category at the initial measurement. The k follow a Gaussian distribution, both for the serial pregnancy
statistic quantifies the extent of tracking between percentile catego- samples and for the repeated measurements, with most samples
ries, beyond the amount of tracking expected by chance alone: k that moved between categories moving to the neighboring cate- [p(A) 0 p(E)]/[1 0 p(E)], where p(A) is the actual tracking of gory (figure 1A, B).
the group and p(E) is the amount of tracking expected if individuals
The correlation between the antibody levels at first and sec-
are randomly assigned to the different groups.
ond pregnancy was high and somewhat stronger for the womenThe Pearson’s product-moment correlation coefficient (r) quan-
with a short (1–2 calendar years) lag between pregnancies thantifies the degree of correlation between measurements.
for women with a long (4–5 calendar years) lag (figure 1C,
Results D). Storage time per se did not appear to affect antibody level
variability, since the correlation coefficients between serialOn the basis of the OD values of the 387 positive sera (23%)
among the first pregnancy samples, 4 quartile groups with an sample measurements were similar for women with their first
Table 1. Tracking of HPV serum antibody levels between pregnancies, in comparison with tracking of HPV antibody levels between repeat
analyses of same serum sample.
Mean { SD Mean { SD Predictive Predictive k coefficient
antibody antibody value k coefficient value between between
No. of level of 1st level of 2nd between between repeat repeat
Antibody level women pregnancy pregnancy 1st & 2nd 1st & 2nd measurements measurements
categories in sample sample pregnancy pregnancy of same of same
(dOD value limits*) category (dOD 1 1000) (dOD 1 1000) sample (%) sample sample† (%) sample
Seronegative, 0–0.051 1169 11.56 { 13.33 26.15 { 70.25 91 .69 89 .86
Indeterminate, 0.052–
0.099 100 70.79 { 14.49 64.43 { 69.33 42 .38 45 .40
1st quartile of positivity,
0.100–0.179 96 140.27 { 24.11 144.13 { 87.5 56 .53 59 .54
2nd quartile of positivity,
0.180–0.299 97 233.61 { 36.97 236.95 { 108.88 47 .44 64 .56
3rd quartile of positivity,
0.300–0.476 97 387.48 { 52.55 358.77 { 133.23 48.5 .45 59 .50
4th quartile of positivity,
0.477–1.208 97 640.29 { 149.30 588.17 { 208.27 67 .65 88 .84
NOTE. dOD, difference in optical density.
* dOD value limits were defined by first pregnancy/first measurement results. Same limits were used to categorize second pregnancy/second measurement
results.
† Based on only 90, 35, 53, 84, 81, and 126 samples in each group, respectively.
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pregnancy during 1983–1984 (r  .875, all women) and for els between first and second pregnancy was also calculated
excluding the seroconverting women (figure 1C, D). The corre-women with their first pregnancy during 1990–1991 (r  .858,
all women) (not shown). lation coefficients were substantially increased and became
comparable to the correlation coefficients found for repeat mea-The population of women who moved from absolutely sero-
negative at first pregnancy to clearly positive at second preg- surements of the same sample (figure 1E).
The rate of seroconversions between the two pregnanciesnancy (seroconverters) is seen in figure 1C, D (boxed areas),
whereas a corresponding group of women moving from clearly was strongly associated with age at first pregnancy, increasing
from 1.3% (when mothers are ⁄30 years of age) to 18.8%positive at first pregnancy to negative at second pregnancy is
not seen. Since seroconversions are a biologic phenomenon (among mothers 18 years of age) (unpublished data). That
very young mothers are at risk of sexually transmitted diseasesreflecting new infections, the correlation between antibody lev-
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Figure 1. Tracking of HPV antibody levels in serial samples taken
at successive pregnancies (A, C, D) compared with tracking of HPV
antibody levels of repeat measurements of same serum sample (B,
E). In A and B, movements between antibody level categories (nega-
tive, 0; indeterminate, //0; first through fourth quartiles of positiv-
ity, 1–4; see table 1) based on first pregnancy or first measurement
results are shown as % of subjects or samples originating in specified
category by category classification at second pregnancy (A) or second
measurement of same sample (B). In C and D, correlation between
exact antibody levels (in difference in optical density [dOD] 1 1000)
between women at first and second pregnancy is depicted, depending
on whether women had 1–2 (C) or 4–5 calendar years (D) between
pregnancies. Subjects classified as seroconverters (moving from sero-
negative at first pregnancy to seropositive at second pregnancy) are
represented by symbols inside box along y axis that defines OD limits
of seroconversion. Correlation coefficients in C and D are calculated
both with and without seroconverting women, for comparison with
correlation found for repeat measurements of same sample (E).
is well known in venereology, supporting that seroconversions pregnancy (figure 1A). Since the movements of these women
are a biologic phenomenon reflecting new infections. The oppo- were clearly outliers from the Gaussian distribution of move-
site phenomenon, seroreversion (i.e., moving from positive to ments (figure 1A, B), the possibility of error should be consid-
negative), had no association with age at first pregnancy. Sero- ered. Laboratory error was excluded by multiple repeat analy-
reversions were detected in 1.8% of the samples, but most of ses, but other possibilities of error exist (e.g., sampling of
the seroreversions (90%) originated in the lowest quartile of the wrong woman, wrong entry of serum identity or personal
positivity and 77% of these ‘‘reverting’’ women moved only identification numbers, and incorrect conditions for specimen
to the indeterminate and not to the seronegative category, sug- handling, transportation, or storage).
gesting that a substantial amount of seroreversions are ex-
plained by misclassification (cf. figure 1A and 1B). In contrast,
88% of seroconversions originated in the seronegative group Discussion
and most (74%) of these seroconversions moved to the 3 higher
The field of HPV epidemiology has provided one of thequartiles of positivity.
clearest practical examples of the devastating effect of misclas-Only 2 women moved from the 3rd or 4th quartile group of
positivity at first pregnancy down to seronegativity at second sification in molecular epidemiology, in which essentially simi-
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lar studies using HPV DNA detection assays with different Thus, simultaneous use of measurements based on different
principles, such as HPV serology, HPV DNA measurements,degrees of reliability have obtained opposite conclusions [1,
2]. Variability in biologic stability over time will, unless cor- and behavioral questionnaires, can be used for validation of
measurements against each other and a reliable identificationrected for, cause a systematic underestimation of relative risk
in epidemiologic studies, known as regression dilution bias of subjects with a history of HPV infection.
In summary, the present study has quantified the biologic[13].
The present study has determined the extent of fluctuation variability of HPV antibody levels over time. The stability of
HPV antibody levels over time has important implications forof HPV antibody levels in serial samples from a population-
based cohort of women. The fact that the antibody levels were interpreting seroepidemiologic studies and for understanding
HPV immunobiology.mostly found to be stable suggests that seropositivity reflects
lifetime exposure, which is in line with the fact that seropreva-
lences are strongly associated with lifetime number of sex part-
Referencesners (rather than with recent number of partners) [7] and with
the lack of consistent age association of HPV seroprevalences 1. Schiffman MH. Epidemiology of human papillomaviruses. Dermatol Clin
1995;13:561–74.[11].
2. Franco EL. The sexually transmitted disease model for cervical cancer:In assessing generalizability of the present study, the fact
incoherent epidemiologic findings and the role of misclassification of
that it was done among pregnant women should be considered, human papillomavirus infection. Epidemiology 1991;2:98–106.
since pregnancy can reactivate certain viral infections. There 3. Olsen A, Dillner J, Gjoen K, Sauer T, O¨rstavik I, Magnus P. A population-
based case control study of human papillomavirus type 16 seropositivityis presently no evidence that pregnancy per se may affect HPV
and incident high-grade dysplasia of the uterine cervix. Int J Cancerantibody levels, and both enrollment and follow-up samples
1996;68:415–9.were taken at the same trimester of pregnancy. If pregnancy
4. Andersson-Ellstro¨m A, Dillner J, Hagmar B, et al. Comparison of develop-
per se would have an effect on HPV antibody levels, sampling ment of serum antibodies to HPV16 and HPV33 and acquisition of
of women during a time period when antibody levels are chang- cervical HPV DNA among sexually experienced and virginal young
girls. A longitudinal cohort study. Sex Transm Dis 1996;23:234–8.ing would have resulted in an increased variability of antibody
5. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of humanlevels between samples. The observed consistency of antibody
papillomavirus type 16 capsid antibodies among a cohort of universitylevels argues against major changes in antibody levels during
women. J Infect Dis 1996;174:927–36.
pregnancy. However, the possibility that antibody levels may 6. Chua K, Wiklund F, Lenner P, et al. A prospective cohort study on the
be even more stable in follow-up studies of nonpregnant risk to develop cervical intraepithelial neoplasia among healthy subjects
with serum antibodies to HPV, in comparison with presence of HPVwomen cannot be excluded.
DNA in cervical smears. Int J Cancer 1996;68:54–9.Previous studies of subjects with new HPV infection found
7. Dillner J, Kallings I, Brihmer C, et al. Seropositivity to human papillomavi-that sometimes transient antibody peaks that return to seronega-
rus types 16, 18, or 33 capsids and to Chlamydia trachomatis are mark-
tivity after clearance of viral DNA may be seen [10]. It is ers of sexual behavior. J Infect Dis 1996;173:1394–8.
probable that very short-lived infections or virus exposures that 8. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller
JT. A virus-like particle ELISA detects serum antibodies in a majoritydo not result in infection might not induce a seroconversion to
of women infected with human papillomavirus type 16. J Natl Cancerstable antibody levels, but when a sample of women not se-
Inst 1994;86:494–9.lected because of recent HPV infection is followed, mostly the
9. Wideroff L, Schiffman MH, Nonnenmacher B, et al. Evaluation of serore-
women with sufficiently long-lasting infection to induce stable activity to human papillomavirus type 16 virus-like particles in an inci-
antibody levels are detected. HPV seropositivity is more com- dent case-control study of cervical neoplasia. J Infect Dis 1995;172:
1425–30.mon among women in whom HPV DNA has been detected on
10. Wikstro¨m A, Van Doornum GJJ, Quint WGV, Schiller JT, Dillner J.two occasions [9, 14]. Detection of HPV on two occasions
Identification of human papillomavirus seroconversions. J Gen Virolsome years apart also increases the probability that the HPV
1995;76:529–39.
DNA test was not misclassified and increases the likelihood that 11. Dillner J, Lehtinen M, Bo¨rge T, et al. Prospective seroepidemiological
the demonstration of viral DNA did indeed reflect an infection. study of human papillomavirus infection as risk factor for invasive
cervical cancer. J Natl Cancer Inst 1997;89:1293–9.Similarly, clearly detectable amounts of viral DNA (high virus
12. Heino P, Eklund C, Fredriksson-Shahnazarian V, Goldman S, Schiller JT,load) are more likely to reflect a correctly classified infection.
Dillner J. Association of serum IgG antibodies against human papillo-In comparing the somewhat variable estimates of the sensi-
mavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer
tivity of HPV serology, it is noteworthy that the studies that Inst 1995;87:437–40.
found sensitivities of ⁄50% [4, 5, 7–9] also were those in 13. McMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary
heart disease. Part I, prolonged differences in blood pressure: prospec-which the known attributes of HPV DNA detectability (such
tive observational studies corrected for the regression dilution bias.as dependence on recent partner change) and case-control dif-
Lancet 1990;335:765–74.ferences between healthy women and women with cervical
14. de Gruijl TD, Bontkes HJ, Walboomers JMM, et al. Immunoglobulin G
intraepithelial neoplasia were most clearly seen. As has been responses against human papillomavirus type 16 virus-like particles in
emphasized previously [1], in the absence of differential mis- a prospective nonintervention cohort study of women with cervical
intraepithelial neoplasia. J Natl Cancer Inst 1997;89:630–8.classification, high correlations do imply correct measurements.
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High Prevalence of Antibodies to Human Herpesvirus 8 in Relatives of Patients
with Classic Kaposi’s Sarcoma from Sardinia
Antonio Angeloni, Lee Heston, Stefania Uccini, Departments of Experimental Medicine and Pathology and of Clinical
Medicine, University of Rome ‘‘La Sapienza,’’ and Department ofMaria Caterina Sirianni, Francesca Cottoni,
Dermatology, Catholic University of Rome, Rome, and Department ofMaria Vittoria Masala, Decio Cerimele, Su-Fang Lin,
Dermatology, University of Sassari, Sassari, Italy; Departments of
Ren Sun, Michael Rigsby, Alberto Faggioni, Pediatrics, Epidemiology and Public Health, Molecular Biophysics and
and George Miller Biochemistry, and Internal Medicine, Yale University School of
Medicine, New Haven, and Department of Veterans Affairs, Connecticut
Healthcare System, West Haven, Connecticut
A survey for antibodies to a recombinant small viral capsid antigen (sVCA) of human herpesvirus
type 8 (HHV-8) was conducted in Sardinia, one of the world’s highest incidence areas for classic
Kaposi’s sarcoma (KS). Prevalence of antibodies to HHV-8 sVCA was greatest in patients with KS
(95%), followed by family members (39%) and a Sardinian control population age- and sex-matched
to the relatives (11%). Within families, prevalence of antibodies was about equal among spouses,
children, and siblings of KS patients, a finding that raises the possibilities of intrafamilial person-
to-person or vertical transmission. Antibodies were detected 2–3 times more frequently in males
than in females. The data show that prevalence of antibodies to HHV-8 sVCA correlates with the
distribution of classic KS in a high- incidence area. Clustering of seroprevalence within some families
suggests the presence of familial risk factors for active HHV-8 infection.
Classic Kaposi’s sarcoma (KS) is one of several distinct There is an association between HHV-8 and classic KS.
Viral DNA was detected by polymerase chain reaction (PCR)clinical and epidemiologic variants of the disease. Human im-
munodeficiency virus (HIV)–associated and endemic KS in in 50%–92% of blood mononuclear cells from patients with
KS residing in Sicily, Greece, and Sardinia [7–9]. By contrast,Africa are thought to be transmitted through sexual contact
with an infectious agent. A gammaherpes virus, variably known HHV-8 genomes were found in the blood of zero to 11% of
patients without KS from these areas. Patients with classicas Kaposi’s sarcoma–associated herpesvirus or human herpes-
virus type 8 (HHV-8), is the leading candidate etiologic agent KS from northern Italy were universally seropositive to latent
nuclear antigens found in HHV-8–infected cells, whereas only[1–3]. The pathogenesis of classic KS is likely to be complex.
Classic KS is characterized by a high incidence in certain 4% of healthy blood donors from Milan in northern Italy were
seropositive [10]. Similarly, 94% of patients with classic KSgeographic areas, for example, in specific regions of the Medi-
terranean countries of Greece, Italy, and Turkey, and by a low from Greece were seropositive to a recombinant capsid antigen;
12% of age- and sex-matched controls were seropositive [8].incidence in northern European countries, such as England and
Sweden [4–6]. Geographic clustering could result from as-yet- Overall, these studies indicate a very high rate of active
HHV-8 infection in patients with KS and suggest that activeundefined genetic or environmental factors, including predispo-
sition to exposure to and reactivation of HHV-8. Moreover, infection, as detected by the presence of serum antibodies or
viral DNA in the blood, is present in a minority of healthyclassic KS is a disease of the elderly, with highest incidence
in the sixth to eighth decades of life. This epidemiologic pattern subjects.
One of the highest incidence areas of classic KS in the worldis more consistent with reactivation of a latent virus or possibly
de novo acquisition of an opportunistic infection as the result is the northern region of the island Sardinia, located in the
Mediterranean Sea west of the Italian mainland. In the periodof waning immunocompetence.
1977–1991, the annual incidence of KS in Sardinia was 2.4
per 105 population in men and 0.8 per 105 population in women
[4]. The 3-fold higher incidence of KS in men than in women
Received 16 July 1997; revised 23 December 1997.
is found in other regions with increased frequency of classicPresented in part: Second International Conference on Human Herpesvirus
KS as well as in regions with sporadic KS [11]. The incidence6, 7 and 8, Pisa, Italy, 8–11 May 1997.
Informed consent was obtained from all patients. in Sardinia is at least 10-fold higher than in northern Europe
Grant support: NIH (CA-70036 to G.M.); Associazione Italiana per la Ric-
[11] and thus affords a unique opportunity to investigate theerca sul Cancro (AIRC); Ministero della Sanita´, Progetto AIDS (to A.F.).
epidemiology of classic KS and to explore its relationship withReprints or correspondence: Dr. George Miller, Dept. of Pediatrics, Yale
University School of Medicine, Room 420 LSOG, 333 Cedar St., New Haven, HHV-8. We have focused on families of patients with KS since
CT 06520 (george miller@qm.yale.edu).
such studies might shed light on the mode of transmission and
The Journal of Infectious Diseases 1998;177:1715–8 other risk factors. In a previous study, we found that HHV-8
q 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0038$02.00 DNA could be detected in peripheral blood mononuclear cells
/ 9d46$$ju46 05-11-98 10:41:02 jinfa UC: J Infect
1716 Concise Communications JID 1998;177 (June)
been described previously, but the correlation with the serostatus(PBMC) of Sardinian KS patients, whereas their relatives were
of the persons was unknown [9]. An additional 33 samples fromHHV-8–negative by this PCR assay [9]. We have now used
controls were studied.sensitive and specific immunoblotting assays for antibodies to
a recombinant small viral capsid component of HHV-8, as well
as PCR, to determine the prevalence of infection in Sardinian
patients with classic KS, in relatives, and in a control popula- Results
tion from Sardinia that was age- and sex-matched to the rela-
tives. Seroprevalence of HHV-8 sVCA in Sardinian patients with
classic KS. Twenty patients with classic KS were studied,
including 17 males and 3 females. The mean age of the KS
patients was 72.3 { 10.6 years. Nineteen of the KS patientsMaterials and Methods
(95%) were seropositive. The 1 seronegative subject was a 68-
Study population. Serum was collected in 1996 from 20 pa- year-old man who also had Castleman’s disease. The presence
tients with classic Kaposi’s sarcoma, 17 males and 3 females, of antibodies to KS was very strongly associated with clinical
seen at the Department of Dermatology, University of Sassari. KS KS, whether comparing the KS patients with their relatives (P
patients had a 5- to 10-year history of disease localized only to  .001) or with controls (P  .001).
the skin. The majority lived in rural areas and worked as farmers or
Seroprevalence to HHV-8 sVCA among relatives of patientsshepherds. Sera were obtained from 36 of their relatives, including
with classic KS. Seroreactivity to HHV-8 was significantlyspouses, children, and siblings, all of them living in Sardinia. The
more prevalent among the relatives of KS patients (39% sero-couples lived together for an average of 30 years, and the children
positive) than among the controls (11% seropositive; OR, 5.2;lived with the family for 25 years. Control subjects were 51
healthy persons and 40 patients with other diseases recruited in 95% CI, 1.8–14.8). A demographic comparison of the relatives
Sardinia for comparison with the relatives of KS patients. Target of KS patients with the Sardinian controls (table 1) showed
numbers for control subjects in various age and sex strata were that the 2 groups were well matched in sex and age distribution.
calculated to match the characteristics of the relatives and to pro- The higher seroprevalence among relatives was true for both
vide 2 controls for each subject. Target numbers for recruitment men and women, although the association between seroreactiv-
of control subjects were exceeded in several strata, particularly ity and being the relative of a KS patient was stronger for
among elderly female controls. However, to avoid potential bias,
women than for men. The relatives of KS patients included
all samples collected were included in the analysis.
spouses, children, and siblings (table 2). Among relatives, theData collection and analysis. Clinical and demographic data
high rate of seroprevalence, which varied between 33% andwere recorded on standardized forms that were linked to the serum
43%, was similar for spouses of an affected family member,samples by numeric code. KS patients, their relatives, and controls
for children, and for siblings (table 2). There was no significantwere compared using Student’s t test for age, and x2 or Fisher’s
exact test for comparison of other characteristics. Odds ratios difference between seroprevalence in spouses compared with
(ORs) were calculated with Cornfield 95% confidence intervals other relatives. Furthermore, the association between seroreac-
(CIs). Means are expressed {SD. Statistical calculations were per- tivity and being a relative of a KS patient remained significant
formed with Epi Info software (USD, Stone Mountain, GA). when only nonspousal relatives were considered (P  .007;
Serologic assays. All serologic assays were performed and OR, 4.63; 95% CI, 1.37–15.75).
interpreted while the serum samples remained coded. The sera Closer analysis of the 17 families of patients with KS
were tested by an immunoblot assay for antibodies to purified
provided evidence for clustering of the serologic response
recombinant HHV-8 capsid antigen protein, designated sVCA, ex-
within families. Family members other than the index casepressed in Escherichia coli [12]. Extensive studies have shown
were seropositive in 9 of the 17 families. In these 9 families,that human and rabbit antibodies to HHV-8 sVCA do not cross-
14 (61%) of 23 relatives were seropositive. In 1 family, therereact with its EBV homologue [12]. sVCA was cloned in pET30b
were 4 seropositive family members, including 2 children(Novagen, Madison, WI), expressed in E. coli strain BL21 (DE3)-
pLysS, and purified on a nickel column. Comparable fractions of and 2 siblings. In another family, there were 6 seronegative
a column containing E. coli extract transformed with the pET30 members, including 3 children and 3 siblings. Thus, the sero-
vector without an insert served as a negative control. Each lane logic response among family members did not seem to be
of a 12% polyacrylamide gel was loaded with 8 ng of antigen. randomly distributed. Additional evidence for clustering was
The gels were blotted and incubated with sera that had been heated the concordance between the serostatus of wives of affected
at 567C for 30 min and diluted 1:100 in 5% skim milk. Immunore- patients and their children. In 2 families, both the mother
activity was detected by addition of 1 mCi of 125I-labeled protein
and child were seropositive; in 5 families, the mother and
A. The blots were exposed to XAR film for 48 h. The presence
her children were seronegative. Thus, among all 7 familiesof a band at 29 kDa in the sVCA lane and its absence in the
in which sera from mothers and children were available,control lane defined a positive reaction.
there was no example of a healthy seropositive mother withPCR assays for HHV-8 DNA. PBMC samples were assayed
seronegative children or of a seronegative mother with sero-for HHV-8 sequences by a nested PCR technique [9]. Results of
PCR analysis of samples from 10 patients and 11 relatives have positive children.
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Table 1. Demographic characteristics and seroprevalence to HHV-8 recombinant small viral capsid
antigen in Sardinia.
Kaposi’s
sarcoma Relatives Controls P*
n 20 36 91
Male 17 (85%) 9 (25%) 21 (23%) NS
Female 3 (15%) 27 (75%) 70 (77%) NS
Mean age ({SD) 72.3 (10.6) 53.9 (17.4) 57.9 (18.1) NS
Male 72.9 (11.3) 55.3 (17.8) 67.3 (14.1) NS
Female 73.7 (11.0) 53.4 (17.6) 55.1 (18.3) NS
HHV-8 seropositive 73.2 (11.2) 60.2 (18.5) 60.2 (16.9) NS
HHV-8 seropositive 19 (95%) 14 (39%) 10 (11%) 0.0003†
Male 16 (94%) 6 (67%) 5 (24%) 0.04
Female 3 (100%) 8 (30%) 4 (7%) 0.007
* Relatives vs. controls.
† Odds ratio  5.15; 95% confidence interval  1.82–14.81.
Effect of age and sex on seroprevalence. Since patients Discussion
with KS were nearly universally seropositive, the effect of
This preliminary exploration indicates that the seropreva-age and sex on seroprevalence could only be considered in
lence of HHV-8 infection in Sardinia mirrors the epidemiologythe relatives and control population from Sardinia. Among
of classic KS in several notable respects. The study demon-relatives, the median age of those who were seropositive
strates, using both serology and detection of viral DNA, thewas 61 years, and that of those who were seronegative was
nearly invariable association of HHV-8 infection and classic49.4 years; among the control subjects from Sardinia, the
KS in Sardinia. Relatives of patients with KS and the controlmedian age of those who were seropositive was 60.2 years,
population from Sardinia, a place of high incidence of classicand that of those who were seronegative was 57.6 years.
KS, have a higher prevalence of antibodies to HHV-8 thanAlthough seropositive individuals tended to be slightly older
does a population from central Italy, which is not a high inci-than seronegative individuals, these differences were not sta-
dence area for KS. We failed to detect any seropositive personstistically significant. In both the relatives and the controls,
among 40 control subjects from Rome who were age- andmales were two to three times more frequently seropositive
sex-matched to the Sardinian relatives (data not shown). Thethan females. This difference was not statistically significant
prevalence of antibodies among relatives and healthy personsamong the relatives but was of borderline significance among
from Sardinia is 2- to 3-fold higher among males than amongthe controls (P  .05).
females, similar to the male-to-female ratio of 3:1 in the inci-PCR detection of HHV-8 in PBMC. As previously re-
dence of classic KS prior to the AIDS epidemic [11]. Amongported, a PCR signal for HHV-8 was detected in PBMC from
Sardinians, antibody to HHV-8, like KS, tends to be detectedpatients with KS [9]. All 10 samples from KS patients were
more frequently with increasing age, thus correlating with thepositive by PCR, including 1 from the patient who was sero-
higher incidence of classic KS in the elderly. However, a morenegative. Among 11 relatives studied, none was positive by
detailed survey of age-specific prevalence of HHV-8 antibodiesPCR, including 5 who were seropositive. None of the 33
in the general population is needed before firm conclusions cancontrol samples from Sardinia was positive by PCR; this
be drawn.group included samples from 6 persons who were seroposi-
A trend that emerges from this and other seroepidemiologictive. Thus, among relatives or control subjects, antibody
investigations is that there are three distinct patterns ofscreening was a more sensitive indicator of HHV-8 infection
HHV-8 seroprevalence among different patient groups withinthan was PCR-based detection of the viral genome in PBMC.
the same geographic region. Among patients with HIV-associ-
ated or classic KS, antibodies to HHV-8 are nearly invariant
Table 2. Seroprevalence to HHV-8 recombinant small viral capsid ([3, 12], this study). In a second, high-risk group, such as
antigen among relatives of patients with classic KS. HIV-1–infected patients without KS, or in this study, relatives
of patients with classic KS, the prevalence of antibodies isMale Female Total %
intermediate, from 20% to 40%. In the third group, the general
Spouse 1/1 5/13 6/14 43 population, seroprevalence is lower than in the high-risk group.
Child 3/5 2/10 5/15 33 However, the rate of seroprevalence in the general population
Sibling 2/3 1/4 3/7 43 varies dramatically within geographic regions; furthermore,
Total 6/9 8/27 14/36 39
this seroprevalence rate appears to correlate with the incidence
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2. Gao S, Kingsley L, Hoover D, et al. Seroconversion to antibodies againstof the disease KS. In North America, northern Italy, and the
Kaposi’s sarcoma–associated herpesvirus—related latent nuclear anti-United Kingdom, where KS is infrequent, seroprevalence is
gens before the development of Kaposi’s sarcoma. N Engl J Med 1996;
low, ranging from 1% to 5% [2, 8]. However, in Uganda, where 335:233–41.
KS is endemic, the prevalence of infection is 50%–60% in the 3. Kedes D, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The
seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma–associ-general population [8, 10]. Places such as Greece and Sardinia,
ated herpesvirus): distribution of infection in KS risk groups and evi-which are foci of classic KS, appear to have an intermediate
dence for sexual transmission. Nat Med 1996;2:918–24.HHV-8 seroprevalence of12% in the general population ([8],
4. Cottoni F, De Marco R, Montesu MA. Classical Kaposi’s sarcoma in
this study). North-east Sardinia: an overview from 1977 to 1991. Br J Cancer 1996;
No previous studies have examined the serologic response 73:1132–3.
5. Grulich AE, Beral V, Swerdlow AJ. Kaposi’s sarcoma in England andof family members of patients with classic KS. Our study
Wales before the AIDS epidemic. Br J Cancer 1992;66:1135–7.shows that there is a high seroprevalence of antibodies to
6. Dictor M, Attewell R. Epidemiology of Kaposi’s sarcoma in Sweden priorHHV-8 among family members, 3-fold higher than in an
to acquired immunodeficiency syndrome. Int J Cancer 1988;42:
age- and sex-matched Sardinian control group. The existence of 346–51.
a familial risk factor is suggested by clustering of seropositive 7. Viviano E, Vitale F, Ajello F, et al. Human herpesvirus type 8 DNA
sequences in biological samples of HIV-positive and negative individu-persons within certain families. Since this higher rate extends
als in Sicily. AIDS 1997;11:607–12.to children and siblings as well as spouses, it is possible that
8. Simpson G, Schulz T, Whitby D, et al. Prevalence of Kaposi’s sarcomathere is vertical transmission or nonsexual person-to-person
associated herpesvirus infection measured by antibodies to recombinant
spread within families. The recent description of salivary shed- capsid protein and latent immunofluorescence antigen. Lancet 1996;
ding of HHV-8 provides a possible mode of intrafamilial trans- 349:1133–8.
9. Uccini S, Pilozzi E, Stoppacciaro A, et al. Kaposi’s sarcoma–associatedmission [14]. There may also be familial protective factors
herpesvirus/human herpesvirus 8 (KSHV/HHV8) is not detectable insince lack of seroreactivity in the mother was associated with
peripheral blood mononuclear cells of the relatives of sporadic KSseronegativity in the children in 5 families. The nature of the
patients. J Invest Dermat 1997;108:119–20.
factors that predispose to familial clustering of HHV-8 infec- 10. Gao S, Kingsley L, Li M, et al. KSHV antibodies among Americans,
tion is not known; they may relate to viral strain, propensity Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med
1996;2:925–8.for viral reactivation, or immune response to the virus. Some
11. Franceschi S, Geddes M. Epidemiology of classic Kaposi’s sarcoma, withof these factors appear to be exportable: In places of low KS
special reference to Mediterranean population. Tumori 1995;81:
incidence, such as the United States and northern Europe, clas-
308–14.
sic KS and posttransplant KS tend to occur in individuals of 12. Lin S, Sun R, Heston L, et al. Identification, expression, and immunogenic-
Mediterranean ancestry [15]. Familial clustering of HHV-8 in- ity of Kaposi’s sarcoma–associated herpesvirus-encoded small viral
capsid antigen. J Virol 1997;71:3069–76.fection may also account for the occasional occurrence of KS
13. Boshoff C, Whitby D, Hatzlionnou T, et al. Kaposi’s sarcoma associatedin families, usually in male siblings [16]. However, since
herpesvirus in HIV-negative Kaposi’s sarcoma. Lancet 1995;345:
HHV-8 infection is relatively common in the families of pa- 1043–4.
tients with classic KS in Sardinia, but familial classic KS itself 14. Koelle DM, Huang ML, Chandra B, Vieira J, Piepkorn M, Corey, L.
Frequent detection of Kaposi’s sarcoma–associated herpesvirus (humanis relatively rare, events in addition to HHV-8 infection must
herpesvirus 8) DNA in saliva of human immunodeficiency virus–in-be needed for development of classic KS.
fected men: clinical and immunologic correlates. J Infect Dis 1997;176:
94–102.
15. Brunson ME, Balakrishnan K, Penn I. HLA and Kaposi’s sarcoma in solid
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GB Virus C Infection in Patients with Primary Antibody Deficiency
A. Morris, A. D. B. Webster, D. Brown, T. J. Harrison, Department of Clinical Immunology, Medical Research Council
Immunodeficiency Clinic, Royal Free Hospital, and Department ofand G. Dusheiko
Medicine, Royal Free Hospital and School of Medicine, London, United
Kingdom
Sera from 77 patients with common variable immunodeficiency (CVID) were tested for GB virus
C (GBV-C) RNA, because they are prone to unexplained chronic hepatitis, and from 28 patients
with X-linked agammaglobulinemia (XLA) who have a similar primary antibody deficiency but are
not prone to hepatitis. Eight CVID and 8 XLA patients were positive; 6 positive CVID and 3 XLA
patients had abnormal liver enzymes, explained in 3 by either hepatitis B or C virus infection. Most
patients tested had antibodies to the E2 antigen of GBV-C, apparently passively acquired from
their immunoglobulin therapy. The high prevalence of GBV-C viremia in CVID and XLA patients
is probably explained by their long-term exposure to blood products. Our data indicate that GBV-
C does not cause chronic hepatitis in immunocompromised XLA patients and is not the cause of
chronic non-B or -C hepatitis in the majority of CVID patients.
There have been six reported clusters of hepatitis C virus GBV-C infection, using a polymerase chain reaction (PCR)
technique to identify viral RNA. Serum was also screened(HCV) infection in patients with primary immunodeficiency
since 1982. Five of these have been related to HCV contamina- from patients with X-linked agammaglobulinemia (XLA), a
disease that is caused by genetic mutations in the btk genetion of batches of pooled immunoglobulin used in their therapy
[1]. Recently, Quinti et al. in Italy [2] reported a high preva- expressed in B lymphocytes and in which non-A, -B, and
-C hepatitis is very rare [8].lence of HCV infection in patients with common variable im-
munodeficiency (CVID) that could not be linked to contami-
nated immunoglobulin. Although a subsequent study in the
Patients and Methods
United Kingdom [3] found no evidence of unexplained HCV
infection in similar patients, the Italian experience raises the Seventy-seven CVID patients (36 female) were studied; the
mean age was 46 years (range, 19–83), and the mean time fromquestion of whether HCV or related flaviviruses might be im-
diagnosis was 15 years. The diagnosis was based on the Worldportant in the pathogenesis of CVID, which is thought to be a
Health Organization criteria [9]. Sera from 28 XLA patients, diag-polygenic disorder of immune regulation, possibly triggered
nosed by early onset of infection and very low or absent circulatingby viral infection [4]. Other viruses that are spread by the
B lymphocytes, were also screened; XLA was confirmed by geno-parenteral route have recently been cloned and designated as
typing in 18 patients. The mean age was 30 years (range, 2–45),
GB virus C (GBV-C) [5] and hepatitis G virus (HGV) [6];
and the mean time from diagnosis was 25 years. All patients were
these are now known to be different isolates of the same virus. being followed up in the Medical Research Council Immunodefi-
Both are known to be transmitted by blood transfusion, and ciency Clinic, Royal Free Hospital, London. Sera were collected
one estimate puts the prevalence of viremia in the blood donor during the period from mid-1995 to the end of 1996, except from
population at 1% [7]. 7 patients (5 CVID, 2 XLA) who had died or left the UK; those
samples had been stored for up to 20 years at 0707C. Serum wasHepatitis, sometimes leading to cirrhosis, occurs in about
separated from blood within 6 h and stored at 0207C or 0707C10% of CVID patients in the United Kingdom [4]. Liver
until tested.biopsy usually shows various degrees of periportal lympho-
Reverse transcription (RT)-PCR for GBV-C RNA. Sera fromcytic infiltration, sometimes associated with scattered granu-
83 patients were tested as follows: GBV-C RNA was detectedlomas. Some patients may have splenomegaly with multiple
using an automated procedure (LCx GBV-C assay; Abbott Diag-granulomas in the spleen and adjacent lymph nodes. We
nostics, North Chicago) according to the manufacturer’s instruc-
have screened sera from a large group of CVID patients for
tions. Briefly, RT-PCR was used to generate amplified products
from viral RNA in the clinical samples using a primer-probe
set specific for the 5*UTR of the genome. An antisense oligonu-
cleotide acts as the primer for cDNA synthesis and for the PCR
reaction with a second (sense) oligonucleotide, the rTth poly-Received 8 September 1997; revised 29 December 1997.
Local ethical committee permission was granted for this study (no. 57/94). merase catalyzing both reactions. A third oligonucleotide, which
Correspondence: Dr. A. D. B. Webster, MRC Immunodeficiency Research is complementary to one of the strands of the PCR product, acts
Group, Dept. of Clinical Immunology, Royal Free Hospital School of Medicine,
as a probe, allowing capture of the product and subsequentRowland Hill St., London NW3 2PF, UK (dwebster@rfhsm.ac.uk).
detection via a hapten that is bound to the PCR primers (and
The Journal of Infectious Diseases 1998;177:1719–22
products) and is recognized by an antibody conjugated to alka-q 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0039$02.00 line phosphatase. Sera from the remaining 22 patients were
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tested by either an in-house nested PCR based on the method Results
described by Jarvis et al. [7] and/or that described by Linnen
et al. [6]. The former method was compared with the LCx assay Eight of 77 CVID and 8 of 28 XLA patients were positive for
for 102 selected sera from patients with a variety of liver dis- GBV-C RNA. Five positive sera were double-checked either by
eases, of which 51 were known to be positive in the LCx assay. confirming positivity on a separate serum sample using a differ-
There was 95% concurrence between these two assays. ent PCR assay or by sequencing the PCR products to confirm
GBV-C E2 antibody immunoassay. The primary assay was a their viral origin. Table 1 shows details of the CVID and XLA
direct binding assay in which an E2-coated polystyrene bead reacts patients who were positive for GBV-C RNA. Three of the 8
with anti-E2 antibodies present in human samples, followed by
positive XLA patients had consistently abnormal liver function
the addition of horseradish peroxidase (HRPO)–goat anti-human
tests, which were explained in 2 by either chronic HBV orIgG. To confirm the primary result, a sandwich assay was devel-
HCV infection. In the 8 CVID patients who were positive, 6oped, in which an E2 coated bead reacts with anti-E2 antibodies
had abnormal liver function tests, explained in 1 by chronicin the sample, followed by addition of biotinylated E2 and then
HCV infection.anti-biotin antibody conjugated to HRPO [10]. Sera were screened
GBV-C infection was associated with symptomatic chronicfor hepatitis B virus (HBV) surface antigen by a routine method
and for HCV RNA as previously described [3]. inflammatory bowel disease in 4 CVID patients and 2 XLA
Table 1. Features of GBV-C–positive patients.
Recent liver
enzymesAge when
Diagnosis, Current Age at ALT/ALP Liver Blood
case no. age, y diagnosis, y first raised, y ALT ALP biopsy products Other unusual features
Common variable immunodeficiency
1 20 5 5 n // 5 y: periportal a,c Presented at 5 y with hepatosplenomegaly,
lymphocytic lung granulomas, and lymphadenopathy;
inflammation, 20 y: splenectomy, granulomas in
granulomas spleen
2 48 29 46 / n ND a,b,c Mild inflammatory bowel disease with
normal jejunal villi
3 39 15 — / / ND a,c Partial villous atrophy in jejunum,
response to gluten-free diet; HCV-
positive from contaminated IVIG
4 56 40 45 / / Granulomas in a,b,c Previous mycoplasma arthritis
parenchyma (1987)
5 74 41 — n n ND a,c
6 44 32 41 / / ND a,c Severe chronic inflammatory bowel
disease, alopecia
7 36 35 — n n ND c Steroid responsive thrombocytopenic
purpura
8 52 16 12 / /// 19 y: few lymphocytes a,b,c 12 y: hepatosplenomegaly; 19 y:
in some portal splenectomy, lymphadenopathy, chronic
tracts; 23 y: small inflammatory bowel disease; 50 y:





9 27 1 n n — a,b,c Nil
10 35 1 n n — a,b,c Nil
11 38 2 31 / / Early cirrhosis (1997) b,c Crohn’s-like bowel disease, HBsAg-
positive




13 22 5 — n n — a,b,c Nil
14 26 1 — n n — a,c Chronic mycoplasma joint infections
15 34 8 — n n — a,c Nil
16 32 9 28 n /// ND a,b,c Chronic inflammatory bowel disease with
partial jejunal villous atrophy
NOTE. ALT, alanine aminotransferase (/  40–100); ALP, alkaline phosphatase (/  130–200, //  200, ///  300 IU/L); y, years; n, normal; a, intramuscular
immunoglobulin; b, fresh frozen plasma; c, intravenous immune globulin (IVIG); ND, not done; HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen.
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patients, compared with 9 with bowel disease in the remaining general population, with 10% of CVID and 29% of XLA pa-
69 GBV-C–negative CVID patients and none of the remaining tients in our series being positive. This may not be surprising
26 XLA patients. Overall, 38% of GBV-C–positive patients in view of the substantial amounts of blood products that these
had symptomatic bowel disease, compared with 8% who were patients have received over many years. Furthermore, it is
GBV-C–negative (table 2). There were 26 CVID patients with likely that many of those patients who were diagnosed before
signs of chronic hepatitis who were GBV-C–negative. In 3 of 1980 acquired the infection from regular FFP therapy. This
those 26, this was explained by HCV infection, and 2 of those may explain the particularly high prevalence in XLA patients,
3 developed cirrhosis. However, there were 3 HBV–, since many of them received plasma in the 1970s before IVIG
HCV–, and GBV-C–negative patients who died from cirrhosis. was available. It is also possible that some patients acquired
Most of the patients had been treated since diagnosis of their infection from contaminated IVIG therapy, as a recent report
immunodeficiency with regular immunoglobulin therapy for has shown that some batches from one particular product were
many years at 2-week intervals. All but 1 of the patients who positive for GBV-C when tested by PCR for viral RNA [7];
were GBV-C–positive had received substantial amounts of we found no evidence of this in preparations currently used in
intravenous immune globulin (IVIG) over many years, and our clinic. The high prevalence of GBV-C contrasts with our
many had received fresh frozen plasma (FFP) therapy before previous finding that only 3 of 44 patients, most of whom were
IVIG was introduced into the United Kingdom in 1983. In included in this study, were negative for HCV RNA [3].
general, the XLA patients had had immunoglobulin therapy, The presence of 23 CVID patients in our series with chronic
including FFP, for longer than the CVID patients (mean, 25 hepatitis that could not be explained by HBV, HCV, or
vs. 15 years). GBV-C infection suggests that these patients are prone to an-
Fifty-eight patients (10 XLA, 48 CVID) were tested for other hepatitis virus. Unlike XLA patients, CVID patients have
antibodies to E2, and only 7 were negative; 4 of the negative a functional defect in CD4 T lymphocyte antigenic responses
patients had never received immunoglobulin therapy, 2 were and may be prone to certain viruses [4]. However, many CVID
on low-dose immunoglobulin, and only 1 was on standard IVIG patients also display features of immune dysregulation, such
(200 mg/kg every 2 weeks), in contrast to the remaining 51 as their circulating lymphocytes having the capacity to produce
who were on standard IVIG therapy. Nine patients were both high levels of interferon-g and TNF-a [11]. This, together with
viremic for GBV-C and seropositive for E2; 1 patient who the finding of granulomas in the livers of some of these patients
had not received immunoglobulin treatment was viremic and suggests an inappropriate inflammatory response to chronic
seronegative. infection, GBV-C being one possible candidate.
Six separate batches of IVIG (3 of Sandoglobulin [Novartis, The finding that the majority of patients were negative for
Switzerland] and 3 of Alphaglobin [Alpha Therapeutic, Barce- GBV-C, despite many years of IVIG treatment, shows that if
lona, Spain]) were tested for antibodies to E2 after 2-fold dilu- infection occurs from contaminated IVIG, it is rare. If contami-
tions from 1:5 to 1:100 were made of the 5% or 6% infusion nation of IVIG has occurred over the past 15 years, the small
solutions. All were positive at the 1:5 dilution, with variation number of infected patients could be explained by the virus
in positivity to the higher dilutions between batches, indicating being present as an antibody-virus complex that may neutralize
different levels of antibody in these batches. Six batches each infectivity. Experience with HCV-contaminated IVIG suggests
of Alphaglobin and Sandoglobulin were tested for GBV-C that patients were partially protected from infection when the
RNA with the LCx PCR assay, and all were negative.
immunoglobulin contained specific antibody [12]. This is sup-
ported by our finding that all six batches of IVIG tested con-
Discussion tained some antibody to E2; it is likely that all current commer-
cially available batches of IVIG will contain antibodies to E2,There is clearly a raised prevalence of GBV-C infection in
patients with primary antibody deficiency compared with the as the starting plasma pools for individual batches usually con-
Table 2. Association of gut and liver disease with GBV-C viremia.
GBV-C–positive GBV-C–negative
Total Total no. No. with raised No. with Total No. with raised No. with
tested (%) liver enzymes IBD no. liver enzymes IBD
CVID 77 8 (10) 6 (1 HCV) 4 69 26 (3 HCV) 9
XLA 28 8 (29) 3 (1 HCV) 2 20 4 (3 HCV) 0
(1 HBV)
NOTE. IBD, inflammatory bowel disease; CVID, common variable immunodeficiency; XLA, X-linked agamma-
globulinemia; HCV, hepatitis C virus; HBV, hepatitis B virus.
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GB Virus C/Hepatitis G Virus Infection: A Favorable Prognostic Factor in
Human Immunodeficiency Virus–Infected Patients?
Stefan Heringlake, Johann Ockenga, Hans L. Tillmann, Departments of Gastroenterology and Hepatology and of Clinical
Immunology, Medizinische Hochschule, Hannover, Germany; AbbottChristian Trautwein, Do¨rte Meissner, Matthias Stoll,
Diagnostic Division, Probe and Immunoassay Discovery, AbbottJeffrey Hunt, Cynthia Jou, Natalie Solomon,
Laboratories, Abbott Park, Illinois
Reinhold E. Schmidt, and Michael P. Manns
To investigate a possible influence of GB virus C (GBV-C) in immunocompromised patients, the
prevalences of GBV-C RNA and anti–E2 antibody in 197 human immunodeficiency virus (HIV)–
infected patients and in 120 control blood donors were studied. GBV-C RNA was detected in 33
of 197 HIV-infected patients (16.8%) compared with 1 in 120 blood donors (0.8%) (P  .001).
Previous exposure to GBV-C (anti–E2 antibody–positive) was shown in 56.8% of HIV patients and
in 9% of blood donors. GBV-C viremia was not associated with hepatitis. Despite approximately
equal duration of HIV infection in all subgroups, the CD4 cell counts were significantly higher in
GBV-C–viremic patients (344 cells/mL) compared with exposed (259 cells/mL) and unexposed (170
cells/mL) patients (P  .017 and P  .001). Furthermore, Kaplan-Meier analysis demonstrated
significantly better cumulative survival in GBV-C RNA–positive HIV-infected patients, suggesting
that GBV-C might be a favorable prognostic factor in HIV disease.
The stage of disease was classified according to the revised CentersCoinfection with hepatitis B virus (HBV) or hepatitis C virus
for Disease Control and Prevention (CDC) staging system with(HCV) is a common complication in human immunodeficiency
respect to the European modification of this classification. Onevirus (HIV) infection, having implications on the outcome of
hundred twenty randomly selected blood donors from our bloodaffected patients [1, 2]. Recently, 2 new virus isolates related to
bank served as controls.the flaviviridae family, GB virus C (GBV-C) and hepatitis G virus
Serologic studies for the detection of HIV, HBV, and HCV.
(HGV), were identified in human sera, some from patients with
HIV antibodies were detected using an ELISA (Abbott Labora-
cryptogenic or posttransfusion hepatitis [3, 4]. GBV-C and HGV tories, Abbott Park, IL). Positive ELISA results were confirmed by
are closely related isolates of the same virus, with95% sequence Western blot. All participants were tested for anti–HCV antibodies
homology [5]. Although the new virus was detected in patients (Abbott 2nd generation test), and positive sera were also tested
with various forms of liver disease, its wide distribution among for HCV-RNA by nested PCR of the 5* untranslated region. Virus
markers for HBV infection were evidence of hepatitis B surfacehealthy persons made its clinical significance as a hepatitis agent
antigen and hepatitis B core antibodies (Abbott Laboratories).uncertain [4, 6–8]. However, no data are available, to our knowl-
CD4 lymphocytes were measured by fluorescence-activated celledge, concerning the implication of GBV-C in HIV infection.
analysis (FACScan; Becton Dickinson, Heidelberg, Germany).Therefore, we retrospectively studied the seroprevalences of
Detection of GBV-C RNA. RNA extracted from the equivalentGBV-C RNA and anti–E2 antibodies in HIV-infected patients
of 5 mL of serum was amplified in a single-tube RT-PCR asand correlated the results with the clinical follow-up data of the
previously described [11]. Briefly, cDNA synthesis was performed
patients. The anti–E2 antibody is directed against the envelope at 607C for 30 min using rTth polymerase (Roche Molecular Sys-
2 protein of GBV-C and was recently demonstrated to indicate tems, Branchburg, NJ) and a gene-specific antisense primer, fol-
exposure to the virus. Its appearance is mostly associated with lowed by 35 cycles of amplification in a two-temperature PCR
viral clearance (GBV-C RNA–negative by reverse transcriptase– protocol (947C for 40 s, 637C for 60 s). PCR products were hybrid-
polymerase chain reaction [RT-PCR]) [9, 10]. ized at 157C for 10 min to an internal GBV-C–specific oligonucle-
otide probe. Sequences of sense and antisense primers and the
Patients and Methods hybridization probe were deduced from the 5* untranslated region
of GBV-C [11]. PCR amplicon-probe complexes were specificallyWe enrolled 197 HIV-infected patients who regularly attended
detected by a microparticle capture EIA (Abbott Laboratories).our outpatient clinic between January 1993 and December 1994.
Two dilutions of a GBV-C–positive serum served as a positive
control, and a GBV-C–negative serum served as a negative con-
trol. The specificity of the method was demonstrated by a referenceReceived 28 July 1997; revised 22 December 1997.
PCR and dot-blot hybridization using different primers and a dif-Grant support: Bundesministerium fu¨r Bildung, Wissenschaft, Forschung
und Technologie (01 GB 94 07/2). ferent hybridization probe [11]. The detection limit of the assay
Reprints or correspondence: Prof. M. P. Manns, Dept. of Gastroenterology was 100 molecules of an in vitro transcript per reaction.
and Hepatology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, EIA for the detection of anti–E2 antibodies. All sera were
30625 Hannover, Germany (manns.michael@mh-hannover.de).
investigated by an EIA (Abbott Laboratories) for the presence of
The Journal of Infectious Diseases 1998;177:1723–6 the anti–E2 antibody, which is directed against the E2 part of the
q 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0040$02.00 presumed envelope protein of GBV-C [10].
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Statistical analysis. Categorical variables were analyzed by transferase), albumin, or cholinesterase levels between virus-
positive, exposed, and unexposed patients. On average, viremicthe x2 test. Group means were compared by the Student‘s t test
or the Mann-Whitney U test, if appropriate. Cumulative patient patients were younger than exposed patients (33.9 { 8.8 years
survival was assessed by Kaplan-Meier analysis. Equality of sur- vs. 40 { 10.3 years; P  .006), but they did not significantly
vival distribution was calculated by log-rank test. P  .05 was differ from unexposed patients. However, GBV-C RNA–posi-
considered statistically significant. The Cox proportional-hazard tive patients had significantly higher CD4 cell counts than pa-
regression model was performed to calculate relative risks in a tients without any exposure to GBV-C (344 cells/mL { 189
multivariable model including categories for sex, age (36 years vs. 170 { 211; P  .001) or to anti–E2 antibody–positive
or ⁄36 years), detection of GBV-C RNA (positive or negative), patients who had already cleared the virus (259 cells/mL {
anti–E2 antibody status (positive or negative), HBV status (hepati- 270; P .017). In analyzing subgroups in those GBV-C RNA–
tis B surface antigen–positive or –negative), and HCV status positive patients without HBV or HCV coinfection, higher
(anti–HCV antibody–positive or –negative) [12]. CD4 cell counts were also evident compared with GBV-C
RNA–negative patients of the same subpopulation.
Of 197 HIV-infected patients, 38 (19.3%) were classified as
Results CDC stage I, 81 (41.1%) as CDC stage II, and 78 (39.6%) as
CDC stage III. CDC stage analysis of the 33 GBV-C RNA–Prevalences of hepatitis B and C and GBV-C. Among 197
positive patients revealed the following distribution: 13 CDCHIV-infected patients, 20 (10.2%) were hepatitis B carriers
stage I (39.4%), 19 CDC stage II (57.6%), and 1 CDC stage(HBsAg-positive), and 51 (25.9%) were HCV antibody–posi-
III (3%). In comparison, 40.1% of the exposed patients andtive. HCV RNA was detected in 39 of these 51 HCV antibody–
61.6% of the patients without exposure to GBV-C were diag-positive patients. Three patients (1.5%) were coinfected with
nosed as CDC stage III. Significantly fewer patients had pro-HBV and HCV. GBV-C RNA was detectable in 33 of 197
gressed to CDC stage III in the GBV-C RNA–positive groupHIV-infected patients (16.8%) and in 1 of 120 reference group
(P  .001).blood donors (0.8%; P  .001). Analysis of all sera for the
Total RNA of peripheral blood mononuclear cells (PBMC)presence of the anti–E2 antibody (by EIA) revealed a seroprev-
from 3 viremic patients in the CDC stage I subgroup wasalence of 56.8% (112/197). In comparison, only 11 of 120 (9%)
investigated by strand-specific reverse transcription followedblood donors were positive for the anti–E2 antibody (P 
by RNase H digestion and nested PCR of the 5* untranslated.001). None of the antibody-positive patients had detectable
region. Only positive- (not negative-) strand GBV-C RNA wasGBV-C RNA levels. Only 52 of 197 HIV patients (26.4%) had
detected in all 3 samples.no markers of GBV-C infection. With respect to GBV-C status,
Survival analysis. For this analysis, we calculated the pe-we differentiated viremic (GBV-C RNA–positive), exposed
riod from the first positive HIV test, available for 179 of 197(anti–E2 antibody–positive/GBV-C RNA–negative), and un-
patients, to a cutoff date or death, because the exact date ofexposed (anti–E2 antibody–negative/GBV-C RNA–negative)
HIV seroconversion was not known. Follow-up data for 28HIV-infected patients.
GBV-C RNA–positive patients, 104 anti–E2 antibody–posi-Transmission risk factors for an infection with GBV-C were
tive patients, and 47 patients without exposure to GBV-C re-deduced from the viral prevalence in the HIV risk groups.
vealed that HIV infection was of approximately equal durationIntravenous drug use (51.5%) and homosexuality (39.4%) were
in all groups before serum for the GBV-C test was taken (1530the main risk factors in our patients (table 1).
{ 1403 days, 1490 { 1224 days, and 1302 { 1132 days,Implication of GBV-C viremia and anti–E2 antibody preva-
respectively; difference not significant). Mean survival time inlence. No significant differences were found in means of
aminotransferases (aspartate aminotransferase, alanine amino- the GBV-C RNA–positive group of HIV patients was 4590 {
Table 1. Prevalence of GBV-C RNA and anti–E2 antibody in HIV-infected patients in relation to
risk factors for virus transmission.
All HIV-infected GBV-C RNA–positive Anti–E2 antibody–
patients patients positive patients
Risk factor Frequency % Frequency % Frequency %
Homosexual promiscuity 104 52.8 13 39.4 59 52.7
Intravenous drug use 60 30.5 17 51.5 31 27.7
Heterosexual promiscuity 26 13.2 1 3.0 18 16.1
Hemophilia 7 3.5 2 6.1 4 3.5
Total 197 100 33 100 112 100
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Figure 1. Kaplan-Meier survival analy-
sis of HIV-infected patients relative to
GBV-C status: GBV-C viremia (GBV-C
RNA–positive), exposure to virus (anti–E2
antibody–positive, GBV-C RNA–nega-
tive), and no evidence of GBV-C infection
(anti–E2 antibody–negative, GBV-C
RNA–negative). Nos. of surviving patients
were as follows: 25 (89%) of 28 in the
GBV-C–viremic patients, 71 (68%) of 104
in exposed patients, and 24 (51%) of 47
in unexposed patients. Survival time was
calculated from date of first positive HIV
test (available for 179 patients). HIV infec-
tion was of equal duration in all groups
before serum for GBV-C serology was
taken. Survival difference is statistically
significant; P  .001 (log-rank test).
279 days (95% confidence interval [CI], 4043–5137) compared group corresponds to that of volunteer blood donors reported
by others [4, 7, 8].with 3239 { 143 days (95% CI, 2959–3519) in the anti–E2
antibody–positive group (P  .031, log-rank test) and with Major transmission risk factors for infection with GBV-C
were intravenous drug use and homosexuality. In view of the2591 { 217 days (95% CI, 2165–3017) in the unexposed
patients (P  .001, log-rank test). The Kaplan-Meier survival report by Persico et al. [13], who demonstrated the presence
of GBV-C RNA in cell-free seminal plasma, the high preva-analysis is illustrated in figure 1.
In the absence of detailed information about acquisition of lence of GBV-C RNA in homosexuals in our study is under-
standable.GBV-C infection, we additionally analyzed the mean survival
beginning from the date when serum was taken for analysis of In some studies, HBV and HCV infection were demonstrated
to worsen the clinical course and the outcome of HIV-infectedthe GBV-C status. For these calculations, all 197 HIV-positive
patients could be considered. Twenty-nine (87.9%) of 33 GBV- patients [1, 2]. We found no hepatitis (as measured by increased
transaminases) associated with GBV-C infection in the immu-C RNA–positive patients had survived beyond the cutoff date
compared with 77 (68.8%) of 112 anti–E2 antibody–positive nocompromised patients. Mean levels of transaminases,
slightly above the upper normal range, did not differ betweenpatients and with 29 (55.8%) of 52 patients without exposure to
GBV-C. Mean survival of the GBV-C RNA–positive patients patients with CDC stage I, II, or III of HIV infection, indicating
the same degree of liver damage in all three CDC stages.was 1052 { 42 days (95% CI, 970–1134) versus 930 { 42 days
(95% CI, 847–1013) in the antibody-positive group (P  .041, Of interest, GBV-C–viremic patients had distinctly higher
CD4 cell counts and progressed less frequently to CDC stagelog-rank test) and versus 777 { 67 days (95% CI, 646–909) in
the unexposed group of patients (P  .002, log-rank test). III compared with exposed and unexposed patients. However,
HIV infections were of approximately equal duration in allA Cox proportional-hazard regression model indicated that
GBV-C RNA (hazard ratio, 0.22; P  .007) is an independent subgroups up to the time when samples were taken for GBV-C
serology. Kaplan-Meier analysis indicated significantly betterfactor associated with a relative benefit on survival more dis-
tinctly than the presence of the anti–E2 antibody (hazard ratio, cumulative survival after the first positive HIV test in the GBV-
C–viremic patients (figure 1). Although GBV-C RNA–posi-0.52; P  .017). Age of 36 years as well as HBV infection
were associated with relative risks of death (hazard ratio, 2.68; tive patients were significantly younger than antibody-positive
patients, they were about the same age as the unexposed pa-P  .006 and hazard ratio, 2.26; P  .029, respectively). Gen-
der and HCV antibody status had no prognostic value for the tients. A multivariable Cox regression analysis confirmed that
GBV-C viremia was associated with a relative benefit on sur-patients studied.
vival in the HIV-infected patients independent of other vari-
ables such as age. However, the number of GBV-C RNA–
Discussion
positive HIV-infected patients in our study (n  33) is rela-
tively small, and these results need confirmation in larger stud-We found a significantly increased GBV-C RNA prevalence
in the HIV-infected patients compared with the control group ies. Analyses of sequential samples might help to elucidate
whether GBV-C and HIV are simultaneously acquired byblood donors (16.8% vs. 0.8%). The prevalence in our control
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Cross-Clade Inhibition of Human Immunodeficiency Virus Type 1 Primary
Isolates by Monoclonal Anti-CD4
Michael H. Shearer, Dusti K. Timanus, Department of Microbiology and Immunology, University of Oklahoma
Health Sciences Center, Oklahoma City; Department of VeterinaryPatricia A. Benton, D. Rick Lee, and Ronald C. Kennedy
Sciences, University of Texas M. D. Anderson Cancer Center,
Bastrop, Texas
A murine monoclonal antibody (MAb) with human CD4 specificity was tested for the ability to
inhibit primary human immunodeficiency virus type 1 (HIV-1) isolates clades A through E. Human
peripheral blood mononuclear cells (PBMC) were used as target cells for infectivity. The HIV-1
primary isolates were examined for the capacity to infect PBMC targets in the presence or absence
of the anti-CD4 MAb, designated P1. P1 broadly inhibited clade A, C, D, and E isolates, based on
a reduction of HIV-1 p24 antigen concentrations compared with untreated controls. Little to no
virus-inhibiting activity was observed with a primary HIV-1 clade B isolate, designated BZ167.
Additionally, a second primary clade B isolate was efficiently inhibited from infecting PBMC targets
by P1. The data indicate that P1 exhibits group-specific inhibiting activity against non–clade B
primary HIV-1 isolates in vitro.
Research Center (New York), and the AIDS Research and Refer-Primary isolates from all clades of human immunodeficiency
ence Reagent Program (Rockville, MD). Stocks were expanded invirus type 1 (HIV-1) are relatively resistant to inhibition by serum
fresh human peripheral blood mononuclear cell (PBMC) blasts byantibodies, irrespective of the clade infecting the serum donor [1].
weekly coculture. Briefly, 2 1 106 blasts were washed in salineIn addition, vaccine candidates tested to date have failed to induce
and pelleted. Cell pellets were infected with 200 mL of virus stockantibodies able to inhibit primary HIV-1 isolates across all identi-
for 2 h at 377C with shaking every 15 min. After 2 h, the virus
fied clades [2–4], and inhibition by HIV-1–positive sera both
inoculum was washed away with saline, and the infected cells
within and across clades tends to be highly variable [5, 6]. were resuspended in 2 mL of RPMI/interleukin-2 medium and
HIV infection is initiated by contact between the virus envelope plated into an individual well of a 24-well tissue culture plate. On
glycoprotein, gp120, and the T cell receptor, CD4. Since the initial day 4, 1 mL of the culture was removed and replaced with 1 mL
binding step of all HIV isolates occurs through this gp120/CD4 of fresh medium. On day 7, 1 mL of culture was removed and
interaction, antibodies specific for CD4 might be effective against replaced with 1 mL of 2 1 106 fresh blasts. The following HIV-
multiple HIV-1 isolates. It has been shown that some anti-CD4 1 isolates were used in neutralization assays: UG029 (Uganda)
subtype A, BZ167 (Brazil) subtype B, A284 (Argentina) subtypemonoclonal antibodies (MAbs) bind to CD4 via a site close to that
B, IN905 (India) subtype C, UG001 (Uganda) subtype D, andbinding gp120 and prevent subsequent binding of HIV-1 laboratory
KH005 (Thailand) subtype E. Each of the isolates induces syncytiaisolates to CD4 [7] (reviewed in [8]). In addition, it has been
in PBMC, and the stock titers ranged from 103 to 105 TCID50/mL.shown that HIV-1–infected patients may be treated with anti-
Antigen-capture ELISA. To quantify p24 levels in our experi-CD4 MAb without any apparent deleterious effects [9]. Chimeric
ments, we used a modification of an HIV-1 p24 antigen assaymurine/human anti-CD4 has also been infused into patients in
(Coulter, Miami). Briefly, individual wells of 96-well microtiter
milligram quantities, for weeks at a time, with no significant deple-
plates were coated with 50 mL of MAb anti-p24 (10 mg/mL) diluted
tion of CD4-positive cells and no alteration of the phenotype of in borate-buffered saline (BBS) for 1 h at 377C. The unbound sites
peripheral blood lymphocytes [10]. In this set of experiments, we were blocked by addition of 200 mL of 5% goat serum diluted in
used a murine anti-CD4 MAb, designated P1, to test neutralization BBS (GSBBS) for 30 min at 377C. The wells were then washed
of various HIV-1 primary isolates across clades. five times with BBS containing 0.05% Tween 20 (BBST). Samples
(50 mL) were loaded and incubated for 1 h at 377C and washed
Materials and Methods five times with BBST. The anti-p24 biotin reagent from the kit
was then diluted 1:4 in GSBBS, and 50-mL volumes were addedVirus stocks. HIV-1 primary isolates were obtained from Qual-
to the wells for 1 h at 377C. Unbound material was washed awayity Biologicals (Gaithersburg, MD), the Aaron Diamond AIDS
with five washes with BBST. Finally, 50 mL of a predetermined
dilution of streptavidin–horseradish peroxidase diluted in GSBBS
was added for 30 min at 377C. Unbound streptavidin–horseradishReceived 28 July 1997; revised 14 November 1997.
Grant support: NIH (CA-74101). peroxidase was washed away with BBST, and the assay was devel-
Reprints or correspondence: Dr. Ronald C. Kennedy, Dept. of Microbiology oped by addition of 50 mL of tetramethylbenzidine. The develop-
and Immunology, University of Oklahoma Health Sciences Center, 940 Stanton ment was stopped after 30 min by addition of 20 mL of 1 M HCl,
L. Young Blvd, Oklahoma City, OK 73190 (ronald-kennedy@uokhsc.edu).
and the assay was read at 450 nm in a microplate reader. Each
The Journal of Infectious Diseases 1998;177:1727–9 point was assayed in duplicate, and the linear range of this modifiedq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0041$02.00 HIV-1 p24 assay, based on optical density at 450 nm, was 0.12–
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1.40. This corresponded with an HIV-1 p24 concentration of 10–
600 ng/mL as determined from the linear portion of the standard
curve (data not shown).
TCID50 determination. HIV-1 stocks were serially diluted
(1:10) in saline, and 2 1 106 PBMC blasts were infected for 2 h
at 377C. The virus inoculum was washed away with saline, and
the cells were resuspended in 1 mL of medium. The cells were
then aliquoted into 10 wells of a 96-well tissue culture plate (100
mL/well). On day 4, 100 mL of fresh medium was added, and on
day 7, the wells were tested for p24. The TCID50/mL was deter-
mined by the Reed-Muench method.
Cell viability assay. To evaluate the viability of our PBMC
preparations, we used MTT as an indicator of metabolic activity.
Briefly, samples of cells from our neutralization experiments were
harvested, and 0.1 vol of MTT (5 mg/mL) in RPMI was added
for 4 h at 377C. Converted dye was then solubilized with an equal
volume of 1 M HCl and vigorous pipetting. The assay was mea-
sured spectrophotometrically on an ELISA plate reader at 570 nm.
MAb P1. P1 is a murine MAb generated by the fusion of
SP2/0 myeloma cells with BALB/c immune splenocytes. P1 is an
Figure 1. Kinetics of HIV-1 primary isolate replication in humanIgG1/k, was produced as an ascitic tumor, and was subsequently
PBMC. Antigen-capture ELISA was used to estimate HIV-1 p24purified on protein A–sepharose by standard procedures. P1 has
levels in infected PBMC; 100 (j), 10 (l), and 1 (m) TCID50/mLbeen shown to be identical to Leu-3a in epitope specificity. In
inocula were tested to examine kinetics of viral replication over 10-
addition, P1 varies by only 2 conserved amino acids in the heavy- day period and determine dose for neutralization experiments.
chain variable region and is identical in light-chain variable region
amino sequence to Leu-3a [11].
Neutralization assay. Fresh 3 day–blasted human PBMC, formed similar studies with the other HIV-1 isolates (data not
2 1 106/experiment, were harvested and washed two times in shown) and also found 100 TCID50/mL to be optimal.
saline. Cells were pretreated or not with the anti-CD4 MAb, P1, Effect of P1 on PBMC viability. Before testing for inhibi-
or isotype-matched control MAb and pelleted before infection for
tion, it was necessary to test whether P1 itself had any toxic
2 h at 377C with 200 mL of HIV stock in medium. Infected cells
effect on the PBMC blasts. To evaluate toxicity, we used thewere shaken every 15 min during the 2-h infection, after which
MTT cell viability assay. No significant decrease in viabilitythe PBMC were pelleted, and unadsorbed virus was washed away
was observed in the presence of P1 at 10 and 100 mg/mL (datawith saline. Finally, the infected cells were resuspended in 2 mL
not shown). The results indicate that P1 is not toxic to theof RPMI/interleukin-2 medium and added to individual wells of
24-well tissue culture plates. Cells were fed on days 4, 7, and 10 PBMC blasts that will serve as targets for subsequent infectivity
by removing 1 mL of culture and replacing it with 1 mL of fresh assays.
medium. The level of infectivity was determined on the basis of Inhibition of HIV-1 primary isolates by MAb anti-CD4.
optical density values from the HIV-1 p24 ELISA. Levels of HIV-1 p24 in cultures of human PBMC infected with
representative primary isolates in the presence or absence of
anti-CD4 MAb P1 are shown in table 1. On days 4, 7, and 10,
the clade A isolate was inhibited with 10 mg/mL by 91%,Results
7%, and 0, and with 100 mg/mL by 91%, 100%, and 98%,
respectively. Clade B (BZ167) was inhibited with 10 mg/mLKinetics of viral replication. Before examining the ability
of P1 to inhibit the various primary isolate clades, it was neces- by 54%, 0, and 0, and with 100 mg/mL by 91%, 15%, and
12%, respectively. The clade C isolate was inhibited with 10sary to determine the kinetics of HIV-1 replication in human
PBMC. We infected phytohemagglutinin-blasted PBMC as de- mg/mL by 76%, 97%, and 91%, and with 100 mg/mL by 84%,
95%, and 98%. Similarly, 10 mg/mL decreased clade D byscribed above. Inocula of 1, 10, and 100 TCID50/mL were
tested. Samples were taken at days 4, 7, and 10 and assayed 100%, 93%, and 90%, and 100 mg/mL by 100%, 100%, and
100%, respectively. The clade E isolate was inhibited by 91%,by p24 antigen capture. In figure 1, the kinetics of HIV-1
(UG001) replication are depicted. On the basis of HIV-1 p24 99%, and 98% and by 90%, 98%, and 98% with 10 mg/mL
and 100 mg/mL, respectively. In replicate cultures that con-levels, at 100 TCID50/mL inoculum, virus titers are maximum
and constant from days 4, 7, and 10. At 10 TCID50/mL, tained the same concentrations of a control MAb specific for
hepatitis B surface antigen, inhibition of HIV-1 infectivity wasthe virus titers steadily increase from day 4 to day 10. At 1
TCID50/mL, the titers are not sufficient even at day 10. For 15%. To address the issue regarding the lack of efficient
inhibitory activity against the clade B isolate, we examinedevaluating the inhibitory activity of the anti-CD4, a 100
TCID50/mL inoculum was selected for further studies. We per- a second clade B isolate, along with other primary isolates
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Table 1. Levels of p24 in cultures of human peripheral blood mononuclear cells infected with HIV-1 primary isolates in presence of
monoclonal anti-CD4.
Clade
A B C D E
Days after Anti-CD4
infection (mg/mL) OD % inhibition OD % inhibition OD % inhibition OD % inhibition OD % inhibition
4 0 0.011 0 0.751 0 0.983 0 0.458 0 1.143 0
10 0.001 91 0.344 54 0.233 76 0.001 100 0.106 91
100 0.001 91 0.063 92 0.158 84 0.001 100 0.111 90
7 0 0.332 0 0.913 0 1.149 0 0.727 0 0.980 0
10 0.308 7 0.907 1 0.035 97 0.053 93 0.014 98
100 0.001 100 0.772 15 0.057 95 0.001 100 0.023 98
10 0 0.806 0 0.714 0 1.127 0 1.070 0 0.874 0
10 0.860 0 0.694 0 0.105 91 0.108 90 0.018 98
100 0.014 98 0.627 12 0.027 98 0.001 100 0.014 98
NOTE. Levels of p24 were determined by antigen-capture ELISA. Optical densities (ODs) were determined at 450 nm (means of duplicate determinations).
% inhibition is in comparison to control infected values.
representing the other clades. P1 efficiently inhibited the second B primary isolates. These data suggest that BZ167 may infect
PBMC without the need for a CD4 interaction or may interactclade B isolate (A284), similar to the levels of inhibition ob-
served with the representative clade A, C, D, and E isolates with a CD4 epitope not recognized by P1 and different from
the CD4 epitope used by the other primary isolates of HIV-1.(data not shown).
References
Discussion 1. Mascola JR, Louwagie J, McCutchan FE, et al. Two antigenically distinct
subtypes of HIV-1: viral genotype predicts neutralization serotype. J
In this study, we examined the inhibition potential of an Infect Dis 1994;169:48–54.
2. Hanson CV. Measuring vaccine-induced HIV neutralization: report of aanti-CD4 MAb, P1, on HIV-1 primary isolates. We first deter-
workshop. AIDS Res Hum Retroviruses 1994;10:645–8.mined, in vitro, that P1 did not affect the viability of the PBMC
3. Matthews TJ. Dilemma of neutralization resistance of HIV-1 field isolatespreparations that were used as target cells in the inhibition
and vaccine development. AIDS Res Hum Retroviruses 1994;10:
assay. The inhibition results demonstrate that the anti-CD4 631–2.
MAb, P1, exhibits broad inhibitory activity against HIV-1 clade 4. Cohen J. Jitters jeopardize AIDS vaccine trials. Science 1993;262:
980–1.A, C, D, and E isolates, based on a reduction of HIV-1 p24
5. Dostrikis LG, Bagldades E, Cao Y, Zhand L, Dimitriou D, Ho DD. Geneticantigen concentrations compared with untreated controls and
analysis of human immunodeficiency virus type 1 strains from patientscontrols treated with an irrelevant MAb. Inhibitory concentra-
in Cyprus: identification of a new subtype designated subtype I. J Virol
tions of P1 (100 mg/mL) are well within the range of anti-CD4 1995;69:6122–30.
MAbs that have been infused into patients and maintained for 6. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter- and intraclade
neutralization of human immunodeficiency virus type 1: genetic cladesweeks at a time with no deleterious effects [10]. Interestingly,
do not correspond to neutralization serotypes but partially correspondlittle to no inhibition activity was observed with the primary
to gp120 antigenic serotypes. J Virol 1996;70:427–44.HIV-1 clade B isolate BZ167. This lack of inhibitory activity
7. Attanasio R, Allan JS, Kennedy RC. Monoclonal anti-CD4 as immunopro-
against the BZ167 isolate did not appear to reflect infectious phylactic agents for human immunodeficiency virus infection. J Infect
titer. Other clades that exhibited titers higher than or equivalent Dis 1993;168:515–6.
8. Kieber-Emmons T, Janeson B, Morrow W. The gp120/CD4 interface;to that of BZ167 were efficiently inhibited by P1. If the input
structural, immunological, and pathological considerations. Biochimtiter of BZ167 was reduced to 10 TCID50, P1 was capable of
Biophys Acta 1989;989:281–300.neutralizing infectivity (data not shown). The reasons for the
9. Wilks D, Walker LC, Habeshaw JA, Webster ADB, Dalgleish AG. Antiid-
inability of P1 to effectively inhibit this primary HIV-1 clade iotypic responses to immunization with anti-Leu 3a in human immuno-
B isolate at titers at which other non–clade B isolates are deficiency virus–seropositive individuals. J Infect Dis 1991;163:
389–92.neutralized is unknown. It is possible that BZ167 is not repre-
10. Knox S, Levy R, Hodgkinson S, et al. Observations of the effect ofsentative of other clade B primary isolates. Indeed, a second
chimeric anti-CD4 monoclonal antibody in patients with mycosis fun-clade B primary isolate, designated A284, along with other
goides. Blood 1991;77:20–30.
non–clade B isolates, were inhibited from infecting PBMC by 11. Lohman KL, Attanasio R, Buck DW, et al. Characteristics of murine
P1, similar to the data presented in table 1 (data not shown). monoclonal anti-CD4: epitope recognition, idiotype expression, and
variable region gene sequence. Immunology 1992;149:3247–53.This suggests that BZ167 is not representative of other clade
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Human Immunodeficiency Virus Proviral DNA from Peripheral Blood and
Lymph Nodes Demonstrates Concordant Resistance Mutations to Zidovudine
(Codon 215) and Didanosine (Codon 74)
Douglas Mayers, James Bethel, Mark A. Wainberg, Naval Medical Research Institute and Division of AIDS, National
Institute of Allergy and Infectious Diseases, National Institutes ofOwen Weislow, and Steven Schnittman, for the Division
Health, Bethesda, Maryland; WESTAT, Inc., and SRA Technologies,of AIDS Treatment Research Initiative 003 Study Group
Rockville, Maryland; Walter Reed Army Institute of Research,
Washington, DC; Sir Mortimor B. Davis Jewish General Hospital,
Montreal, Canada
Genotypes that confer drug resistance were evaluated in human immunodeficiency virus (HIV)
proviral DNA obtained from peripheral blood mononuclear cells (PBMC) and lymphoid tissue at
baseline and after 8 weeks of therapy with zidovudine alone or in combination with didanosine from
22 patients (8 zidovudine-naive and 14 zidovudine-experienced). There was evidence of zidovudine
resistance at codon 215 in 27.3% (6/22) of patients. All 20 patients evaluable for codon 74 (site of
didanosine resistance) had virus that remained wild type during the 8-week study period. When
HIV proviral DNA from PBMC was compared with that from lymphoid tissue, 94.7% (18/19) of
evaluable samples were concordant at codon 215 at baseline, while 85.7% (12/14) were concordant
at week 8. Resistance in PBMC (but not in lymphoid tissue) developed in 1 of 8 zidovudine-naive
patients; an increased proportion of resistant strains in PBMC (but not in lymphoid tissue) was
observed in 2 of 14 zidovudine-experienced patients. These results suggest high concordance for
drug resistance mutations in HIV proviral DNA from blood and lymph node tissue.
Drug-resistant human immunodeficiency virus type 1 There are isolated reports comparing viral drug resistance
genotypes in blood with those obtained from tissues from HIV-(HIV-1) isolates have been detected in clinical samples from
patients receiving all of the currently approved antiretroviral infected patients receiving therapy. The relationship of emer-
gence of drug-resistant virus in tissue versus blood has notagents. These isolates are detected in peripheral blood after
variable lengths of time, depending on the host immune status, been carefully evaluated in clinical trials. Discordant genotypes
have been reported for zidovudine-resistant virus in peripheralvirus load, and antiviral potency of the drug or drug combina-
tion used for treatment [1]. For nucleoside antiviral agents, blood and brain tissue samples obtained at autopsy [4]. No
drug resistance data have been presented for sequential samplesdrug-resistant virus is detected first in the plasma viral RNA
or virus isolates cocultured from peripheral blood mononuclear of blood and lymphoid tissue obtained from patients while
receiving antiretroviral therapy. Here we describe the resultscells (PBMC), followed by gradual replacement of the PBMC
proviral DNA with mutant virus [2]. The picture is less clear of genotypic drug resistance analyses of HIV proviral DNA
from PBMC and lymph node samples obtained at baseline andfor HIV protease inhibitors, with one recent report describing
simultaneous detection of drug resistance mutations in the after 8 weeks of randomly assigned antiretroviral therapy.
plasma HIV RNA and proviral DNA from PBMC [3].
Methods
The Division of AIDS Treatment Research Initiative 003 study
Received 15 May 1997; revised 8 December 1997. enrolled 35 HIV-infected persons between June 1992 and March
Human experimentation guidelines of the US Department of Health and
1993, and 32 completed the 8-week study [5, 6]. Sixteen antiret-Human Services were followed in the conduct of this study. The protocol was
roviral-naive patients with CD4 cell counts ⁄350/mm3 were ran-approved by the institutional review boards of each participating site. Informed
consent was obtained from all study participants. domly assigned to either zidovudine at 500 mg/day or no treatment;
The opinions and assertions contained herein are the private views of the the 8 untreated patients were excluded from this analysis. Sixteen
authors and are not to be construed as official or as reflecting the views of the patients with ⁄26 weeks of continuous zidovudine and CD4 cell
Departments of the Army, Navy, or Defense.
counts ⁄250/mm3 were randomly assigned to either continuedFinancial support: NIH (AI-15123), US Army Medical Research and Mate-
zidovudine monotherapy or zidovudine plus didanosine for 8riel Command, and Health Canada. Study medications were provided by the
former Burroughs Wellcome (now Glaxo Wellcome, Research Triangle Park, weeks; of these patients, 2 were excluded from this analysis be-
NC) and Bristol-Myers Squibb (Princeton, NJ). cause of unavailability of samples.
Reprints or correspondence: Dr. Douglas Mayers, 8901 Wisconsin Ave.,
Specimen collection and processing. Mononuclear cells wereP.O. Box 207, Bethesda, MD 20889-5000 (dmayers@pasteur.hjf.org).
obtained from peripheral blood and axillary or cervical lymph
The Journal of Infectious Diseases 1998;177:1730–3
nodes, and pelleted cells were frozen at 0707C until use. Theq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0042$02.00 specimen collection and processing methods and the consistency
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of histopathologic and virus burden measurements in a given indi- Results
vidual’s lymph nodes, regardless of source, have been described
Patients. Samples from 22 study participants were ana-previously [5, 6].
lyzed for this study. Most patients (20/22) were men and hadAnalysis of genotypic resistance in peripheral blood and lymph
male homosexual contact as their HIV risk factor (17/22). Fornode mononuclear cells by differential polymerase chain reaction
the 8 zidovudine-naive and 14 zidovudine-experienced pa-(PCR). Lysates corresponding to 105 cells in 50 mL were mixed
with 30.5 mL of diethyl pyrocarbonate (DEPC) H2O, 5 mL of PCR tients, the mean age was 35 and 37 years, and the mean CD4
101 buffer (Perkin-Elmer Cetus, Norwalk, CT), 5 mL (0.25 mg) of cell count was 655 and 414 cells/mm3, respectively. The zido-
primer A (5*-TTGGTTGCACTTTAAATTTTCCCATTAGTCCTA- vudine-experienced patients had been receiving the drug for an
TT-3*), 5 mL (0.25 mg) of NE1 primer (5*-CCCACTAACTTCTGTA- average of 26.8 months, and the mean baseline phosphorylated
TGTCATTGACAGTCCAGCT-3*), 4 mL of 25 mM MgCl2, and 2.5 zidovudine level in lymphoid tissue cells was 20.8 pmol/106
U of Taq polymerase (Perkin-Elmer Cetus) for the first PCR reaction. cells. The baseline drug resistance analysis included PBMC
The PCR profile is as follows: 947C for 1 min; 30 cycles of 947C
and lymphoid tissue samples from 8 zidovudine-naive patients
for 1 min, 557C for 30 s, and 727C for 2 min; and then 727C for 10
and 13 zidovudine-experienced patients. The week 8 drug resis-min.
tance analysis included PBMC and lymphoid tissue samplesCodon 215 differential PCR [7]. Master mixes for the 215
from 8 patients who were zidovudine-naive at enrollment andmutation and wild type codon were set up as follows: 10 mL of
then received 8 weeks of zidovudine and from 6 patients whomanufacturer’s 101 PCR buffer, 3 mL of 25 mM MgCl2, 10 mL
of dNTPs, and 3 mL of forward primer B (5*-GGATGGAAAGGA- were zidovudine-experienced and then received 8 weeks of
TCACC-3*) and the 215W primer (5*-ATGTTTTTTGTCTGG- zidovudine and didanosine.
TGTGGT-3*) or 215M primer (5*-ATGTTTTTTGTCTGGTGT- Codon 215 (zidovudine resistance) mutations in peripheral
GAA-3*). Next, 10 mL of the diluted A/NE1 first PCR product blood and lymphoid tissues. The majority of samples had
was added to each of the 215 mixes along with 56 mL of H2O and detectable signal. All 35 PBMC samples and 34 of 35 lymphoid
0.5 mL of Taq polymerase. The cycling profile for both reactions tissue samples were evaluable for codon 215 mutations.
was as follows: 947C for 5 min; 20 cycles of 947C for 1 min, 487C
During the 8-week study, 27.3% of the participants (95%
for 30 s, and 727C for 30 s; and then 727C for 10 min. PCR product
CI, 14%–45%) showed some evidence of resistance at codon(10 mL) was analyzed on an agarose gel for presence or absence
215 (table 1). Of the 8 participants who were zidovudine-naiveof the specific product.
at entry, 1 showed resistance at baseline; a second who hadCodon 74 differential PCR [8]. Master mixes for the 74 muta-
wild type virus at entry had virus that had become mixed aftertion and wild type codon were set up as follows: 10 mL of manufac-
turer’s 101 PCR buffer, 3 mL of 25 mM MgCl2, 10 mL of dNTPs, 8 weeks (95% CI, 3%–37%). In the former participant, it is
and 3 mL of forward primer A (5*-TTCCCATTAGTCCTATT-3*) not known whether primary infection was with a drug-resistant
and the 74W primer (5*-AAGTTCTCTGAAATCTACTTA-3*) or virus or if there was unacknowledged prior exposure to zido-
74M primer (5*-AAGTTCTCTGAAATCTACTTC-3*). Next, 10 vudine. In the latter participant, this change was apparent only
mL of the diluted A/NE1 first PCR product was added to each of from PBMC samples, with all tissue samples showing wild
the 74 mixes along with 56 mL of H2O and 0.5 mL of Taq polymer- type virus. Of the 14 participants with prior zidovudine use, 2
ase. The cycling profile for both reactions was as follows: 947C
showed increased resistance (95% CI, 5%–34%). One patient,
for 5 min; 20 cycles of 947C for 1 min, 487C for 30 s, and 727C
whose virus was wild type at entry, had virus that had becomefor 30 s; and then 727C for 10 min. PCR product (10 mL) was
mixed by 8 weeks; another whose virus had been mixed atanalyzed on an agarose gel for the presence or absence of the
entry had resistant virus by 8 weeks. In both patients, thesespecific product.
changes in resistance were evident only from PBMC samples.All mixtures were serially diluted to determine that a mixture
of genotypes was present and to avoid artifact due to template
overload. Previous studies with defined mixtures of wild type and
Table 1. Summary of codon 215 resistance analysis.
mutant virus at codon 215 have shown that differential PCR will
yield a wild type result if 10% of the virus is mutant, while Lymphoid tissue result
mixtures with 10%–60% mutant virus will be classified as mixed
and mixtures with 60% mutant virus will be classified as resis- Blood result Wild type Mixed Resistant
tant.
Phosphorylated zidovudine levels. Phosphorylated zidovudine Baseline*
Wild type 15 1 0levels were measured on lymphoid tissue cell lysates by RIA as
Mixed 0 1 0described previously [9].
Resistant 0 0 2Statistical analysis. Confidence intervals (CIs) and upper
Week 8bounds for patients with resistant virus were computed by use of
Wild type 9 0 0exact methods [10]. Separate logistic regression models were used
Mixed 1 1 0
to evaluate the association between likelihood of developing resis-
Resistant 0 1 2
tance and virus load, prior zidovudine use, and intracellular zido-
vudine phosphorylation. Logistic regression analysis was con- * At baseline, 1 peripheral blood mononuclear cell sample and 2 lymphoid
tissue samples (from 3 different patients) were not available for analysis.ducted by use of the SAS LOGISTIC procedure [11].
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Results of the codon 215 analysis were concordant in 94.7% the pathway using the 151 mutation. All patients who entered the
study had virus that was wild type at codon 74 and remained(18/19 evaluable persons; 95% CI, 82%–99%) of the study
participants at baseline. At week 8, 85.7% (12/14 evaluable wild type during the 8 weeks of combined therapy with zidovudine
and didanosine. The low frequency of new resistance mutationsparticipants; 95% CI, 66%–95%) were concordant. Of the dis-
cordant samples, 1 was wild type in tissue and mixed in blood; seen in this study is most likely due to the short period of follow-
up, although changes at other codons in the reverse transcriptase1 was mixed in tissue and wild type in blood; and 1 was mixed
in tissue and resistant in blood. No samples were wild type in gene might have been detected if the samples had been sequenced.
Previous studies evaluating drug resistance genotypes in pe-one compartment and resistant in the other.
Codon 74 (didanosine resistance) mutation. All 20 evalu- ripheral blood and brain tissue have suggested different popula-
tions of zidovudine-resistant virus in these tissue compartmentsable patients’ virus remained wild type at codon 74 during the
8 weeks of the study (the 95% upper confidence limit for the [4]. This could be related to differential cell tropism by virus
strains or differential drug exposure because of the blood-brainpercentage resistant at codon 74 is 13%).
Parameters associated with zidovudine resistance. There was barrier. In this study, the great majority of sample pairs from
PBMC and lymph node tissue were concordant at codons 74no association between baseline virus load (HIV DNA or RNA),
duration of previous zidovudine exposure, or intracellular phos- and 215, suggesting that similar drug-resistant populations were
present in both compartments. All discordant samples involvedphorylation of zidovudine and the presence of zidovudine-resistant
HIV strains in this small group of patients (data not shown). mixtures of sensitive and resistant virus. Further studies will
be needed to characterize the time course and potential tissue
compartment heterogeneity of drug-resistant HIV-1 in blood,
Discussion
lymphoid tissue, the central nervous system, and semen. These
data suggest that PBMC- and lymph node–associated HIV-1Zidovudine resistance has been associated with the develop-
ment of mutations at codons 41, 67, 70, 215, and 219 for the have comparable drug resistance genotypes in patients treated
with nucleoside antiretroviral agents.HIV reverse transcriptase gene [12, 13]. The codon 215 mutation
is required for development of high-level phenotypic drug resis-
tance, typically in combination with mutations at either codon 41
or 67 and 70. These mutations arise after weeks to months of Acknowledgments
therapy, and high-level drug resistance (zidovudine IC50 1 mM)
We thank the patients who volunteered to participate in thisusually begins to emerge after 6 months of zidovudine monother-
study. Brian Stretcher, University of Cincinnati College of Medi-apy. In this study, 27.3% of study participants had genotypic
cine, provided the measurements of intracellular zidovudine phos-
evidence of zidovudine resistance, with mutations detected at co-
phorylation levels.
don 215. Three patients showed evidence of an increase in the
fraction of mutant virus detected in the HIV proviral DNA during
the 8 weeks of the study. The majority of paired samples were
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Effect of Granulocyte Colony-Stimulating Factor (G-CSF) in Human
Immunodeficiency Virus–Infected Patients: Increase in Numbers of Naive CD4
Cells and CD34 Cells Makes G-CSF a Candidate for Use in Gene Therapy or to
Support Antiretroviral Therapy
Susanne D. Nielsen, Pia Afzelius, Sanne Dam-Larsen, Department of Infectious Diseases, Hvidovre Hospital, Hvidovre, and
Retrovirus Laboratory, Statens Seruminstitut, Copenhagen, DenmarkClaus Nielsen, Jens O. Nielsen, Lars Mathiesen,
and John-Erik S. Hansen
The potential of granulocyte colony-stimulating factor (G-CSF) to mobilize CD4 cells and/or
CD34 cells for use in gene therapy or to support antiretroviral therapy was examined. Ten human
immunodeficiency virus–infected patients were treated with G-CSF (300 mg/day) for 5 days. Num-
bers of CD4 and CD34 cells were measured. To examine the numbers of naive and memory type
CD4 cells, CD4 cell coexpression of CD45RA and CD45RO was measured. Functionality of mobi-
lized CD4 cells was examined by use of the proliferation assay and interleukin-2 ELISA. The number
of CD34 cells increased from 1.50 to 20.01/mL (P  .002). The CD4 cell count increased from 236
to 452/mL (P .002). The CD45RA/CD45RO ratio increased from 0.50 to 0.57 (P  .03). Mobilized
CD4 cells were functionally intact. In conclusion, G-CSF induced increases in numbers of CD34
cells and CD4 cells in HIV-infected patients. Furthermore, the fraction of naive CD4 cells increased.
These findings have implications for the design of immunotherapy or gene therapy protocols.
Granulocyte colony-stimulating factor (G-CSF) is a hemato- (HIV)–infected patients [1–4]. In the present study, we exam-
ined whether G-CSF might be useful in gene therapy or topoietic growth factor that increases the numbers of circulating
hematopoietic progenitor cells (CD34 cells) and CD4-positive support antiretroviral treatment. The G-CSF–induced increase
in numbers of CD34 cells and CD4 cells in HIV-infected pa-T lymphocytes (CD4 cells) in human immunodeficiency virus
tients was examined. CD4 cell coexpression of CD45RA and
CD45RO was used to characterize mobilized CD4 cells as
naive and memory cells, respectively. Furthermore, the func-
tionality of mobilized CD4 cells was examined.Received 29 September 1997; revised 24 November 1997.
The protocol was approved by the local ethical committee (KF 02-194/
96). Informed consent was obtained from all patients after the nature and
consequences of the study had been fully explained.
Patients and MethodsFinancial support: 17-12-1981 Foundation, Fonden til laegevidenskabens
fremme, SSVF, Amgen, the John and Birthe Meyer Foundation, and the Danish
AIDS Foundation. Patients and study design. Ten HIV-infected patients were
Reprints or correspondence: Dr. J.-E. S. Hansen, Laboratory for Infectious included (table 1). The patients received G-CSF (300 mg of filgras-
Diseases, 144, Hvidovre Hospital, 2650 Hvidovre, Denmark (infejesh@inet
tim/day; Amgen, Thousand Oaks, CA) administered subcutane-.uni2.dk).
ously once a day for 5 consecutive days. Baseline variation was
The Journal of Infectious Diseases 1998;177:1733–6
determined with blood samples collected on 4 days before G-CSFq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0043$02.00 treatment (days 06 to 03). To determine the effect of G-CSF
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Table 1. Entry data of 10 HIV-positive patients in study of G-CSF treatment.
Patient Age CD4 cell Virus load
no. Sex (years) count/mL (copies/mL) Clinical symptoms Antiviral treatment
1 M 53 269 1867 VZV D4T, ddI, saquinavir, ritonavir
2 M 53 235 200 HIV wasting 3TC, ddI, indinavir
3 M 48 103 357 Kaposi’s sarcoma 3TC, D4T, indinavir
4 M 50 242 200 VZV AZT, 3TC, indinavir
5 M 30 288 67,308 Esophageal candidiasis AZT, 3TC
6 M 31 246 15,348 Multiple bacterial pneumonias 3TC, D4T, indinavir
7 M 59 323 42,970 Pneumocystis carinii pneumonia AZT, 3TC, saquinavir
8 M 42 300 200 VZV AZT, 3TC, indinavir
9 M 49 237 200 Pulmonary tuberculosis AZT, 3TC, indinavir
10 M 65 115 200 Oral candidiasis AZT, 3TC, indinavir
Mean 48 236 12,885
Range 30–65 103–323 200–67,308
NOTE. VZV, varicella-zoster virus. D4T, stavudine; ddI, didanosine; 3TC, lamivudine; AZT, zidovudine.
treatment, blood samples were collected during G-CSF treatment used to quantitate IL-2 production. The assay was done according
to the instructions of the manufacturer. Results are reported as(days 0–4) and on the following 4 days (days 5–8). Blood col-
lected in tubes containing EDTA was used to obtain a full blood IL-2 production in response to PHA stimulation minus response
to plain culture medium. All results are medians of values fromcell count and for flow cytometry. On days 06, 03, 0, 4, and 8,
additional blood samples were drawn into tubes containing heparin duplicate cultures.
Measurements of virus load. To determine virus load, quanti-to obtain peripheral blood mononuclear cells (PBMC) by means
of density gradient centrifugation. fication of viral RNA in plasma was done with a polymerase chain
reaction quantitative kit (Amplicor Monitor HIV-1 PCR; Roche,Flow cytometry. Flow cytometric analyses were done as de-
scribed [4]. The fluorescence of 5000 cells (lymphocyte subsets) Branchburg, NJ) according to the instructions of the manufacturer.
Plasma was obtained after centrifugation at 400 g for 7 min, har-or 50,000 cells (CD34 and isotype controls) was measured. To
determine the absolute numbers of CD34 cells and lymphocytes vested, and immediately stored at 0707C until use.
Statistical analysis. Data points obtained from multiple experi-in peripheral blood, the percentage of the cells expressing CD34
was multiplied by the white blood cell count, while the percentage ments were reported as means ({SEs). Significance levels were
determined by Student’s t test analysis. For comparisons withinof cells expressing CD3, CD4, and CD8 in a lymphocyte gate was
multiplied by the lymphocyte count. The following combinations the group, we used a paired-sample t test.
of monoclonal antibodies were used to determine phenotypes: iso-
type control; CD3 (Leu-4, SK7), CD4 (Leu-3a, SK3), CD8 (Leu-
Results2a, SK1); CD4 (Leu-3a, SK3), CD45RA (Leu-18, L48), CD45RO
(Leu-45RO, UCHL-1); CD4 (Leu-3a, SK3), CD25 (2A3), CD69 G-CSF effect on the absolute numbers of CD34 and CD4
(Leu-23, L78); CD34 (anti-HPCA-2). All monoclonal antibodies cells. The absolute number of circulating CD34 cells in-
were purchased from Becton Dickinson (San Jose, CA).
creased significantly during G-CSF treatment (figure 1A). On
Proliferation assay. On days 06, 03, 0, 4, and 8, PBMC were
day 0, the mean number of CD34 cells was 1.50/mL ({0.11).used for proliferation assay, done essentially as described [5]. Cell
On day 2, the number of CD34 cells had increased significantlycultures were prepared in microtiter plates (Nunc, Roskilde, Den-
(P  .04), and the mean number of CD34 cells peaked on daymark) containing 51 104 PBMC/well. Culture medium was RPMI
5 after initiation of G-CSF treatment, at 20.01/mL ({0.83, P1640 (Gibco, Paisley, UK) supplemented with 10% heat-inacti-
vated fetal bovine serum (Gibco) and a mixture of penicillin, strep-  .002). By day 8, the number of CD34 cells had almost
tomycin, and gentamicin. To stimulate cultures, 5 mg/mL phyto- returned to baseline (figure 1A). In contrast, there was no sig-
hemagglutinin (PHA; Sigma, St. Louis) was added. In each case, nificant variation in the number of CD34 cells before G-CSF
control experiments without stimulation were done. Results are treatment. The number of CD34 cells increased in all 10 pa-
reported as proliferation response to PHA minus response to plain tients. The increase in number of CD34 cells was partly due
culture medium. All results are medians of values from quadrupli- to an increase in white blood cell count from 5.97 1 109/L
cate cultures.
({0.48) to 24.45 1 109/L ({2.63).
Interleukin-2 (IL-2) ELISA. PBMC were used for IL-2 ELISA.
Before G-CSF treatment, there was only minor variation inBriefly, cell cultures were prepared in microtiter plates (Nunc)
the mean CD4 cell count (from 236 to 279/mL, figure 1B). Oncontaining 105 PBMC/well. To the cultures, 4 mg/mL PHA (Sigma)
day 0, the mean number of CD4 cells was 236/mL ({23). Onwas added. In each case, control experiments without stimulation
day 1, the CD4 cell count had increased significantly (P were done. After 3 days in a cell incubator, the culture supernatants
were harvested. Predicta IL-2 kit (Genzyme, Cambridge, MA) was .02), and the number of CD4 cells peaked on day 3 after
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percentage of CD45RO-positive cells decreased, there was an
increase in the absolute number of both CD45RA- and
CD45RO-positive cells. Thus, on day 0, the mean numbers of
CD4 cells expressing CD45RA and CD45RO were 79 and 155/
mL. On day 4, the mean numbers of CD4 cells expressing
CD45RA and CD45RO were 154 and 267/mL.
No evidence of peripheral proliferation. To evaluate if
CD4 cells were generated by peripheral proliferation, we mea-
sured CD4 cells coexpressing the activation antigens CD69
and CD25. On day 0, 12.4% ({5.5) of CD4 cells expressed
CD69, and on day 4 this fraction was reduced to 9.3% ({5.6)
(P  .04). In contrast, no differences were found between
values for day 0 and day 06, 03, or 8. Furthermore, on day
0 we found that 13.0% ({3.6) of CD4 cells coexpressed CD25.
This fraction was not different from the fractions we found on
any other day.
Functionality of mobilized CD4 cells. The functionality of
CD4 cells was examined by use of a proliferation assay. All
patients responded to PHA, with a mean proliferative response
of 110.7 1 103 cpm on day 0. There were no significant differ-
ences between proliferative responses on day 0 and on any
other day. In addition, the functionality of the CD4 cells was
evaluated by IL-2 production. On day 0, PBMC from 7 patients
produced IL-2 in response to stimulation with PHA (mean, 33
pg/mL [{14]). On day 4, PBMC from 8 patients produced
IL-2 in response to PHA (mean, 81 pg/mL [{59]). However,
no significant differences in IL-2 production in response to
PHA were found. Thus, the CD4 cells mobilized by G-CSF
treatment appear to have normal functionality.
Virus load during G-CSF therapy. Virus load during
Figure 1. Numbers of circulating CD34 cells (A) and CD4 cells
G-CSF treatment was tested by use of HIV RNA polymerase(B) (cells/mL, mean { SE) in 10 HIV-positive men before (days 06
chain reaction. In 6 patients, we detected an increase in copyto 03), during (days 0–4), and after (days 5–8) G-CSF treatment.
number per milliliter, in 3 patients the copy number was 200
on day 0 as well as on day 4, and in 1 patient there was a
decrease in virus load. On day 0, the mean copy number wasinitiation of G-CSF treatment, at 452/mL ({52, P  .002).
Interestingly, although there was a decrease in CD4 cell count 12,885/mL ({7421), and on day 4 it was 16,993 ({11,116).
Thus, we found a minor increase in virus load. This increase,during the rest of the study period, it did not return to baseline
(figure 1B). Thus, the CD4 cell count was 323/mL on day 8 however, was not significant (P  .47).
({38, P  .02). For all 10 patients, we found the CD4 cell
count to increase by at least 100/mL. The increase in CD4 cell
Discussion
count was mainly due to an increase in lymphocyte count from
2.26 1 109/L ({0.38) to 3.28 1 109/L ({0.48). This study demonstrates that G-CSF increases both CD34
and CD4 cells in HIV-infected persons. Furthermore, we foundIncrease in CD45RA/CD45RO ratio. To evaluate the num-
bers of naive and memory-type CD4 cells, we measured CD4 an increase in percentage of naive CD4 cells. These data make
G-CSF a candidate for use in gene therapy or to support antiret-cells coexpressing CD45RA and CD45RO. On day 0, the mean
percentage of CD4 cells expressing CD45RA and CD45RO roviral therapy.
Three events might explain the rise in CD4 cell count:was 31.2% ({3.6) and 68.1% ({3.7), respectively. CD45RA
and CD45RO values on day 4 were 33.4% ({3.9) and 65.8% differentiation of CD34 cells, peripheral proliferation, and
redistribution of CD4 cells from the lymphatics. Studies in({4.2). The increase in percentage of CD45RA cells was sig-
nificant, as was the decrease in CD45RO cells (P  .01). The mice have shown that naive CD4 cells exported from the
thymus express CD45RA. By contrast, memory CD4 cellsmean CD45RA/CD45RO ratio was 0.50 on day 0, and the ratio
increased significantly to 0.57 on day 4 and 0.61 on day 8 (P derived from peripheral proliferation express CD45RO [6].
However, interconversion between CD45RA and CD45RO .03). In contrast, no significant differences were found to
exist between ratios on day 0 and day 06 or 03. Although the has been demonstrated [7], suggesting that isoform expres-
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sion may not reflect a unidirectional maturation from naive cells. These findings have implications for the design of gene
therapy protocols.to memory type cells. Thus, the rise in CD45RA/CD45RO
ratio does support differentiation of CD34 cells but does
not provide definite proof. The rapid increase in CD4 cell
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Apparent Enhancement of Perinatal Transmission of Human Immunodeficiency
Virus Type 1 by High Maternal Anti-gp160 Antibody Titer
Gianfranco Pancino, Thierry Leste-Lasserre, Ge´ne´tique des Virus et Immunopharmacologie Mole´culaire, Institut
Cochin de Ge´ne´tique Mole´culaire, Laboratoire de Virologie and Unite´Marianne Burgard, Dominique Costagliola, Serge Ivanoff,
d’Immunologie-He´matologie Pe´diatrique, Hoˆpital Necker-EnfantsSte´phane Blanche, Christine Rouzioux, and Pierre Sonigo
Malades, B3E INSERM SC4, and Institut Saint-Antoine de Recherches
en Sante´, Universite´ Pierre et Marie Curie, Paris, France
The presence of antibodies able to enhance infection in vitro in sera from human immunodeficiency
virus (HIV)-1–infected patients raises the possibility that antibodies exert a deleterious activity
during natural infection. The anti–HIV-1 humoral response and plasma HIV-1 RNA were measured
in a cohort of 98 infected mothers, included in the French Prospective Study on Pediatric HIV
Infection, 49 of whom transmitted HIV to their children. Transmission from mother to child was
associated with antibody responses to the envelope gp160 (P  .009 for serum dilution of 1/400)
and to a highly conserved domain of the transmembrane glycoprotein (P  .055 for serum dilution
of 1/400) and with plasma HIV-1 RNA levels (P  .0001). Multivariate logistic regression indicated
that a high anti-gp160 response and a high plasma virus load are independent risk factors for
perinatal transmission of HIV-1 (odds ratio, 3.4; 95% confidence interval, 1.1–9.9 for anti-gp160;
odds ratio, 2.8; 95% confidence interval, 1.6–5.0 for virus load).
The role of the humoral immune response in human immuno- against the principal neutralizing domain of the HIV-1 envelope
gp120, the V3 loop, have been correlated with a lower transmis-deficiency virus type 1 (HIV-1) infection, whether protective
or harmful, is a matter of debate. Although neutralizing anti- sion [4–6]. However, such correlations were not confirmed
by other groups [7–9], and two studies pointed out a directbodies are detectable during the chronic phase of infection in
most seropositive persons, antibodies capable of enhancing vi- correlation between antibodies directed to V3 epitopes and
higher perinatal transmission [10, 11].ral infection are also frequently found in sera from HIV-1–
infected persons [1]. Antibody-mediated enhancement of We decided to analyze the anti–HIV-1 humoral response at
delivery in a cohort of both Caucasian and African mothers inHIV-1 infectivity in vitro has been correlated with clinical
progression to disease in HIV-1–infected patients [2]. More- relation to materno-fetal transmission. Our study was focused
on antibodies against the viral envelope, since these have beenover, an association between the antibody responses to certain
epitopes of HIV-1 envelope in the first months after seroconver- most directly implicated in neutralization or enhancement phe-
nomena. The use of the envelope precursor, the gp160, wassion and progression to disease was found in HIV-1–infected
adults [3]. aimed at obtaining a global evaluation of the anti-envelope
humoral response and reducing the bias due to the variabilityWe thought that an appropriate situation in which to address
the role of HIV-enhancing antibodies in vivo would be the of the gp120 and, in particular, the immunodominant V3 do-
main. To test the possibility that disparate observations weretransmission of infection from mother to child. During preg-
nancy of HIV-1–infected women, anti-viral IgG may affect due to the complexity of the antibody response against neu-
tralizing and enhancing epitopes on the envelope, we dissectedvirus transmission by interacting with virus in either the mater-
nal or the fetal circulation after passive transfer of antibodies the humoral response by selecting peptides corresponding to
two highly conserved antigenic domains of the extracellularto the fetus during the last months of pregnancy. At present,
data concerning the relationship between maternal antibodies gp120 (SU) and the transmembrane gp41 (TM) glycoproteins
of HIV-1. In particular, we used a peptide corresponding toand risk of mother-to-child transmission of infection are contro-
versial. HIV-1–neutralizing antibodies or antibodies directed the principal immunodominant domain (PID) of the TM, which
is the most conserved antigenic domain of the envelope of
HIV-1 [12].
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send blood specimens to the virology laboratory of the Hoˆpital by subtraction of the background level observed using the p313
peptide.Necker-Enfants Malades. Forty-nine women transmitted HIV-1
infection to their infants (‘‘transmitters’’), while 49 women did Quantification of plasma virus load. HIV-1 RNAs in plasma
were titrated by reverse transcription followed by polymerase chainnot (‘‘nontransmitters’’). Pairs in which infected infants were born
between December 1988 and March 1994 were included if blood reaction (RT-PCR; AMPLICOR HIV Monitor test; Roche Diag-
nostic Systems, Nutley, NJ). For African mothers, extra primerssamples of the mother were available. Nontransmission controls
were matched for the nearest time of entry in the French Cohort (add-in primers), provided by Roche, were used to improve quanti-
fication of HIV-1 clades other than B. The add-in primers werewith the transmission cases. Seventy-four mothers (34 nontrans-
mitters and 40 transmitters) were of Caucasian origin, and 24 designed to amplify the same region of the HIV-1 gag gene that
is amplified by the standard primers of the AMPLICOR HIV Moni-mothers (15 nontransmitters and 9 transmitters) were of African
origin. tor test. The add-in primers were added to the standard primers in
the same PCR reaction. This method has been validated in severalTwelve of 49 infected children developed an early and severe
form of disease, defined by the following criteria occurring before laboratories, and in particular by our laboratory in experiments on
50 well-characterized non-B HIV-1 isolates (data not shown). As18 months of age: classification in C category (1994 CDC classifi-
cation for children) for 5 children, severe lymphopenia (category plasmas were collected on sodium heparin, which inhibits the test,
measurements were done on viral pellets obtained by ultracentrifu-3) for 5 children, death for 2 children.
Maternal plasma samples, in which anti-HIV antibodies, p24 gation.
p24 antigenemia was measured by use of kits from Abbott Labo-antigenemia, and HIV-1 RNA were measured, were collected at
delivery or in the first week after delivery. ratories (Abbott Park, IL) or Organon Teknika (Baxtel, The Neth-
erlands).Antigens. Various antigens were used in this study. Peptides
were the SUpep peptide (obtained from ANRS, Paris) from the Statistical analysis. ELISA (antibody titers) and RT-PCR
(plasma virus load) results were compared between groups byC-terminal sequence of the SU (HIV-1LAI aa 491–516: YKVVKI-
EPLGVAPTKAKRRVVQREKR) and the PID peptide (HIV-1LAI nonparametric Mann-Whitney test. To assess the role of the hu-
moral response and potential confounding factors on the risk ofaa 598–611: LGIWGCSGKLICTT; Neosystem, Strasbourg,
France), cycled between cysteines to simulate the natural loop vertical transmission, univariate and multivariate stepwise logistic
regression analyses were used (SPSS software; SPSS, Chicago).conformation of the principal immunodominant domain of the TM.
The p25-LAI protein, produced in Escherichia coli, corresponds Antibody responses were considered as continuous variables. The
confounding maternal factors that were considered were as fol-to the HIV-1 capsid, referred to in this study as p24. The gp160s-
MN/LAI, produced by recombinant vaccinia virus–infected BHK lows: CDC stage (A, B-C, unknown), origin (African, Caucasian),
CD4 cell counts (£350, 351–500, 500 cells/mm3, unknown),cells, corresponds to a soluble form of Env precursor. Recombinant
proteins were provided by Transgene (Strasbourg, France). p24 antigenemia (positive, negative), and plasma HIV RNA taken
as a continuous variable. We also entered in the model the interac-All antigens were tested by use of a panel of uninfected or HIV-
1–infected sera, to optimize ELISA conditions. As a control, an tion terms between each confounding factor (CDC stage, ethnic
origin, CD4 cell counts, p24 antigenemia, plasma HIV RNA) andirrelevant 18-aa peptide from the ICAM protein of rat (p313) was
used. the antibody response against each antigen studied. Only interac-
tion terms exhibiting a P value below the commonly used thresholdELISA. Microtiter plates (Immulon 2; Dynatech, Chantilly,
VA) were coated with peptides and proteins in 100 mL of 0.1 M of .20 were included in the final model.
sodium carbonate buffer, pH 9.6, at 47C overnight. The peptides
were used at a concentration of 5 mg/mL, the p24 protein at 1.5
Resultsmg/mL, and the gp160s protein at 0.25 mg/mL. The plates were
blocked with 200 mL of 5% fetal calf serum (FCS) in PBS for 2 Antibody response against HIV-1 antigens. Sera from 49
h at room temperature. After three washes with PBS containing
nontransmitting mothers and 49 sera from transmitting mothers
0.5% Tween 20 (washing buffer), 100 mL of mothers’ sera diluted
were tested for reactivity against SU and PID peptides and p24in PBS with 5% FCS and 0.5% Tween 20 (dilution buffer) was
and gp160s proteins. Both groups showed a wide diversity inadded to the wells and incubated for 2 h at room temperature.
the level of antibody responses. Serum dilutions that producedAfter five washes, a peroxidase-conjugated anti-human IgG Fc
absorbance values in the dynamic range for most sera (1/400(Jackson ImmunoResearch Laboratories, West Grove, PA) diluted
to 0.8 mg/mL in dilution buffer was added for 1 h at room tempera- and 1/800 for p24, gp160s, and PID and 1/200 and 1/400
ture. After five washes, the reaction was visualized with 0.4 mg/ for SUpep) were used for the comparison of transmitter and
mL ABTS (Sigma, St. Louis) in 0.6% acetic acid, pH 4.7, con- nontransmitter groups. Figure 1A shows box plots of the distri-
taining 0.012% hydrogen peroxide. After 30 min, optical density bution of maternal antibody reactivity with the four HIV-1
was measured at 405 nm (Multiskan RC; Labsystems, Helsinki). antigens at one serum dilution.
Assays were done in duplicate and results expressed as means. In
The anti-gp160 response was significantly higher in transmit-
each microplate, wells coated with the PID peptide and incubated
ting mothers (P  .009 and .005 for dilutions of 1/400 andwith a reference pool of HIV-1–positive human sera diluted at 1/
1/800, respectively). Anti-PID reactivity was also higher in1350 were included. Normalization of the results in relation to the
transmitting mothers (P  .055 and .067 for dilutions ofreference serum allowed a direct comparison of ELISA results
1/400 and 1/800, respectively), while no association was foundobtained at different times and on separate plates. Moreover, opti-
cal density values obtained with HIV-1 antigens were corrected between anti-SUpep reactivity and transmission (P  .322 and
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Figure 1. A, Box plots of distribution of maternal antibodies to HIV-1 antigens in transmitters (T) and nontransmitters (NT). Corrected
optical density values obtained at 1 serum dilution are shown. Similar patterns of distributions were found at serum dilutions of 1:800 for
gp160, p24, and PID (principal immunodominant domain), and 1:400 for SUpep (peptide from C-terminal sequence of extracellular gp120).
Each box plot is composed of 5 horizontal lines representing 10th, 25th, 50th, and 90th percentiles of distribution of sera reactivity. B, Plasma
HIV-1 RNA measured by quantitative reverse transcription–polymerase chain reaction. Box plot shows distribution of RNA copy number
expressed as log-transformed values.
.220 for dilutions of 1/200 and 1/400, respectively). No signifi- wide range in both groups (figure 1B), were higher in mothers
who transmitted the virus (P  .0001). Median RNA levels,cant difference in serum reactivity to p24 between transmitters
and nontransmitters was observed (P  .303 and .500 for expressed as logs, were 4.4 and 3.6 in transmitters and non-
transmitters, respectively. There was no difference in plasma1/400 and 1/800 dilutions, respectively). Considering that at
the late stage of disease, there is a decline in the anti–HIV-1 virus loads between Caucasian and African mothers (P .626).
Logistic regression analysis. Univariate logistic regressionimmune response, we analyzed data after exclusion of mothers
classified at CDC clinical stage C (3 nontransmitting and 2 confirmed the correlation between anti-gp160 reactivity and trans-
mission and the trend to an association between anti-PID reactivitytransmitting mothers). The association between transmission
and anti-gp160 reactivity still held (P  .01 and .007 for and transmission (table 1). Multivariate stepwise logistic regres-
sion analysis indicated that among the maternal variables consid-1/400 and 1/800 dilutions), while the difference between trans-
mitters’ and nontransmitters’ anti-PID reactivity became more ered, the anti-gp160 response and virus load were predictors of
the risk of transmission. Consideration of these two variablessignificant (P  .03 for both 1/400 and 1/800 dilutions). The
reactivities against HIV-1 antigens were lower in African than allowed correct classification in 72.4% of the cases: 69.4% of
uninfected infants and 75.5% of infected infants were correctlyin Caucasian mothers (P  .0001 for gp160; P  .0194 for
p24; P  .0764 for PID for a dilution of 1/400 and P  .0004 classified. For an increase of 1 optical density unit in anti-gp160
reactivity, the risk of transmission increased by a factor of 3.4,for SUpep for a dilution of 1/200). However, the differences
between anti-gp160 antibody reactivity between transmitters and for 1 log increase in virus load, the risk of transmission
increased by a factor of 2.8. No interaction terms reached theand nontransmitters were similar in both groups (median, 1.762
vs. 1.561, P  .070, and median, 1.377 vs. 1.177, P  .060, threshold value of P  .20 (not shown). In particular, the interac-
tion terms between maternal origin and anti-gp160 reactivity (Pfor Caucasian mothers and African mothers, respectively, for
a 1/400 dilution).  .29) or virus load (P  .43) were not significant, meaning that
the associations between the risk of transmission and anti-gp160We then asked whether there was a relationship between
maternal antibody response and progression of disease in in- reactivity or virus load were not found different in magnitude
irrespective of mothers’ ethnic origin. Anti-PID reactivity andfected children. On comparison of the antibody responses of
12 transmitting mothers whose children rapidly progressed to antigenemia were strongly correlated with anti-gp160 reactivity
and plasma viremia, respectively, and did not emerge as indepen-disease with that of the 37 transmitting mothers whose children
did not develop a severe form of disease, no significant differ- dent risk factors in the model.
ences were observed (not shown).
DiscussionVirus load. p24 antigenemia was detected in 3 of 49 non-
transmitters and in 14 of 49 transmitters (P  .0001). Accord- In the current study, we analyzed the humoral response to
HIV-1 and plasma HIV-1 RNA levels in infected mothers iningly, plasma HIV-1 RNA levels, although dispersed over a
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Table 1. Maternal factors associated with risk of vertical transmission of HIV-1.
Univariate analysis Multivariate stepwise analysis
No. of
Variable patients Odds ratio 95% CI P Odds ratio 95% CI P
Anti-gp160 98 3.5 1.3–9.4 .0116 3.4 1.1–9.9 .0270
Anti-p24 98 0.8 0.5–1.3 .3290
Anti-PID 98 2.1 0.9–4.8 .0736
Anti-SUpep 98 1.7 0.7–4.5 .2543
Log virus load 98 2.9 1.6–5.1 .0002 2.8 1.6–5.0 .0004
Origin .1623
Caucasian 74 1.0
African 24 0.5 0.2–1.3
CDC stage .4640
A 79 1.0
B or C 12 2.2 0.6–7.8
Unknown 7 0.8 0.2–3.9
p24 antigen .0072
Negative 81 1.0
Positive 17 6.1 1.6–23.0
CD4 cell count .6887
£350 23 1.0
351–500 14 0.9 0.2–3.5
500 25 0.6 0.2–1.9
Unknown 36 1.1 0.4–3.3
NOTE. Serum dilutions used are 1:800 for gp160, p24, and PID (principal immunodominant domain) and 1:400
for SUpep (peptide from C-terminal sequence of extracellular gp120). Logistic regression analysis using serum
dilutions of 1:400 for gp160, p24, and PID and 1:200 for SUpep gave similar results. CI, confidence interval.
relation to mother-to-child transmission of HIV-1 and to dis- mothers. Higher anti-PID reactivity for transmitting mothers,
together with higher anti-V3 reactivity, was also observed inease progression in infected children. Anti-gp160 and anti-
PID antibody responses were associated with transmission from Congolese women [10]. Our data confirm and extend these
observations in a cohort composed of mothers of Caucasianmother to child, while the anti-p24 response was not signifi-
cantly different in transmitter and nontransmitter groups. In and African origins, in which the two ethnic groups displayed
similar plasma virus loads. This suggests that the associationagreement with previous reports [14], maternal virus burden
was strongly associated with transmission of HIV-1. By multi- of anti–HIV-1 envelope antibodies and mother-to-child trans-
mission is of general significance and is not restricted to avariate analysis, the anti-gp160 response and plasma HIV-1
RNA levels were found to be independently associated with particular African group. Interestingly, the significance of the
association between anti-PID antibodies and transmission in-the risk of transmission.
To identify a protective antibody response, several studies creased when the mothers with advanced disease (CDC stage
C) were excluded from the analysis, suggesting that differenceshave focused on the humoral response to single neutralizing
domains, such as the V3 loop, or to the external glycoprotein of between transmitters and nontransmitters in antibody response
against certain HIV epitopes may be lost owing to immunosup-the viral envelope, the gp120, where most neutralizing epitopes
have been mapped. However, these domains, involved in cell pression.
A high anti-gp160 response is a risk factor for mother-to-tropism and neutralization, are highly variable, and quantitative
analysis of serum reactivity against peptides corresponding to child transmission of HIV-1. Higher antibody production in
transmitting mothers may be elicited by a higher load of repli-these regions could be affected by sequence divergence of
infecting virus and peptides used in the assay. By focusing on cating virus or, by favoring viral dissemination, may augment
the virus load, or both phenomena may operate synergistically.conserved immunogenic domains of the envelope, and by using
ELISAs that permit detection of low-affinity cross-reactive an- Although it is difficult to differentiate between these possibilit-
ies, in the logistic regression model the anti-gp160 responsetibodies, our goal was to study the anti-viral response, including
nonneutralizing or enhancing antibodies, and thus contribute was an independent variable that improved prediction based
solely on plasma HIV-1 RNA levels. This observation arguesto more detailed dissection of the role of the humoral response
in mother-to-child transmission of HIV. for a direct link between these antibodies and perinatal trans-
mission. However, the influence of other confounding factors,We found that maternal serum reactivity to gp160 and PID
was more elevated in transmitting than in nontransmitting not considered in the present study, cannot be formally ex-
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2. Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodefi-cluded. Viral sensitivity to antibody-mediated enhancement of
ciency virus (HIV) infection correlates with disease in HIV-infectedinfection has been advanced as a factor favoring mother-to-
individuals. J Virol 1990;64:1437–40.
child transmission [15]. The conflicting data in the literature 3. Zwart G, Van Der Hoek L, Valk M, et al. Antibody response to HIV-1
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High Levels of Human Immunodeficiency Virus Type 1 in Blood and Semen of
Seropositive Men in Sub-Saharan Africa
John R. Dyer,* Peter Kazembe, Pietro L. Vernazza, Department of Medicine, Department of Epidemiology, and Department
of Microbiology and Immunology, University of North Carolina, ChapelBruce L. Gilliam,* Martin Maida, Dick Zimba,
Hill, North Carolina; Department of Medicine, Kantonsspital, St.Irving F. Hoffman, Rachel A. Royce, Jody L. Schock,
Gallen, Switzerland; Lilongwe Central Hospital, Lilongwe, Malawi
Susan A. Fiscus, Myron S. Cohen, and Joseph J. Eron, Jr.
High levels of human immunodeficiency virus type 1 (HIV-1) replication, as reflected in HIV-1
RNA concentrations in blood and semen, probably contribute to both rapid disease progression and
enhanced sexual transmission. Semen and blood were collected from 49 Malawian and 61 US and
Swiss (US/Swiss) HIV-1–seropositive men with similar CD4 cell counts and no urethritis or exposure
to antiretroviral drugs. Median seminal plasma and blood plasma HIV-1 RNA concentrations were
3-fold (P  .034) and 5-fold (P  .0003) higher, respectively, in the Malawian men. Similar
differences were observed in subsets of the Malawian and US/Swiss study groups matched individu-
ally for CD4 cell count (P  .035 and P  .002, respectively). These observations may help explain
the high rates of HIV-1 sexual transmission and accelerated HIV-1 disease progression in sub-
Saharan Africa.
Most human immunodeficiency virus type 1 (HIV-1)–in- HIV-1 RNA measures independently predict prognosis in
North American and European populations [7], but HIV-1 RNAfected people live in regions of Africa and Asia, where hetero-
sexual transmission predominates [1]. The continued rapid concentrations in sub-Saharan Africans have not previously
been reported. In this study, we examined the hypothesis thatexpansion of this heterosexual epidemic likely reflects interac-
tions among many behavioral and biologic factors. Analogous levels of HIV-1 in blood and semen in a Malawian population
sampled in a cross-sectional fashion would exceed those into other sexually transmitted diseases (STDs), the HIV-1 inocu-
lum in semen is probably a major determinant of transmission a comparable group of North American and European men,
providing a biologic basis for the observed heterogeneity infrom men. In support of this hypothesis, plasma HIV-1 RNA
concentrations, which often predict semen levels [2, 3], corre- rates of HIV-1 transmission and progression.
late with transmission between stable partners [4]. Mucosal
STDs significantly increase seminal plasma viral RNA [5],
Materials and Methodshelping to explain their association with HIV transmission.
HIV-1 disease may progress faster in sub-Saharan Africa
Study population. Forty-nine consecutive HIV-1–seropositivethan in North America and western Europe [6]. Single plasma
men attending dermatology clinics at Lilongwe Central Hospital
(Malawian subjects) who served as a control group for a previously
reported study [5] and 61 HIV-1–seropositive male volunteers
Received 4 August 1997; revised 6 January 1998. from infectious diseases clinics at the University of North Carolina
Presented in part: 4th Conference on Retroviruses and Opportunistic Infec- and the Kantonsspital, St. Gallen (US/Swiss subjects), were stud-
tions, Washington DC, 22–26 January 1997 (abstract 26). ied. The 61 US/Swiss men were an antiretroviral naive subset of
Informed consent was obtained from all patients participating in this study.
a larger cohort of men studied [3]. Clinic evidence of mucosal orThis research was conducted according to the human experimentation guide-
ulcerative STDs led to exclusion from the study. In Malawianlines of the US Department of Health and Human Services. The protocol was
approved by the University of North Carolina Committee on the Protection of men, urethral infection with Neisseria gonorrhoeae, Trichomonas
Human Rights and The Malawi Health Sciences Research Committee. vaginalis, or Chlamydia trachomatis was excluded by Gram’s
Information contained herein does not necessarily reflect the views or poli-
stain, culture, and C. trachomatis ligase chain reaction (Uriprobecies of the US Agency for International Development.
LCR; Abbott Diagnostics, Abbott Park, IL) of urethral swabs.Financial support: US Agency for International Development (USAID) as
part of Family Health International’s AIDS Control and Prevention (AIDS- Malawian men were confirmed as HIV-1–seropositive by two
CAP) Project (623-02380A-00-4031-00); World Health Organization (award EIAs (HIV-1/HIV-2 EIA; Genetic Systems, Seattle; Murex HIV-
SD1/94/009); NIH (UO-31496 and DK-49381), NIH Office of AIDS Research; 1 / 2, Murex Diagnostics, Dartford, UK), followed by Western
Pfizer; Swiss National Science Foundation (32-38818.93).
blot (Organon Teknika, Durham, NC) for results that were equivo-Reprints or correspondence: Dr. Joseph J. Eron, Jr., Dept. of Medicine, CB#
cal. HIV-1 seropositivity was confirmed in all US/Swiss men by7030, 547 Burnett-Womack Bldg., University of North Carolina, Chapel Hill,
NC 27599-7030 (jeron@med.unc.edu). Western blot.
* Present affiliations: Infectious Diseases Unit, Townsville General Hospital, Specimen collection and laboratory procedures. Semen was
Queensland, Australia (J.R.D.); The Henry M. Jackson Foundation, Rockville,
processed as previously described [2]. US/Swiss samples wereMaryland (B.L.G.).
diluted in 2.5 mL of transport medium before processing. Blood
The Journal of Infectious Diseases 1998;177:1742–6
plasma (BP) was separated and frozen at 0707C within 1 day ofq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0045$02.00 semen collection. HIV-1 RNA concentrations in BP and cell free
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seminal plasma (SP) were quantified using nucleic acid sequence– US/Swiss men and BP from 42 and 49 men, respectively.
based amplification assay (NASBA; Organon Teknika, Boxtel, Significantly higher levels of HIV-1 RNA were observed in
The Netherlands) [2], with a sensitivity of 1000 RNA copies/mL. Malawian than in US/Swiss BP and SP (median, 15.5 1 104
T cell subsets were measured in blood collected from Malawian copies/mL vs. 2.88 1 104 copies/mL, P  .0003; and 1.51 1
men at the same time as BP for HIV-1 RNA quantification. In the 104 copies/mL vs. 0.46 1 104 copies/mL, P  .034, respec-
US/Swiss men, the CD4 cell count closest to the time of semen
tively, figure 1A).
collection, within 1 month in each case, was used. HIV-1 subtype
Paired analysis compared SP RNA concentrations in 33 pairsin Malawian men was determined by envelope V3 peptide immu-
of Malawian and US/Swiss subjects individually matched fornoassay using antigens specific for clades A through F [8].
CD4 cell count (median CD4 cell counts, 299 cells/mL andStatistics. Samples containing undetectable HIV-1 RNA were
300/mL, respectively). BP HIV-1 RNA levels were availableassigned a value half the assay detection limit (500 copies/mL).
Arithmetic correction for dilution was made, except for undetect- for 22 of these pairs. As shown in figure 1B, median Malawian
able RNA levels. The Mann-Whitney U test was used for compari- SP HIV-1 RNA concentration was 1.70 1 104 copies/mL com-
sons between groups and Wilcoxon rank sum test for paired com- pared with 500 copies/mL (below detectable) in US/Swiss men
parisons. For paired analysis, individual Malawian and US/Swiss (P  .035), with a median BP RNA of 15.5 1 104 copies/mL
subjects were matched for CD4 cell counts within 10 cells/mL versus 2.34 1 104 copies/mL (P  .003).
of one another without knowledge of BP and SP HIV-1 RNA Distributions of SP and BP HIV-1 RNA concentrations in
concentrations. Linear regression was used to identify independent
the two study populations are illustrated in figures 1C and D.
predictors of BP and SP HIV-1 RNA.
Fifty-seven percent (24/42) of Malawian men had blood HIV-
1 RNA levels 125,000 copies/mL compared with only 20%
Results (10/49) of US/Swiss men (P  .0005, figure 1D). The BP RNA
level was below the assay detection limit of 1000 copies/mLCharacteristics of patient populations. Table 1 shows clinical
in 12% of US/Swiss compared with 10% of Malawian men;and demographic characteristics of the subjects. In all but 5 cases,
SP RNA was undetectable in 42% and 22%, respectively. Thedermatologic disorders in Malawian men were minor, including
differences between BP and SP log HIV-1 RNA values (equiva-superficial mycosis, seborrheic dermatitis, superficial bacterial in-
lent to ratios between absolute BP and SP RNA levels) offection, urticaria, pityriasis rosea, warts, molluscum contagiosum,
individual subjects were similar in Malawian and US/Swisseczema, psoriasis, and drug eruption. Five men had herpes zoster
groups (data not shown).or primary varicella infection. No US/Swiss man described sig-
Malawian origin and CD4 cell count correlated significantlynificant symptoms at the time of sample collection.
with the BP HIV-1 RNA concentration and independently pre-Comparisons of HIV-1 RNA concentrations in blood and
dicted BP RNA level in multiple regression analysis (adjustedsemen. SP samples were collected from 49 Malawian and 61
total R2  .35, P  .0001 for absolute CD4 cell count, P 
.004 for country of origin). Although Malawian origin, CD4
cell count, BP RNA, and HIV-1 disease stage all individuallyTable 1. Clinical and demographic characteristics of 49 Malawian
and 61 US and Swiss (US/Swiss) HIV-1–seropositive men. correlated with SP HIV-1 RNA, the sole independent predictor
following multiple linear regression analysis was BP RNA
US/Swiss concentration (adjusted total R2  .24, P  .0012).
Malawian treatment-naive P*
Eight Malawian men had evidence of active systemic infec-
tions at the time of sampling (see table 1 footnote), while allMean age (years) { SD 32 { 7.5 35 { 8.0 .017
Median CD4 cell count US/Swiss subjects were clinically well. The actively infected
(cells/mL), interquartile range 305 (190–479) 339 (160–500) .73 men had marginally higher BP HIV-1 RNA levels than the
Asymptomatic (CDC stage A) 36 (73%) 52 (85%) .15 remainder of the Malawian group (median, 3.24 1 105 copies/
Symptomatic
mL [n  7] compared with 1.41 1 105 copies/mL, P  .39)(CDC stage B or C) 13 (27%) 9 (15%)
and similar SP RNA concentrations (median, 1.35 1 104 vs.Active systemic infection 8 (16%)† 0
Mode of HIV-1 acquisition ND 1.51 1 104 copies/mL, P  .98). When these 8 men were
Heterosexual 14 (23%) excluded from analysis, both BP and SP HIV-1 RNA concen-
Homosexual 37 (61%) trations remained significantly higher in Malawian than US/
Intravenous drug users 10 (16%)
Swiss men (P  .002 and P  .04, respectively). The same
NOTE. In the Malawian group, 41 subjects had absolute CD4 cell counts observation held for paired analysis with matching for CD4
available, and 42 had CD4 percentages available. In the US/Swiss group, all cell count, when the five pairs including an actively infected
had CD4 cell counts done. ND, not determined.
Malawian patient were excluded (P  .008 for comparison of* Continuous data were compared by Mann-Whitney U test, and dichoto-
mous variables were compared by Fisher’s exact test. BP HIV-1 RNA concentrations and P  .006 for SP RNA).
† Includes 4 subjects with dermatomal herpes zoster, 1 with disseminated Of 42 Malawian men whose samples were submitted for
varicella-zoster infection, 1 with secondary syphilis, 1 with active tuberculosis
subtype analysis, 40 had typeable virus. Thirty-seven had anti-and possible drug-induced lupus, and 1 with possible tuberculosis (chronic
cough, fever, night sweats, and weight loss.) body directed only to peptide antigen specific for clade C, 1 had
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Figure 1. Comparison of blood (BP) and seminal plasma (SP)
HIV-1 RNA concentrations (expressed as log10 values) in antiretrovi-
ral-naive Malawian and US/Swiss groups. Distribution of values is
depicted in boxplots for subgroups matched individually for absolute
CD4 cell count (A) and by histograms of log10 SP (C) and BP (D)
HIV-1 RNA concentrations in US/Swiss (speckled bars) and Mala-
wian (filled bars) subjects, plotted in multiples of 5 above detection
limit of 1000 copies/mL. In boxplots, horizontal lines represent me-
dian (25th and 75th percentiles), vertical lines extend to 10th and
90th percentiles, and small filled box is mean (calculated using 500
RNA copies/mL for values below assay detection limit).
antibodies cross-reactive to clades A and C, 1 had antibodies to late with improved prognosis [7]. We found Malawian origin
and residence to be a highly significant predictor of the BPclades A, C, and F, and 1 had antibody to clade A only. All
US/Swiss men had acquired HIV-1 infection in the United HIV-1 RNA concentration, independent of CD4 cell count.
High levels of HIV-1 replication could account for more rapidStates or Switzerland and were considered likely to harbor
clade B virus [1]. disease progression in sub-Saharan Africa than in the United
States and Europe.
High levels of viral shedding in semen may partly explain the
Discussion
continuing rapid heterosexual spread of HIV-1 in sub-Saharan
Africa [1]. We found 3- to 4-fold higher concentrations of SPWe observed a 5- to 7-fold higher median BP viral RNA
concentration in HIV-1–infected Malawian men than in a HIV-1 RNA in Malawian men than in CD4 cell level–matched
US/Swiss subjects receiving no antiretroviral therapy. In bothgroup of untreated US and Swiss men with similar CD4 cell
counts. Recent studies indicate that blood levels of viral RNA groups, HIV-1 RNA levels in blood correlated with those in
SP, the BP concentration being the only independent predictorare powerful predictors of progression to AIDS and death inde-
pendent of CD4 cell count and other markers and that reduc- of seminal HIV-1 shedding. Blood-to-semen HIV-1 RNA ratios
did not differ between the 2 groups, suggesting that similartions in plasma HIV-1 RNA after antiviral drug therapy corre-
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factors were responsible for increased levels of virus in both The causes of the expanding heterosexual HIV-1 epidemics
in sub-Saharan Africa and southern Asia are not clear. Behav-body fluids in the Malawian men. Whether production of geni-
tal tract HIV-1 occurs in a separate biologic compartment, as ioral factors may provide a partial explanation. However, dis-
tinct biologic aspects of the virus, the host, and the environmentsuggested by previous studies [9], cannot be determined by the
data presented here. may be important determinants of regional patterns of HIV-1
spread and disease progression. The high HIV-1 RNA concen-A number of host- or virus-related factors could explain the
differences observed between BP and SP HIV-1 RNA levels trations in blood and semen in this African population probably
reflect interactions among genetic, immunologic, environmen-of the 2 groups. Immune activation by infection or vaccination
can reversibly elevate BP viral RNA concentrations [10]. Al- tal, and viral influences. Modifiable environmental factors, es-
pecially acute and chronic bacterial and parasitic infections,though 8 Malawian subjects had evidence of active systemic
infection, they did not account for the elevated blood and semen may result in immune activation and increased systemic and
genital tract HIV RNA concentrations. Dissecting the relativeRNA levels in the group as a whole. Nevertheless, common
endemic infections such as tuberculosis and parasitic diseases importance of these influences should enable development of
new public health initiatives to control this epidemic.could enhance viral replication while remaining clinically inap-
parent. High levels of serum immune activation markers have
been described in HIV-1–infected Africans [11]. Furthermore,
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Proinflammatory Cytokine and Human Immunodeficiency Virus RNA Levels
during Early Mycobacterium avium Complex Bacteremia in Advanced AIDS
David W. Haas, Michael M. Lederman, Lisa A. Clough, Department of Medicine, Microbiology, and Immunology, Division of
Infectious Diseases, Vanderbilt University School of Medicine,Robert S. Wallis, David Chernoff, and Sheri L. Crampton
Nashville, Tennessee; Department of Medicine, Division of Infectious
Diseases, Case Western Reserve University School of Medicine,
Cleveland, Ohio; Chiron Corp., Emeryville, California;
Abbott Laboratories, Abbott Park, Illinois
The relationship between Mycobacterium avium complex (MAC) bacteremia and proinflammatory
cytokine and human immunodeficiency virus type 1 (HIV-1) RNA levels in AIDS was investigated.
During a prospective study, blood samples were drawn monthly for mycobacterial cultures. Sera
were available at baseline and onset of MAC bacteremia from 20 cases and at corresponding times
from 19 controls. Mean interleukin-6 (IL-6) levels were 154% greater at the time of MAC bacteremia
in cases than in controls. The IL-6 levels correlated with body temperature, serum tumor necrosis
factor (TNF-a) levels, and alkaline phosphatase levels (P £ .004 for each). Although TNF-a levels
tended to rise more in MAC patients than in controls, the difference was not significant. However,
among both cases and controls, serum TNF-a levels rose significantly from baseline to the time of
last sample, irrespective of MAC infection (P  .015). Bacteremia was not associated with increased
serum HIV-1 RNA levels. Thus, early MAC bacteremia is associated with increases in serum IL-6
levels, while TNF-a levels rise over time during advanced AIDS.
Disseminated Mycobacterium avium complex (MAC) dis- HIV-infected patients, active viral replication drives progres-
sive CD4 cell depletion [4]. Current treatment strategies focusease is common during advanced AIDS. Cellular expression of
tumor necrosis factor-a (TNF-a) is induced by mycobacterial on minimizing HIV replication. The present study investigated
whether early MAC bacteremia was associated with changesproteins in vitro [1] and during tuberculosis in human immuno-
deficiency virus (HIV)–infected persons [2]. In addition, im- in serum IL-6, TNF-a, and HIV RNA levels in patients with
AIDS.mune activating events such as febrile illnesses and immuniza-
tions cause transient increases in plasma HIV RNA. Cytokines
that promote HIV expression in vitro, such as TNF-a and
interleukin-6 (IL-6), may enhance HIV replication [3]. Among Materials and Methods
Patients. Patients previously enrolled in a prospective clinical
trial of clarithromycin prophylaxis in AIDS were studied [5]. Pa-
Received 28 February 1997; revised 18 December 1997. tients with 100 CD4/ cells/mm3 and baseline blood cultures
This study was performed with the written approval of the Vanderbilt Uni-
negative for MAC were randomized to twice daily clarithromycinversity Committee for the Protection of Human Subjects, following the guide-
or placebo. Only patients from the placebo arm were included inlines of this institution.
Grant support: Abbott Laboratories. the present analysis. Blood was drawn monthly for MAC surveil-
Reprints or correspondence: Dr. David W. Haas, Dept. of Medicine, Microbi- lance cultures, and sera were sampled every 16 weeks. All patients
ology, and Immunology, Vanderbilt University School of Medicine, 1211 21st
with adequate stored sera and for whom matched controls could beAve. S., Suite 539, Nashville, TN 37212 (david.w.haas@vanderbilt.edu).
identified were included. We identified 20 patients who developed
The Journal of Infectious Diseases 1998;177:1746–9
MAC bacteremia (cases). A control was selected for each (exceptq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0046$02.00 1 patient who was a control for 2 cases). Cases and controls were
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matched for baseline CD4/ cell count and time from baseline to Cases and controls had similar IL-6 and TNF-a levels at
last serum sample. baseline (table 1). However, MAC bacteremia was associated
Antiretroviral use. Many patients received antiretroviral with elevated IL-6 levels (P  .03). Similarly, when cases
agents (zidovudine, didanosine, zalcitabine, stavudine, or foscar- and controls were compared based on calculated differences
net). These drugs were included in the analysis only if prescribed between individual final and baseline IL-6 levels (to control
for at least 1 week before the pertinent serum sample. Antiretrovi-
for interpatient variability), the change in IL-6 levels remained
rals started after baseline but stopped at least 1 week before the
significant (P  .027).pertinent sampling were not included in the analysis.
In contrast, although TNF-a levels tended to rise moreSample processing. Whole blood was collected, and serum
among cases, the increase specifically associated with MACwas separated by centrifugation and stored at 0707C. Sera from
bacteremia was not significant (table 1). Levels of TNF-a weresome time points were not available, and plasma samples were
unavailable. higher among both groups at final sample time (42.5 { 5.2 pg/
Cytokine assays. Sera were analyzed for TNF-a (Medgenix, mL) compared with baseline (28.4 { 2.4 pg/mL), regardless
Stillwater, MN) and IL-6 (R&D Systems, Minneapolis) in a of bacteremia (P  .015). There was no correlation between
blinded manner. The lower limit of IL-6 detection was 0.15 pg/ TNF-a levels and duration of storage (not shown).
mL. Lower values were censored to 0.15 pg/mL. The lower limit The HIV RNA levels varied widely among the 39 subjects
of TNF-a detection was 16 pg/mL. All results exceeded this level.
at all times, from 500 copies/mL to 4,266,000 copies/mL.
HIV RNA analysis. Sera were assayed for HIV RNA in a blinded
Assays using serum have been shown to yield HIV RNA valuesmanner using the branched-chain DNA method (Chiron) [6].
38% lower than plasma levels [7]. Mean baseline log HIVMycobacterial cultures. MAC was isolated from blood using
RNA level was similar in cases and controls (table 1), and HIV7H11 agar or 7H12 broth (or both) by a radiometric method.
RNA levels at the time of bacteremia in cases did not differStatistical analysis. Nominal and ordinal variables were com-
from levels in control patients. To control for interpatient vari-pared by x2, and interval and ratio variables were assessed by Stu-
dent’s t test or Pearson’s correlation coefficient. For multiple linear ability, the change over time in individual patients was calcu-
regression, entry and exit probabilities of .05 and .10 were used, lated based on the first and last sample. This difference was
respectively. All P values were based on two-tailed tests. Subjects not significant.
with missing data were excluded from individual analyses. We further examined the relationship between clinical char-
acteristics and MAC bacteremia. Other than a trend toward
higher mean body temperatures (99.2{ 0.47F vs. 98.3{ 0.27F,
P  .059) and lower hemoglobin levels (11.1 { 0.6 vs. 12.4Results
{ 0.4 g/dL, P  .069) in cases versus controls, respectively,
Between November 1992 and July 1993, 682 patients with MAC bacteremia was not associated with changes in white
blood cultures negative for mycobacteria at baseline partici- blood, platelet, CD4, or CD8 cell counts or percentages,
pated in a study of clarithromycin prophylaxis for disseminated serum alkaline phosphatase, triglycerides, or body weight
MAC infection [5]. Of 334 randomized to placebo, 53 devel- (P  .05).
oped disseminated MAC infection, as defined by a positive
blood culture. Twenty of these 53 patients, for whom adequate
serum samples were available, were included in these analyses,
Table 1. Comparison of serum levels of HIV RNA, tumor necrosisas were 19 matched controls. None received specific MAC
factor-a (TNF-a), and interleukin-6 (IL-6) in MAC cases and con-therapy during the study, including times when samples for the
trols.
present analyses were collected. Of the 39 subjects, 90% were
male, mean weight at baseline was 150 { 5 lbs, age was 38.2 Characteristic MAC cases Controls P
{ 1.1 years, CD4/ cell number was 23.1 { 3.6 cells/mm3,
IL-6 level (pg/mL)CD4/ cell percentage was 3.3% { 0.5%, CD8/ cell number
Baseline sample 4.2 (0.6) 5.6 (2.3) NSwas 530 { 59 cells/mm3, and CD8/ cell percentage was 61.5%
Last sample* 13.7 (3.6) 5.4 (1.0) .03{ 2.0%. Groups did not differ with regard to sex or weight or Last minus baseline 9.6 (3.6) 00.2 (2.4) .027
CD4 or CD8 cell numbers or percentages (P  .05), although TNF-a level (pg/mL)
Baseline sample 28.2 (3.9) 28.6 (3.0) NScases were slightly younger (P  .046).
Last sample 45.4 (7.8) 39.7 (6.5) NSFor MAC cases, time from baseline to last serum sample
Last minus baseline 17.8 (7.0) 11.5 (6.5) NS(at or following onset of MAC bacteremia) ranged from 64
Log10 HIV RNA (copies/mL)
to 474 days (median, 250). Time from first positive MAC Baseline sample 4.47 (0.16) 4.42 (0.17) NS
culture to last sample ranged from 0 (both obtained the same Last sample 4.46 (0.12) 4.40 (0.20) NS
Last minus baseline 00.01 (0.14) 00.02 (0.12) NSday) to 4 months. This interval was 0, 1, 2, 3, and 4 months
for 6, 10, 1, 2, and 1 case(s), respectively. For controls, time
NOTE. MAC, M. avium complex infections. Mean values are shown (SE).
between samples was similar, ranging from 19 to 484 days * Last sample  sample at or following onset of MAC bacteremia in cases
and corresponding sample from controls.(median, 253).
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In addition to baseline and time of MAC bacteremia, sam- previous report, we identified patients from a prospective, ran-
domized study which lasted for over a year [5]. Of interest, inples from intermediate time points were available from some
patients, yielding a total of 53 sera from cases and 54 from this prospective study, serum TNF-a levels rose in all patients
irrespective of MAC disease, suggesting that TNF-a expressioncontrols. Analysis of these 107 samples (including baseline and
final samples) revealed that serum IL-6 correlated with alkaline increases over time in HIV disease as has been suggested by
some [11] but not all [12] earlier cross-sectional studies.phosphatase (r  .41, P  .001) and body temperature
(r  .38, P  .001). For TNF-a, weaker correlations were The cytokines TNF-a and IL-6 participate in the host im-
mune response to various intracellular pathogens, includingobserved with triglycerides (r .25, P .011) and hemoglobin
(r  0.23, P  .022). There was a strong correlation between mycobacteria. Increased production of TNF-a has been demon-
strated during tuberculosis [1, 8], and serum TNF-a levelsIL-6 levels and TNF-a levels (r  .38, P  .001). Neither
cytokine correlated with log HIV RNA. fall when HIV-infected adults with active tuberculosis receive
effective therapy [13]. While the mechanisms involved are notWe repeated the above analyses after controlling for antiret-
roviral use. At baseline, 19 (95%) cases and 17 (89.5%) con- well understood, exposure of peripheral blood mononuclear
cells from healthy, tuberculin-positive volunteers to live Myco-trols were receiving at least one antiretroviral agent, for a mean
of 1.10 ({0.10) and 1.16 ({0.14) agents per case and control bacterium tuberculosis induces transcription of TNF-a and IL-
6 mRNA. Similarly, mononuclear cells from patients with ac-patient, respectively. At the time of final sample, 5 patients in
each group had started at least one new agent. In addition, tive pulmonary tuberculosis demonstrate elevated cytokine
mRNA levels and increased production of TNF-a in responsesome drugs received at baseline were discontinued, so that at
study end controls and cases were receiving a mean of 1.0 { to exogenous stimuli [8]. During mycobacterial infection, TNF-
a may be involved in immune pathways that result in fever0.2 and 0.8 { 0.1 agents, respectively.
When the 10 patients who started new agents were compared and tissue necrosis, inhibit mycobacterial growth, and promote
granuloma formation. Furthermore, TNF-a facilitates killingwith the other 29 patients, there was no difference in IL-6,
TNF-a, or log HIV RNA levels from baseline to final sample of intracellular MAC, while both TNF-a and IL-6 production
may correlate with increased survival of MAC-infected macro-(P .05 for each). Although the number of patients was small,
among the 20 MAC case patients, there were no significant phages [14].
The physiologic effects of TNF-a and IL-6 occur largely indifferences in changes in IL-6, TNF-a, or log HIV RNA levels
among the 5 patients who had new antiretrovirals added com- the local tissue microenvironment at sites of infection. In the
present study, activation of cytokine or HIV-1 expression maypared with the 15 who did not.
Infectious or neoplastic complications other than MAC bac- have been greater in the tissues during MAC bacteremia but
was not reflected by circulating levels. Our findings of changesteremia could influence cytokine or HIV-1 RNA levels. How-
ever, such events were equally distributed between groups. At in IL-6 but not TNF-a or HIV-1 RNA levels may also reflect
stage of MAC disease. In the present study, MAC bacteremialeast one major infectious or neoplastic disease was diagnosed
after collection of baseline but before last serum samples in 9 was probably diagnosed before extensive lymphoreticular or-
gan involvement. This was predicted by the study design, whichcase and 9 control patients, and included cytomegalovirus reti-
nitis (7), Pneumocystis carinii pneumonia (4), Kaposi’s sar- involved monthly blood cultures, regardless of symptoms, and
is supported by the minimal clinical abnormalities specificallycoma (3), nonretinal cytomegalovirus disease (2), bacterial
pneumonia (2), and lymphoma, pancreatitis, and intravenous associated with bacteremia. This differs from the usual stage
of diagnosis, by which time patients typically have high-gradecatheter infection (1 each). All non-MAC infections except 2
were diagnosed at least 1 month prior to MAC bacteremia (1 fever and anemia. A report describing increased TNF-a levels
during MAC involved such clinically overt disease [10].in a case, 1 in a control). When these 2 subjects were excluded
from analysis, final IL-6 levels remained higher in cases (14.4 In contrast to the present study, Havlir et al. [15] observed
increased circulating HIV-1 RNA levels during early MAC{ 3.7 pg/mL) than controls (5.6 { 1.0 pg/mL, P  .031), and
final temperatures remained higher in cases (99.3{ 0.47F) than bacteremia. Elevated IL-6 levels may precede HIV-1 RNA
increases in bacteremic patients. It is possible that, in the pres-controls (98.3 { 0.27F, P  .04)
ent study, increased HIV-1 RNA levels would have been ob-
served at later times.
Discussion
Improved culture methods and newer macrolide antibiotics
have influenced the approach to MAC infections in patientsThis study demonstrates that early MAC bacteremia is asso-
ciated with increased serum IL-6 but not TNF-a or HIV RNA with AIDS [5]. We have shown that onset of MAC bacteremia
may be associated with minimal clinical or laboratory evidencelevels. These findings were unexpected given the strong associ-
ation between tuberculosis and increased expression of both of disease, increased IL-6 levels, and little evidence of TNF-
a or HIV RNA changes. The opportunity for early preemptiveproinflammatory cytokines and HIV [2, 8, 9]. In addition, a
previous study demonstrated elevated TNF-a levels among therapy at the time of minimal pathogenic effect should abort
subsequent clinical disease and complications. However, in thepatients with disseminated MAC infection [10]. Unlike the
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Genotypic and Phenotypic Changes in the Emergence of Escherichia coli
O157:H7
Peter Feng, Keith A. Lampel, Helge Karch, Center for Food Safety and Applied Nutrition, US Food and Drug
Administration, Washington, DC; Institut fu¨r Hygiene andand Thomas S. Whittam
Mikrobiologie, Universitat Wu¨rzburg, Wu¨rzburg, Germany; and Institute
of Molecular Evolutionary Genetics, Department of Biology,
Pennsylvania State University, University Park, Pennsylvania
Escherichia coli O157:H7 is a foodborne pathogen distinguished from typical E. coli by the
production of Shiga toxins (Stx) and the inability to ferment sorbitol (SOR) and to express b-
glucuronidase (GUD) activity. An allele-specific probe for the GUD gene (uidA) and multilocus
enzyme electrophoresis were used to elucidate stages in the evolutionary emergence of E. coli O157:
H7. A point mutation at /92 in uidA was found only in O157:H7 and its nonmotile relatives,
including a SOR/ O157:H0 clone implicated in outbreaks of hemolytic-uremic syndrome in Ger-
many. The results support a model in which O157:H7 evolved sequentially from an O55:H7 ancestor,
first by acquiring the Stx2 gene and then by diverging into two branches; one became GUD0 SOR0,
resulting in the O157:H7 clone that spread worldwide, and the other lost motility, leading to the
O157:H0 clone that is an increasing public health problem in Europe.
Escherichia coli serotype O157:H7 has emerged as a serious toxigenic O157 variants have been isolated [8, 9]. In particular,
Karch et al. [10] discovered a novel Stx-producing O157 strainfoodborne pathogen that has caused large-scale outbreaks of
gastrointestinal illness in developed countries [1, 2]. These that caused an outbreak of hemolytic-uremic syndrome (HUS)
in Germany. In contrast to typical O157:H7 strains, these non-bacteria have several factors implicated in pathogenesis, includ-
ing Shiga toxins (Stx) and a pathogenicity island called LEE motile O157 strains ferment sorbitol (SOR/) and have DNA
patterns distinct from those of typical O157:H7 isolates [10].that encodes proteins, such as intimin (eaeA), involved in at-
taching effacement [3, 4]. Evolutionarily, the O157:H7 sero- In the study reported here, we used multilocus enzyme elec-
trophoresis to assess the clonal relationships among a varietytype marks a distinct clone that is only distantly related to other
Stx-producing enterohemorrhagic E. coli (EHEC) and is most of cytotoxigenic O157 strains, including nonmotile variants
and other Stx-producing serotypes. We characterized strainsclosely related to an enteropathogenic E. coli (EPEC) clone of
serotype O55:H7, a non–Stx-producing strain associated with for the presence of the uidA /92 allele, Stx genes, and sorbitol
and GUD phenotypes. From a phylogenetic tree based on en-infantile diarrhea [5].
The clonal nature of E. coli O157:H7 has facilitated its iden- zyme allele profiles, we formulated a model for the stepwise
changes in virulence factors and phenotypic markers in thetification because these organisms, in contrast to most E. coli
isolates, do not ferment sorbitol and lack b-glucuronidase recent evolutionary emergence of E. coli O157:H7.
(GUD) activity [2]. The gene encoding GUD (uidA), however,
is intact and is nearly identical to the gene in E. coli K-12 with
two nucleotide differences: an AjT mutation in the putative Materials and Methods
010 promoter region and a TjG mutation at /92 in the
Bacterial strains. This study is based on analysis of 163 E.structural gene [6]. The uidA/92 mutation is conserved among
coli isolates, including 78 O157:H7 strains from contaminatedO157:H7 strains and can be detected by an allele-specific oligo-
foods and patients with hemorrhagic colitis or HUS, 4 Stx-produc-nucleotide probe [7].
ing O157:H0 strains from HUS patients in Germany, 42 nonmotile
Although O157:H7 is the predominant E. coli serotype in-
O157 strains from the United States and Japan, 10 O157 strains
criminated in foodborne disease, various nonmotile and cyto- of a variety of H types other than H7, and 33 strains of various
O:H serotypes, 14 of which were Stx producers.
Strain characterization. All isolates were examined for the
ability to ferment sorbitol and express GUD activity [2]. Shiga
Received 8 September 1997; revised 13 January 1998.
toxin genes (stx1 and stx2) were detected by multiplex polymerasePresented in part: 3rd International Symposium and Workshop on Shiga
chain reaction (PCR) assays [11], and toxin production was con-Toxin (Verocytotoxin)–Producing Escherichia coli Infections, Baltimore, June
1997 (abstract V126/VI). firmed serologically by use of Verotox-F (Denka Seiken, Tokyo).
Reprints or correspondence: Dr. Thomas S. Whittam, IMEG, Dept. of Biol- To identify the /92 allele of the uidA gene, strains were exam-
ogy, 208 Mueller Laboratory, Pennsylvania State University, University Park,
ined by colony blots with an allele-specific probe (PF-27) as de-PA 16802 (tsw1@psu.edu).
scribed previously [7].
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Nucleotide sequence analysis. The 5* terminus of the uidAq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0047$02.00 gene was amplified by PCR with primers that anneal at 0179 and
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/322 from the initiation codon [6]. The amplified 503-bp fragment tests confirmed that the respective Stx was produced by those
was sequenced with the Silver Sequence kit (Promega, Madison, strains. Of the total of 42 nonmotile O157 strains examined, 41
WI). carried the uidA /92 allele and had Stx genes, and except for
Clonal analysis. The genetic relationships among 46 represen- 4 strains of ET4 (see below), all were SOR0 and GUD0. Only
tative strains were determined from allele profiles at 20 enzyme 1 nonmotile O157 strain (USDA 7123, ET10) did not have the
loci determined by multilocus enzyme electrophoresis [5]. Strains
uidA /92 allele, and it was GUD0 and Stx0 (figure 1).
with identical profiles were assigned the same electrophoretic type
The O157:H7 complex also includes 7 O55:H7 isolates(ET) and classified as members of a clone. Allele differences were
(ET5), which differ by a 6-phosphogluconate dehydrogenaseused to estimate genetic distances between strains and to construct
allele from ET1 and are both SOR/ and GUD/ and, thus,dendrograms by the average linkage algorithm [5].
phenotypically distinct from O157:H7 (figure 1). In addition,
O55:H7 isolates are typically Stx-negative, although we found
that 1 strain (USDA 5905) produced Stx2 (figure 1).Results
The most divergent member of the O157:H7 complex is
Clonal analysis and phenotypes. The multilocus enzyme ET4, comprising GUD/ SOR/ O157:H0 strains from Germany
genotypes of 46 strains resolved 15 ETs, whose genetic relat- [12]. These isolates differed from ET1 by two enzyme alleles,
edness is shown in figure 1. The top cluster is the O157:H7 a distinct malate dehydrogenase electromorph and a fast manni-
clone complex and comprises 5 closely related ETs that differ tol-1-phosphate dehydrogenase electromorph. These strains
from one another by one or two enzyme alleles. All O157:H7 were positive for Stx2 and also carried the uidA /92 allele.
and most nonmotile O157 strains were ET1. Two O157 strains The bottom cluster of the dendrogram (ET6–ET15) is com-
differed from this ET by alleles at a single locus; FDA 413 posed of non-H7 flagellar types and nonmotile O157 strains,
(ET2) had a fast-migrating peptidase and CDC G5101 (ET3) as well as some representative Stx producers. All of these
had a slow 6-phosphogluconate dehydrogenase electromorph. strains had ETs that differed by multiple alleles from the O157:
CDC G5101 was also unusual in that it was the only O157: H7 complex. None of the strains in the bottom half of the
H7 strain with a GUD/ phenotype [9]. dendrogram had the uidA /92 allele.
All of the O157:H7 were SOR0 and GUD0, carried the uidA Comparison of uidA gene sequences. To test further the
genetic relationships in figure 1, we sequenced part of uidA/92 allele, and had genes for Stx1, Stx2, or both. Serologic
Figure 1. Dendrogram showing
genetic distances among 46 repre-
sentative isolates based on electro-
phoretic type (ET). ETs are num-
bered 1–15 and listed by serotype,
with reference isolate given in paren-
theses (n  no. of isolates) and pres-
ence of specific genes (stx1, stx2,
and uidA /92 allele) or phenotypes
(SOR0 and GUD0) indicated by
solid circles.
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from all 4 ET4 isolates and 4 of the 7 ET5 isolates and com- O157 strains carried the same 010 and /92 mutations in the
uidA as did O157:H7. Interestingly, ET5 (O55:H7) had thepared the sequences with that of O157:H7 [6]. The ET4 strains
(O157:H0) were identical to O157:H7, whereas the ET5 (O55: 010 but not the /92 mutation, suggesting that the O55:H7
uidA allele is an intermediate stage between the wild type alleleH7) strains had the 010 AjT mutation but did not have the
TjG /92 mutation in uidA. and the uidA allele of O157:H7.
To reconcile the ET profile data, the variety of SOR and GUD
phenotypes, and the distribution of the uidA mutations, we formu-
Discussion
lated an evolutionary model that posits a series of steps that have
occurred in the emergence of the E. coli O157:H7. The model isThe clonal analysis based on multilocus enzyme electropho-
based on three assumptions: that during divergence, the probabil-resis shows that O157:H7 and Stx-producing nonmotile vari-
ity of loss of function greatly exceeds gain of function for meta-ants (O157:H0) belong to a genetically distinct clone complex
bolic genes; that the gain of function usually occurs via lateralthat includes O55:H7 strains. The O157:H7 complex comprises
transfer of genes; and that the sequence of events invoking thea variety of phenotypic variants that appear to have recently
fewest total is the preferred model.gained and lost motility, Shiga toxin genes, and metabolic
The evolutionary steps outlined in the model (figure 2) begintraits, such as the ability to ferment sorbitol. The close relation-
at the left with the ancestral or primitive states and progressship of these strains is supported by the finding that a point
to the right to the contemporary or derived states. The modelmutation at /92 in uidA occurs in O157:H7 and its nonmotile
begins with an EPEC-like ancestor that we assume, like mostrelatives, including an atypical O157:H0 clone implicated in
present-day E. coli, to be able to express b-glucuronidaseoutbreaks of HUS in Germany [10, 12] and in central Europe
[13]. Comparative sequencing confirmed that these nonmotile (GUD/) and ferment sorbitol (SOR/). From this EPEC-like
Figure 2. Proposed evolutionary model for emergence of O157:H7 complex based on mutations in uidA, Stx production, SOR and GUD
phenotypes, and multilocus enzyme electrophoretic profiles of E. coli O157:H7 and its relatives. Phenotypes of ancestors A1–A6 are shown;
changes predicted to have occurred are in bold. Representative isolates are given below each electrophoretic type (ET). Strain with tracts of
ancestor A3 (shaded circle) has not been reported.
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ancestor, the immediate ancestor with the O55 somatic and the represents an early diverging member of the O157:H7 clone
complex, which retained the ancestral ability to ferment sorbitolH7 flagellar antigens evolved. This ancestral cell, labeled A1
in figure 2, represents the most recent common ancestor of the and to express b-glucuronidase activity. The model also stipu-
lates that stx2 was acquired once and at an early stage, beforeET5 (O55:H7) clone and O157:H7 and its relatives and is
assumed to have the uidA 010 mutation that occurs in the the somatic antigen transition to O157 and prior to the acquisi-
tion of the EHEC plasmid and stx1. Hence, aside from theentire O157:H7 complex. The next step, A1jA2, was the
acquisition of stx2, presumably by transduction by a toxin- eaeA and the LEE region, which already existed in the ancestor,
the model predicts that Stx2 gene has been evolving in theconverting bacteriophage, resulting in an Stx2-producing O55:
H7 strain. This primitive stage is represented by strain USDA O157:H7 genome for a longer time than other virulence factors,
such as stx1 and genes on the EHEC plasmid.5905 in ET5 (figure 1). From A2jA3, the uidA /92 mutation
occurred and the somatic antigen changed from O55 to O157
to give rise to a hypothetical O157:H7 Stx2-producing ancestor
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9. Hayes PS, Blom K, Feng P, Lewis J, Strockbine NA, Swaminathan B.O157:H0 clone represented by ET4 (figure 1). Along the upper
Isolation and characterization of b-D-glucuronidase–producing strainspath, the lineage lost the ability to ferment sorbitol and acquired
of Escherichia coli serotype O157:H7. J Clin Microbiol 1995;33:the Stx1 gene (presumably by phage conversion) to give rise to
3347–8.
an intermediate A5 ancestral stage. The A5 has the primitive 10. Karch H, Bo¨hm H, Schmidt H, Gunzer F, Aleksic S, Heesemann J. Clonal
traits, GUD/ and Stx2/, and has the derived states (SOR0, Stx1/) structure and pathogenicity of Shiga-like toxin–producing, sorbitol-fer-
menting Escherichia coli O157:H0. J Clin Microbiol 1993;31:1200–5.in the combination of traits seen in strain CDC G5101 (ET3). In
11. Cebula TA, Payne WL, Feng P. Simultaneous identification of strains ofthe model, A5 then lost GUD activity, producing the immediate
Escherichia coli serotype O157:H7 and their Shiga-like toxin type byancestor (A6) of the common O157:H7 clone (ET1), which
mismatch amplification mutation assay-multiplex PCR. J Clin Microbiol
spread globally, and a rare variant (ET2), which differs by a 1995;33:248–50.
single enzyme allele from ET1. Recent loss of Stx genes and 12. Gunzer F, Bo¨hm H, Ru¨ssmann H, Bitzan M, Aleksic S, Karch H. Molecular
detection of sorbitol-fermenting Escherichia coli O157 in patients withmotility in nature, or during isolation and culture, would account
hemolytic-uremic syndrome. J Clin Microbiol 1992;30:1807–10.for the variants among isolates of the ET1 clone (figure 1).
13. Bitzan M, Ludwig K, Klemt M, Konig H, Buren J, Muller-Wiefel DE. TheIn summary, the phylogenetic model diagrammed in figure
role of Escherichia coli O157 infections in the classical (enteropathic)
2 makes specific predictions about the history of descent and haemolytic uraemic syndrome: results of a central European, multicentre
the order of acquisition of virulence factors in the emergence study. Epidemiol Infect 1993;110:183–96.
14. Levine MM, Xu J, Kaper JB, et al. A DNA probe to identify enterohemor-of the virulent O157:H7 serotype. The model predicts that both
rhagic Escherichia coli of O157:H7 and other serotypes that causeO157:H7 (ET1) and the German O157:H0 (ET4) were derived
hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis 1987;from an EPEC-like O55:H7 ancestor, which carried eaeA and
156:175–82.
acquired the Stx2 gene. This proposition is supported by the 15. Bilge SS, Vary J, Dowell SF, Tarr PI. Role of the Escherichia coli O157:
similarities between these strains and by the presence of identi- H7 O side chain in adherence and analysis of an rfb locus. Infect Immun
1996;64:4795–801.cal mutations in uidA. The German O157:H0 clone, however,
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Serogroup B, Electrophoretic Type 15 Neisseria meningitidis in Canada
Daniel A. Kertesz, Michael B. Coulthart, J. Alan Ryan, Bureau of Infectious Diseases and Bureau of Microbiology, Laboratory
Centre for Disease Control, Health Canada, Ottawa, CanadaWendy M. Johnson, and Fraser E. Ashton
Invasive meningococcal disease is nationally reportable in Canada. In recent years, a serogroup
C genotype, designated electrophoretic type 15 (ET15), has been the most frequently isolated menin-
gococcal genotype in Canada and has caused epidemics across the country. Between August 1993
and September 1995, there were 9 cases of invasive meningococcal disease caused by a variant of
this genotype, expressing group B capsular polysaccharide. The appearance of serogroup B:ET15
was related temporally and geographically to mass immunization campaigns designed to control
serogroup C meningococcal disease in Canada. Since there is no vaccine available to control sero-
group B meningococcal disease, the appearance of this variant may have public-health significance
if it demonstrates the same epidemic potential as its serogroup C counterpart.
In Canada, invasive meningococcal disease (IMD) has been characteristics of 9 cases of invasive serogroup B, serotype 2a,
ET15 N. meningitidis found in Canada since 1993. This geno-a major public-health issue during the last decade. From 1985
to 1993, there was an annual increase in the national incidence type may be especially interesting to public-health officials,
because of its emergence following mass immunization to con-of IMD that was associated with the emergence of a new
serogroup C clone. Multilocus enzyme electrophoresis placed trol serogroup C:ET15 disease, its potential for epidemic dis-
ease (given the behavior of its serogroup C counterpart), andthis clone in the electrophoretic type (ET) 37 complex [1] but
distinguished it by identification of a unique allelic variant the lack of an effective vaccine for serogroup B N. meningitidis.
for the enzyme fumarase [2]. Isolates belonging to this clone,
designated ET15, were predominantly serotype 2a, subtypes
Methods
P1.2,5. From 1988 to 1993, the percentage of all laboratory-
confirmed invasive meningococcal disease in Canada attribut- In Canada, IMD is nationally notifiable according to standard-
ized case definitions [9]. The Laboratory Centre for Disease Con-able to serogroup C:ET15 increased from 2.0% to 51.8%. Epi-
trol (LCDC) maintains a national database that correlates case-by-demiologically, ET15 was associated with a significant increase
case epidemiologic reports with results from laboratory evaluation.in IMD incidence among persons 5–19 years old and a signifi-
The epidemiologic reports include the date of disease onset andcant increase in the case fatality rate for all ages [3]. In response
the patient’s age, sex, residence (health unit), clinical syndrome,to this increase in serogroup C disease, there were 9 mass
and outcome.
immunization campaigns (defined as 20,000 people immu-
All sterile-site meningococcal isolates are forwarded to the
nized in a campaign) against meningococcal disease in Canada LCDC for serogrouping, serotyping, and serosubtyping at the Na-
between 1992 and 1994. Serogroup C:ET15 has also been in- tional Laboratory for Bacterial Diseases [10]. Multilocus enzyme
creasingly responsible for epidemic and endemic disease in the electrophoresis and pulsed-field gel electrophoresis, as described
United States [4], England and Wales [5], and the Czech Re- previously [2, 7], are used routinely to characterize all serogroup
public [6]. C meningococcal isolates as well as serogroup B isolates that are
suspected of belonging to the ET37 complex.In contrast to serogroup C:ET15, which has caused several
community and institutional outbreaks [7], serogroup B Neisse-
ria meningitidis has been responsible primarily for endemic
Results
disease in Canada. From 1987 to the present, most typeable
serogroup B meningococcal isolates have been serotype 15 or From 1985 to the present, there have been 9 cases of invasive
infection with serogroup B:ET15 N. meningitidis in Canada4 [8]. Here, we describe the epidemiologic and microbiologic
(table 1). All cases occurred between August 1993 and Septem-
ber 1995. Eight (89%) of the isolates came from the provinces
of Que´bec (6 isolates) and Saskatchewan (2 isolates). None of
the cases were epidemiologically linked. Two of the isolatesReceived 8 August 1997; revised 29 December 1997.
Presented in part: Tenth International Pathogenic Neisseria Conference, Bal- were from patients in the 5–19 years age group. Three isolates
timore, September 1996. were recovered from blood and 5 from cerebrospinal fluid.Reprints or correspondence: Michael B. Coulthart, National Laboratory for
There was one fatality, a 3-month-old child. Two patients inBacterial Diseases, Bureau of Microbiology, Room 240, HPB Building
AL0700F, Tunney’s Pasture, Ottawa, ON, K1A 0L2, Canada (mike coulthart Que´bec (cases 5 and 6) had been previously immunized with
@hc-sc.gc.ca). an A/C bivalent meningococcal vaccine as part of a mass im-
The Journal of Infectious Diseases 1998;177:1754–7 munization campaign. In cases 3 and 9, the patients had never
q 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0048$02.00 been immunized. The immunization status of the remaining 5
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Table 1. Cases of invasive disease caused by serogroup B, electrophoretic type 15 N. meningitidis in Canada.
Date of
Case onset Age Vaccine Site of Serogroup:
no. Province (d/m/y) (years) Sex status Outcome isolate serotype: subtype
1 Que´bec 24/8/93 20 M U Survived CSF B:2a:P1.–
2 Que´bec 13/9/93 48 F U Survived CSF B:2a:P1.2,5
3 Saskatchewan 2/11/93 3 m M N Died Blood B:2a:P1.2,5
4 New Brunswick 22/4/94 5 F U B:2a:P1.–
5 Que´bec 14/12/94 4 M Y Survived CSF B:2a:P1.2,5
6 Que´bec 11/1/95 2 F Y Survived CSF B:2a:P1.2,5
7 Que´bec 15/2/95 56 F U Survived Blood B:2a:P1.2,5
8 Saskatchewan 23/2/95 19 F U Survived Blood B:2a:P1.2,5
9 Que´bec 30/9/95 2 M N Survived CSF B:2a:P1.2,5
NOTE. d  day, m  month, y  year, M  male, F  female, N  not immunized, Y  immunized, U  immunization status unknown, CSF 
cerebrospinal fluid.
patients was unknown, although 2 would not have been eligible different capsular polysaccharides co-colonize the human naso-
pharynx. The rate at which this occurs has yet to be estimated.to receive publicly funded meningococcal vaccine as part of
any immunization campaign because of age (case 3, 48 years, In the US Pacific Northwest, capsular switching from serogroup
B to C was described among a group of ET5-complex isolatesexceeding maximum age of 20 years) or location (case 4, from
a population in a nonimmunized area of New Brunswick). The during a 1994–1995 outbreak. Molecular genetic analysis of
these isolates suggested that the capsule-switching phenome-remaining 3 patients with unknown vaccine status would have
been eligible for publicly funded vaccine because of their ages non resulted from genetic transformation and recombination at
a locus within the capsule-biosynthetic (syn) operon [12]. Theand locations of residence.
All of the B:ET15 isolates were serotype 2a. Seven were C-to-B capsular switch reported here is the reverse of this B-
to-C switch, but analogous genetic events may have precededsubtype P1.2,5 and 2 were nonsubtypeable (P1.–).
In 1993, 1994, and 1995 there were, respectively, 393, 361, the appearance of B:ET15 isolates in Canada.
Two general types of explanation could be advanced for theand 305 cases of invasive meningococcal disease in Canada,
corresponding to yearly incidences of 1.4, 1.3, and 1.0/100,000, recent appearance of these B:ET15 strains. The first invokes a
fitness advantage for B-encapsulated variants of a prevalent C-respectively. Of all laboratory-confirmed cases during this pe-
riod, 39% were caused by group B strains, of which 36.4% encapsulated genotype. This could occur if the B-encapsulated
variants were subject to less intense selection pressure fromwere nonserotypeable, 28.7% serotype 4, 16.8% serotype 15,
8.3% serotype 14, 3.4% serotype 2a, and 2.1% serotype 2b. the immune systems of the population of human hosts, because
they carry a polysaccharide antigen that is both different fromSerogroup C strains accounted for 48.6% of all laboratory-
confirmed cases during the same time period. Among these, that of the more prevalent group C strains (to which many
potential hosts would already possess antibodies) and less im-87.9% were serotype 2a, 8.9% were nonserotypeable, and 3.2%
were other serotypes, including 14, 15, 4, and 2b. Between munogenic [13]. The resulting fitness advantage of the B vari-
ants may be modest. However, because the background chro-1993 and 1995, ET15 accounted for 93% of all serogroup C
isolates in Canada. mosomal genotypes (here represented by the 2a:P1.2,5:ET15
array of markers) of the two capsular variants would be ex-
tremely similar, one might expect the B and C forms to occupy
Discussion
very similar ecologic niches. Thus, one might reasonably ex-
pect that whatever factors have led to the recent rapid increaseThis report describes the appearance, in Canada, of a variant
form of a prevalent invasive serogroup C meningococcal geno- in prevalence of C:ET15 in Canada [3] might also apply to
B:ET15, and perhaps that intergenotypic competition betweentype (C:2a:P1.2,5:ET15), that instead expresses serogroup B
capsular polysaccharide. B:ET15 and its C:ET15 counterpart contributed to the appear-
ance of the former.Meningococcal strains that are genetically similar to each
other but express serogroup B or C capsular polysaccharide We also raise the question of whether the recent appearance
of invasive disease due to serogroup B:ET15 strains in Canadaantigens have also been described in countries other than Can-
ada [1, 11, 12]. The repeated observation of such variants may be related partly to the widespread use of meningococcal
vaccine in response to epidemics of C:ET15 (figure 1). Elemen-at different times and places and in different chromosomal
backgrounds suggests that they arise frequently in the bacterial tary population genetics theory indicates that the probability
of escape from random loss of a new, selectively advantageouspopulation, as meningococcal strains carrying genes specifying
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immunity to serogroup C invasive disease. It is important to
point out, first, that at least 2 and likely 4 of the 9 patients in
reported cases of B:ET15 disease did not receive vaccine (see
Results). This would mean that vaccine-induced immunity of
these individuals per se cannot be a direct contributing factor
in their having contracted IMD due to B:ET15 meningococci.
Second, although such protective immunity may indeed have
contributed to the recent decline in the overall incidence of
group C disease in Canada (figure 1), it is not clear how this
factor alone could explain the recent appearance of the B:ET15
variants. If the latter had been present at significant frequencies
in the meningococcal population before vaccination, one would
expect them to have been observed at that time. However, it
should also be clear that it is not possible at present to distin-
guish conclusively between explanations based on selectionFigure 1. Percentage of all cases of laboratory confirmed meningo-
acting in the nasopharynx and those based on protective immu-coccal disease attributable to serogroup C, electrophoretic type 15
(ET15) in Canada between 1987 and 1996 is shown (solid line) in nity to invasive disease.
relation to appearance of cases of serogroup B:ET15 isolates (open Finally, despite the apparent plausibility of a selection-
bars). Period during which mass immunization campaigns occurred and/or competition-based explanation for the appearance of
in Canada is bracketed by arrows.
B:ET15 in Canada, alternative scenarios should also be consid-
ered. Foremost among these is the possibility that insufficient
selective advantage of any kind accrues to B:ET15 variants togenetic variant in a population, as well as its rate of frequency
increase if it does escape such random loss, is directly propor- have caused their recent rise in frequency among cases of IMD,
and that the latter effect is simply what one would expect, giventional to the magnitude of its selective advantage [14]. Thus,
one effect of mass vaccination might have been to intensify a moderately high rate of transformation and recombination at
the capsular-polysaccharide locus and high prevalence of aselection pressure past a critical threshold, such that the fre-
quency of B:ET15 variants in the nasopharyngeal meningococ- well-studied and closely observed genotype (C:ET15) on which
selectively neutral B variants would be most likely eventuallycal population rose to a point where they began to appear in
cases of IMD. to occur and to be noticed. We plan to test this alternative
explanation against the above-mentioned selection-based hy-It is suggestive that 7 of 9 invasive B:ET15 isolates were
identified after mass immunization in Que´bec and Saskatche- pothesis, using a molecular population-genetic approach [12].
A switch from serogroup C:ET15 to serogroup B:ET15 maywan, provinces that had carried out the largest campaigns.
Que´bec immunized all persons 6 months to 19 years old be especially significant from a public-health perspective, given
the epidemic behavior of C:ET15 and because no vaccine exists(1,613,000 people) between December 1991 and May 1993,
and Saskatchewan immunized all persons 2–19 years old against the B capsular polysaccharide. None of the B:ET15
isolates have occurred as part of an epidemic or cluster, and(258,000 people) in November and December 1993. By pro-
viding a large segment of the population with antibody against there have been no new cases of invasive B:ET15 infection
since September 1995. This suggests that B:ET15 does notserogroup C capsular polysaccharide, such immunization could
have been another factor influencing the relative fitnesses of have the epidemic potential of C:ET15, at least in Canadian
host populations at this time. However, comparisons of theclosely related strains of N. meningitidis carrying different cap-
sular antigens. It is also noteworthy in this context that invasive epidemiologic behavior of serogroup B:ET15 and serogroup
C:ET15 are limited by the small number of isolates, and contin-B:ET15 strains have not yet been identified in the populous
provinces of British Columbia or Ontario, which used smaller- ued surveillance will be necessary to document further this
behavior in Canada and elsewhere, as well as to study thescale mass immunization campaigns to control epidemic
C:ET15. Though circumstances differed in each province prior possible relationship with mass immunization. The potential
for capsular switching may be one of the many factors public-to immunization, the latter two provinces targeted specific
health units and communities, while Que´bec and Saskatchewan health officials should consider when planning targeted or mass
immunization for epidemic or endemic meningococcal disease.provided vaccine to large segments of entire provincial popula-
tions.
Another form of selection-based explanation is that vaccina-
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Vaccination with a Haemophilus influenzae Type b Conjugate Vaccine Reduces
Oropharyngeal Carriage of H. influenzae Type b among Gambian Children
Richard A. Adegbola, E. Kim Mulholland, Ousman Secka, Medical Research Council Laboratories, Fajara, Banjul, The Gambia;
CHD/ARI World Health Organization, Geneva, Switzerland; LondonShabbar Jaffar, and Brian M. Greenwood
School of Hygiene and Tropical Medicine, London, United Kingdom
The effect of a Haemophilus influenzae type b (Hib) polyribosylribitol phosphate–tetanus toxoid
conjugate vaccine (Hib/PRP-T) on oropharyngeal carriage of Hib was studied during an efficacy
trial in Gambian infants. Children were vaccinated with Hib/PRP-T and diphtheria-tetanus toxoids–
pertussis (DTP) or DTP alone at ages 2, 3, and 4 months. Groups of 1000 children aged 1–2 years
were studied each year for 4 years. Hib was detected by production of a halo on antiserum agar
plates. Carriage was significantly lower among children fully vaccinated with Hib/PRP-T given with
DTP (4.4%; 95% confidence interval [CI], 3.8%–5.7%) than among children fully vaccinated with
DTP alone (11.0%; 95% CI, 8.9%–13.0%) (protective effect adjusted by year  60%; 95% CI, 44%–
72%; P  .001). Hib carriage varied by year among nonvaccinated children. Hib conjugate vaccines
are likely to produce a herd protective effect in underdeveloped communities, as recorded in Europe
and the United States.
Haemophilus influenzae type b (Hib) capsular polysaccha- in developing countries as they are in industrialized communi-
ties.ride vaccines protect against invasive disease in older children
but not against oropharyngeal colonization with Hib [1]. In In The Gambia, West Africa, Hib carriage in children is high
and of short duration. A recently conducted efficacy trial of acontrast, Hib capsular polysaccharide–protein conjugate vac-
cines reduce colonization by Hib, leading to a herd protective Hib–tetanus toxoid protein conjugate vaccine (Hib/PRP-T) in
Gambian infants has provided an opportunity for determiningeffect. Thus, Hib disease has virtually disappeared from many
developed countries in which Hib conjugate vaccines have been the effect of a conjugate vaccine on colonization by Hib in this
developing country.introduced [2–7]. Takala et al. [3] were the first to report that
vaccination with a Hib conjugate vaccine reduced colonization
by Hib in Finish children. However, control rates for carriage
Subjects and Methodswere obtained before the vaccination study was started. Reduc-
tions in carriage of Hib among American Indian children and The study was undertaken in the Western Region of The Gambia
children in Atlanta have been reported following the introduc- during the course of a Hib vaccine efficacy trial [14]. Vaccination
tion of a Hib vaccine [4, 5], but adequate control populations coverage in The Gambia is high; 85% of children have received
their third diphtheria-tetanus toxoids–pertussis (DTP) vaccine bywere not available for these studies.
the age of 1 year. The Gambian Hib vaccine trial was a double-The epidemiology of Hib disease differs significantly be-
blind, randomized, placebo controlled study; 21,490 infants re-tween developed and developing countries [8–10]. Hib car-
ceived Hib/PRP-T with DTP and 21,358 received DTP alone atriage rates are often higher in developing than in industrialized
the ages of 2, 3, and 4 months. A booster dose was not given.countries, and colonization occurs at an earlier age and may
Vaccines used for the trial were Hib/PRP-T (lot nos. S2801 andbe more intensive [9, 11–13]. Thus, it is uncertain whether
S3044), 10 mg/dose, and DTP (lot nos. G5801, J0102, and K5590;
Hib conjugate vaccines will be as effective at reducing carriage
Pasteur Me´rieux, Lyon, France). The outcome measures were pro-
tection against all invasive Hib disease, Hib pneumonia, and Hib
carriage. The vaccine provided 95% protection against invasive
Hib disease in children who had received three doses.
Study site. Children resident in the trial area received theirReceived 17 April 1997; revised 5 November 1997.
Consent was obtained from the family of each child who was admitted to vaccines at 20 main health centers or at vaccination clinics held in
the study. The trial was approved by the Gambia Government/MRC Ethical 43 smaller health centers. For the carriage study, two immunization
Committee. centers, one in an urban and one in a rural area, were selected;
Financial support for the Gambian Haemophilus influenzae type b vaccine
there it was possible to recruit 20 children per week.trial was provided by the UK Medical Research Council, the US Agency for
Study children. During 4 years, 500 well children were re-International Development, the World Health Organization, the United Nations
Children’s Fund, the Children’s Vaccine Initiative, and the United Nations cruited sequentially each year when they presented to an immuni-
Development Fund. zation center. Recruitment was restricted to the months of August
Reprints or correspondence: Dr. Richard A. Adegbola, Medical Research
to December to minimize any possible effect of season on carriage.Council Laboratories, Fajara, Banjul, The Gambia (radegbola@mrc.enda.sn).
Similarly, recruitment was limited to children aged 1–2 years to
The Journal of Infectious Diseases 1998;177:1758–61
restrict variability by age. The first 2000 children studied wereq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0049$02.00 recruited during the pretrial period or during the first year of the
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efficacy trial and had not received Hib/PRP-T vaccine. The final incorrect, leaving 3986 children on whom the following analy-
2000 children were studied during the second and third years of sis is based. Their median age was 16.5 months (range, 12.0–
the efficacy trial and had received either Hib/PRP-T vaccine given 24.0), and the male to female ratio was 1:1. The mean number
with DTP or DTP alone. In addition, all healthy contacts of cases of siblings of carriers, ascertained from 445 children recruited
of Hib disease identified during the trial who were £3 years old in the third year of the trial, was 2.1 (range, 0–11); there was
were studied to investigate the possible effects of vaccination in
no significant difference in the number of siblings between
high-risk households.
carriers and noncarriers.Children were excluded if they had an illness requiring hospital-
Hib carriage over time. The Hib carriage rate varied sub-ization or severe malnutrition or had received antibiotics during
stantially with time among children not vaccinated with Hibthe preceding 2 weeks. A form was completed for each child,
vaccine and DTP. The prevalence of carriage was significantlywhich recorded details of name, age, sex, date of birth, address,
ethnic group, health card number, number of siblings, and Hib lower in the pretrial year (8.2%) than during the first year of
vaccination group. During the last year of the study, the number the trial (15.4%) (x2  24.4; 1 df; P  .001) (table 1). It was
of siblings aged £3 years living in the household of each child 14.4% and 7.7%, respectively, among children fully vaccinated
was recorded also. with DTP alone during the second and third years of the trial.
Sample collection. A swab was collected from the posterior Overall, 9.9% (95% confidence interval [CI], 8.0%–11.7%) of
pharynx with a sterile cotton-tipped swab (Sterilin, Stone, UK). the children were carriers in the second year of the trial com-
The swab was plated directly onto Levinthal agar ASA plates
pared with 6.2% (95% CI, 4.7%–7.7%) in the third year of
containing burro anti-Hib antiserum (0.8 mL/10 mL; provided by
the trial (P  .003, Mantel-Haenszel x2 test stratified by vacci-J. B. Robbins, NIH, Bethesda, MD), bacitracin (5 U/mL), vanco-
nation status).mycin (3.9 mg/mL), and clindamycin (0.78 mg/mL). Inoculated
The households of 31 of 50 children with Hib disease wereASA plates were placed in a CO2 (candle) jar in the field before
visited (the other 19 could not be traced), and 124 householdtransport to the laboratory. All swabs were collected by two inves-
tigators (R.A.A. and O.S.). contacts aged £3 years were studied. The numbers of contacts
Bacteriology. In the laboratory, inoculated ASA plates were who were carriers were 13 (32.5%) of 40, 15 (23.8%) of 63,
incubated at 357C for 48 h at a 5% CO2 concentration. Plates were and 2 (9.5%) of 21 in the first, second, and third years of the
examined for colonies surrounded by a halo, indicating formation trial, respectively (x2 test for trend  3.82; 1 df; P  .051).
of antigen-antiserum complexes. Plates were kept for another 24 Seven contacts had received Hib vaccine and DTP. If these
h at 47C before being considered Hib-negative. Control plates children are excluded, the proportions of carriers among con-
inoculated with a known Hib strain and a non–type b H. influenzae
tacts were 13 (32.5%) of 40 in year 1, 15 (25.4%) of 59 in
were included in each batch of assays. One or two colonies show-
year 2, and 2 (11.1%) of 18 in year 3 (x2 test for trend  2.8;ing a halo were subcultured onto chocolate agar for X and V
1 df; P  .1). A logistic regression model was constructed tofactor dependency determination and serotyped with Hib-specific
take into account the influence of place of residence as wellantiserum (Murex Diagnostics, Dartford, UK). Of 426 strains of
as the year of study. After adjusting for place of residence,Hib isolated, 376 were biotyped and screened for antibiotic sensi-
tivities by disk diffusion and tested for b-lactamase production by there was evidence of a decline in carriage among contacts
use of nitrocefin chromogenic cephalosporin (Unipath, Bedford, with time (change of deviance  3.7; 1 df; P  .05).
UK) [10]. MICs for 100 isolates were determined with E-test strips Age, sex, and ethnic group. The prevalence of carriage was
(AB Biodisk, Solna, Sweden). These included all 11 isolates that not influenced significantly by age, sex, or ethnic group.
were resistant to one or more antibiotics by disk sensitivity testing Urban or rural differences. Equal numbers of children
and the first 22 or 23 isolates obtained each year. lived in rural or in urban areas (1989 and 1997, respectively).
Statistical analysis. Discrete data were compared between
Overall, the proportion of carriers among children who lived
groups with the x2 test with Yates’s correction or Fisher’s exact
in rural areas was 12.5% (95% CI, 11.1%–14.0%), comparedtest, as appropriate. Trend was investigated by use of the x2 test
with a prevalence of 7.4% (95% CI, 6.2%–8.5%) among chil-for trend. Continuous data were not normally distributed and were
dren who lived in urban areas (P  .001). Carriage was highercompared with a Wilcoxon test. Analysis of risk factors for car-
in rural than in urban areas in each year of the study.riage was done using unconditional logistic regression. The effect
of age was investigated as a continuous and as a discrete variable Effect of vaccination on carriage. Among the 1994 chil-
with a cutoff of 18 months; the results were similar, but only the dren who had received Hib vaccine and DTP or DTP alone,
results of the latter are presented for ease of interpretation. Models 1824 (91.5%) had received three doses, 123 (6.2%) two doses,
were compared by change in deviance. The SAS System for Win- and 47 (2.4%) one dose. Among children who had received
dows (SAS Institute, Cary, NC) was used for analyses. three doses of vaccine, the median interval between the admin-
istration of the last dose of vaccine and the time when a swab
was collected was 10.1 months (range, 0.16–19.8); this intervalResults
was similar in each year and for Hib vaccine plus DTP and
DTP recipients. Of the fully vaccinated children who had re-Study children. Four thousand children were swabbed; 14
were excluded because their demographic records could not be ceived DTP alone, 11% (95% CI, 8.9%–13.0%) were carriers,
compared with 4.4% (95% CI, 3.8%–5.7%) of those who hadmatched with the main trial database or because their age was
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Table 1. Hib carriage rates among children during 4 years of vaccine trial of Hib conjugate vaccine
with or without diphtheria-tetanus toxoids–pertussis (DTP).
DTP alone Hib plus DTP
No. of
Year doses Urban Rural Urban Rural
1 — 28/500 (5.6) 54/497 (10.9) — —
2 — 62/498 (12.5) 92/497 (18.5) — —
3 3 25/228 (11.0) 38/210 (18.1) 8/241 (3.3) 16/245 (6.5)
2 0/11 4/13 (30.8) 4/13 (30.8) 1/18 (5.6)
1 0 1/5 (20.0) 1/6 (16.7) 0/4
4 3 12/230 (5.2) 23/225 (10.2) 4/225 (1.8) 13/220 (5.9)
2 1/10 (10.0) 3/24 (12.5) 0/13 1/21 (4.8)
1 1/10 (10.0) 1/4 (25.0) 1/12 (8.3) 2/6 (33.3)
NOTE. Data are no./total (%).
received Hib vaccine plus DTP (Mantel-Haenszel x2 test stra- adjusting for year of study, sex, age, area of residence, and
vaccination status, the time since the last dose of vaccine wastified by year: protective effect  60%; 95% CI, 44%–72%;
P  .001). There was no significant difference in carriage rate not associated with the likelihood of being a carrier (change
in deviance  .06; 1 df; P  .8).between children partially vaccinated with Hib vaccine plus
DTP or DTP alone, but numbers were small. Characteristics of Hib isolates. Detailed bacteriologic
analyses were done on 376 isolates; only 1 was b-lactamase–Multivariate analysis of risk factors for carriage. A logistic
regression model showed that carriage rates were indepen- positive. This isolate was also resistant to ampicillin, chloram-
phenicol, and tetracycline (MICs of 4.0, 8.0, and 16.0 mg/mL,dently and significantly associated with Hib vaccination status,
residence in a rural area, and year of study (table 2). A logistic respectively). Tetracycline resistance was detected in 11 of 100
isolates for which MICs were determined (MICs of 12–32 mg/regression model using only data from children who were in
the efficacy trial gave similar results. In these analyses, after mL). Two isolates were multiply resistant; 1 was resistant to
chloramphenicol, cotrimoxazole, and tetracycline (MICs of 8,
32, and 12 mg/mL, respectively) and the other was the b-
lactamase–positive isolate. No strains were resistant to cefotax-Table 2. Multivariate logistic regression analyses showing indepen-
ime. The prevalent biotypes were I (92%), II (7.7%), and IIIdent effect of year of study, sex, age, area of residence, and vaccina-
tion status on risk of carriage. (0.27%).
Odds ratio
Variable (95% confidence interval) P Discussion
Year We have found significant changes in the prevalence of Hib
1 (pre–efficacy trial year) 1.0 (0.7–1.4) .8 carriage in Gambian children over a 4-year period; the level
2 (1st year of efficacy trial) 2.0 (1.4–2.7) .001
of carriage peaked in the second year of the study without3 (2nd year of efficacy trial) 1.8 (1.2–2.5) .001
obvious reasons. The prevalence of carriage was higher in rural4 (3rd year of efficacy trial) 1.0
Sex than in urban children in all years of the study. The reasons
Female 1.0 (0.8–1.2) .8 for this latter finding are not clear. Living conditions, including
Male 1.0 those associated with crowding, are little different in rural and
Age
urban areas of The Gambia. An analysis of other factors that18 months 1.0 (0.8–1.2) .9
might affect oropharyngeal carriage of Hib, such as the number⁄18 months 1.0
Residence of siblings in the household, showed no significant differences
Rural 1.8 (1.5–2.3) .001 between rural and urban areas.
Urban 1.0 In many countries where Hib conjugate vaccines have been
Vaccination*
introduced, there has been a dramatic reduction in the incidenceFull 0.4 (0.2–0.5) .001
of Hib disease; this reduction was often greater than couldPartial 1.0 (0.5–1.9) .9
Control 1.0 be attributed to the direct effect of vaccination and included
protection from disease in age groups not included in the vacci-
* Fully vaccinated children received 3 doses of Hib vaccine plus diphtheria-
nation program. This has been attributed to a herd protectivetetanus toxoids–pertussis (DTP), partially vaccinated children received 1 or 2
doses of Hib plus DTP, and control children received 1–3 doses of DTP alone. effect achieved through a reduction in carriage [3–7]. Until
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3. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngealthe present study, no information was available on the effect
carriage of Haemophilus influenzae type b (Hib) in children immunizedof Hib conjugate vaccines on carriage of Hib in developing
with an Hib conjugate vaccine. J Infect Dis 1991;164:982–6.
countries. We have now shown that a PRP-T conjugate vaccine 4. Takala AK, Santosham M, Almeido-Hill, et al. Vaccination with Haemo-
given during infancy reduced oropharyngeal carriage of Hib in philus influenzae type b meningococcal protein conjugate vaccine re-
duces oropharyngeal carriage of Haemophilus influenzae type b amongfully vaccinated children by 60% during the second year of
American Indian children. Pediatr Infect Dis J 1993;12:593–9.life in a community in which exposure to Hib is likely to be
5. Mohle-Boetani JC, Ajello G, Breneman E, et al. Carriage of Haemophilusmuch more intense than in industrialized countries. It is also
influenzae type b in children after widespread vaccination with conjugate
possible that the degree of colonization may have been reduced Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 1993;12:
in immunized children, even when prevention of carriage had 589–93.
6. Murphy TV, Pastor PN, Medley FB, Osterholm MT, Granoff DM. De-not occurred. The additional benefit of a herd protective effect
creased Haemophilus colonization in children vaccinated with Haemo-following vaccination with a conjugate vaccine may boost the
philus influenzae type b conjugate vaccine. J Pediatr 1993;122:overall impact of a Hib vaccination program in developing
517–23.
countries, in which vaccine delivery system and coverage are 7. Barbour ML, Mayon-White RT, Coles C, Crook DWM, Moxon ER. The
often constrained. impact of conjugate vaccine on carriage of Haemophilus influenzae type
b. J Infect Dis 1995;171:93–8.
8. Funkhouser A, Steinhoff MC, Ward J. Haemophilus influenzae disease and
Acknowledgments immunization in developing countries. Rev Infect Dis 1991;13(suppl 6):
S542–54.
Vaccines, serology services, and other technical support were 9. Bijlmer HA. Epidemiology of Haemophilus influenzae invasive disease in
provided by Pasteur Me´rieux Serums et Vaccins. The contribution developing countries and intervention strategies. In: Ellis RW, Granoff
of the staff of the Sibanor WEC Mission Hospital and Serekunda DM, eds. Development and uses of Haemophilus b conjugate vaccines.
Health Centre is gratefully acknowledged. J. B. Robbins kindly New York: Marcel Dekker, 1994:247–64.
10. Adegbola RA, Mulholland EK, Falade AG, et al. Haemophilus influenzaesupplied the Hib antiserum used in the study, and P. Smith helped
type b disease in the Western Region of The Gambia: backgroundwith interim analysis. We thank K. McAdam, Director of MRC
surveillance for a vaccine efficacy trial. Ann Trop Paediatr 1996;16:Laboratories in The Gambia, for his support and advice. The Inter-
103–11.national Steering Committee for the vaccine trial consisted of C.
11. Mpairwe Y. Observations on the nasopharyngeal carriage of HaemophilusBroome, N. Pierce, R. Moxon, and M. George.
influenzae type b in children in Kampala, Uganda. J Hyg 1970;68:
337–41.
12. Gratten M, Lupiwa T, Montgomery J, Gerega G. Distribution and relation-
References
ship to serotype of Haemophilus influenzae biotypes isolated from upper
1. Peltola H, Kayhty H, Sivonen A, Makela PH. Haemophilus influenzae respiratory tracts of children and adults in Papua New Guinea. J Clin
type b capsular polysaccharide vaccine in children: a double-blind field Microbiol 1984;19:526–8.
study of 100,000 vaccinees 3 months to 5 years of age in Finland. 13. Bijlmer HA, Lloyd-Evans N, Campbell H, et al. Carriage of Haemophilus
Pediatrics 1977;60:730–7. influenzae in healthy Gambian children. Trans R Soc Trop Med Hyg
2. Eskola J, Kayhty H, Takala AK, et al. A randomized protective field trial 1989;83:831–5.
of a conjugate vaccine in the protection of infants and young children 14. Mulholland K, Hilton S, Adegbola A, et al. Randomised trial of Haemophi-
against invasive Haemophilus influenzae type b disease. N Engl J Med lus influenzae type-b tetanus protein conjugate for prevention of pneu-
monia and meningitis in Gambian infants. Lancet 1997;349:1191–7.1990;323:1381–7.
/ 9d46$$ju46 05-11-98 10:41:02 jinfa UC: J Infect
1762
Humoral Immune Response to Tetanus-Diphtheria Vaccine Given during
Extended Use of Chloroquine or Primaquine Malaria Chemoprophylaxis
David J. Fryauff, Stanley J. Cryz, Hendra Widjaja, US Naval Medical Research Unit No. 2, Jakarta, and Provincial Health
Service, Jayapura, Irian Jaya, Indonesia; Swiss Serum and VaccineEric Mouzin, L. W. Preston Church,
Institute, Berne, Switzerland; US Naval Medical Research Institute,Mochammad A. Sutamihardja, Allen L. Richards,
Bethesda, Maryland
Budi Subianto, and Stephen L. Hoffman
Immune suppression resulting from prolonged chemoprophylaxis and potential drug-vaccine
interaction were investigated within the context of a randomized placebo-controlled trial that com-
pared daily primaquine or weekly chloroquine administration for malaria prevention. After 11
months of prophylaxis, adult male subjects received a tetanus-diphtheria (Td) vaccination. Prophy-
laxis continued 4 weeks longer. Anti-tetanus and anti-diphtheria antibody levels were measured by
ELISA at baseline and at 1, 3, 7, and 14 months after Td vaccination. All groups were comparable
at baseline. Immunization triggered significant increases in anti-tetanus and anti-diphtheria IgG
levels over each group’s pre-Td baseline levels and those of an unvaccinated control group. Geometric
mean anti-tetanus titers (GMTs) in the primaquine group were significantly higher than those of
the placebo group at 1, 3, and 14 months. Anti-tetanus GMTs in placebo and chloroquine groups
declined over 14 months to levels comparable to those of unvaccinated controls, but levels in the
primaquine group remained significantly higher than in controls.
Recent trials in Indonesia and Africa have generated new in the frequency, magnitude, or duration of these responses [5].
However, because protective immunity to tetanus is primarily ifinterest in primaquine for malaria chemoprophylaxis [1–3]. In
Indonesian men, a daily regimen of 0.5 mg of primaquine base not wholly determined by levels of neutralizing antibody and
because antimalarials can inhibit antibody response to rabiesper kilogram of body weight was well-tolerated and yielded
protective efficacies against Plasmodium falciparum and Plas- [6, 7], cholera, and typhoid vaccines [8], we were most inter-
ested in the drug’s effects on humoral responses to the Tdmodium vivax of 90% [3]. In this year-long trial, primaquine
was associated with enhanced lymphoproliferative responses vaccination. This study compared anti-tetanus and anti-diphthe-
ria IgG responses evoked by the Td vaccine among groupsto mitogens and antigens [4]. This unanticipated result
prompted an in vivo immunization trial designed to further receiving primaquine, chloroquine, and placebo.
reveal the immunomodulating effects of the drug or the malaria
protection it conferred. Materials and Methods
A tetanus-diphtheria (Td) vaccination was administered to
Subjects and prophylaxis. The chemoprophylaxis and Td im-groups treated with primaquine, chloroquine, or placebo in the
munization (5 limits of flocculation units [LfU] of tetanus toxoidlast month of the trial. Subjects’ in vitro lymphoproliferative
and 2 LfU of diphtheria toxoid/0.5 mL intramuscularly) compo-responses to tetanus were measured at subsequent time points.
nents of this study have been described [2, 5]. Only 2 of 72 subjects
Primaquine was associated with the highest initial post-Td re-
recalled a previous immunization (10 years prior). None of the
sponses of lymphocytes to tetanus, and no significant differ- subjects had been in military service where there might have been
ences were observed between primaquine and placebo groups greater likelihood of immunization. Primaquine (n  30), chlo-
roquine (n  21), placebo (n  21), and control without prophy-
laxis (n  20) groups were comparable in terms of age (30
years), weight (50 kg), ethnicity (Javanese/Sundanese), and so-
Received 29 August 1997; revised 22 December 1997.
cioeconomic status (new transmigrant farmers). Primaquine-This work was conducted in accordance with US Navy and Republic of
treated subjects had been malaria-free during the 12 months ofIndonesia regulations governing the protection of human subjects in medical
research. American and Indonesian committees for the protection of human prophylaxis, but an estimated 0.8–1.0 cases of malaria/person-
subjects reviewed and approved the procedures followed in this research. Writ- year had occurred in the chloroquine and placebo groups. The
ten informed consent was obtained from each volunteer. monthly incidence of primary postprophylaxis malaria over the 3-
The views of the authors expressed herein do not purport to reflect those of
and 7-month post-Td vaccine sampling points was comparable inthe US Navy, the US Department of Defense, or the Indonesian Ministry of
the 3 groups (0.15–0.3 infections/person-month). Subjects wereHealth.
Financial support: US Naval Medical Research and Development Command malaria-free at vaccination and were screened for infection at each
(work units 620828, 6281453E033, and 6281453UO52). sampling point. Those with symptoms and parasitemia were
Reprints or correspondence: Dr. David J. Fryauff, NAMRU-2, Box 3, Unit
treated, and their samples were omitted from analysis because of8132, APO AP 96520-8132 (fryauff@smtp.namru2.go.id).
potential malaria-induced immune suppression.
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Anti-tetanus and anti-diphtheria IgG assays. Standardizedq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0050$02.00 ELISAs were used to blindly measure anti-tetanus and anti-diph-
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theria IgG levels in coded prophylaxis and control group sera that respectively. Anti-diphtheria GMTs were 0.49, 0.49, and 0.40,
was collected at 5 time points: baseline (before Td vaccination) respectively (Kruskal-Wallace, P  .66).
and 1, 3, 7, and 14 months after Td vaccination. Absorbance values Post-Td anti-tetanus IgG responses (figures 1, 2A). All but
for each sample were expressed as ELISA units (EU) and con- 1 of the 72 prophylaxis group subjects had increased anti-
verted to international units (IU) by the formula: Sample EU/
tetanus IgG titers 1 month after Td vaccination. The proportion
Reference EU 1 Reference Serum IU/mL. (The reference serum
of subjects with protective titers increased significantlyNCIV lot 1 contained 50 IU/mL anti-tetanus IgG and 2.9 IU/
(P  .02) in each group of vacinees. Conversion rates frommL anti-diphtheria IgG). In accordance with current conservative
unprotected to protected status in the primaquine (16/16) andrecommendations, IgG titers⁄0.1 IU/mL were considered protec-
placebo (15/15) groups were marginally greater (P  .05) thantive [9].
Statistical analysis. Comparison between groups was based in the chloroquine group (7/10). Individual elevations in IgG
on log-transformation of each subject’s IU/milliliter values and ranged from 1 to 700 times those of baseline. There was no
analysis of variance (ANOVA) or Kruskal-Wallace nonparametric correlation between baseline levels and those attained 1 month
test. Student’s t test was used for paired comparisons when the after vaccination. Anti-tetanus IgG elevations 1 month after Td
ANOVA or Kruskal-Wallace test indicated significant differences vaccination in primaquine, chloroquine, and placebo groups
among groups. Differences within or between groups in the propor-
averaged 9.5, 5.6, and 5.2 times their respective baseline levels,
tion of subjects with protective IgG levels⁄1.0 IU/mL were com-
and all group GMTs were significantly greater than at baselinepared by x2 or Fisher’s exact test. Two-tailed P values were calcu-
(P  .01). Anti-tetanus GMTs 1 month after Td vaccinationlated; the cutoff level for significance was P £ .05.
in the chloroquine and placebo groups were marginally higher
than in the unvaccinated controls (P  .04). The anti-tetanus
Results GMT in the primaquine group at this time was marginally
above that of the vaccinated placebo group (P  .04) andBaseline IgG responses. Baseline anti-tetanus IgG re-
significantly greater than that of the unvaccinated control groupsponses in primaquine, chloroquine, and placebo groups were
(P  .001).comparable, with individual titers ranging from 0 to 0.44
In all vaccinated groups, the proportion of protective anti-IU/mL. Protective anti-tetanus titers were found in 47%, 52%,
tetanus titers and the GMTs fell from the peak levels attainedand 29% of the respective groups (figure 1, P  .25). Anti-
1 month post-Td. Relative to these peaks, end-point proportionstetanus geometric mean titers (GMTs) were 0.09, 0.09, and
with protective titers declined significantly in primaquine0.07 IU/mL, respectively (ANOVA, P  .66). Individual base-
(100% vs. 82%, P  .03) and placebo (100% vs. 58%, P line anti-diphtheria IgG titers ranged from 0.02 to 5.28 IU/mL.
.001) groups. End-point proportions of subjects with protectiveProtective anti-diphtheria titers were found in 93%, 95%, and
100% of the primaquine, chloroquine, and placebo groups, titers in the placebo (58%) and chloroquine (67%) groups fell
Figure 1. Proportion of subjects
in prophylaxis groups with protec-
tive anti-tetanus IgG titers 0.1 IU/
mL at baseline (0) and at 1, 3, 7, and
14 months after tetanus-diptheria
(Td) immunization. Placebo (n 
21), primaquine (n  30), and chlo-
roquine (n  21) groups were inocu-
lated with Td at time 0.
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any postvaccination sample point (P  .17). Despite falling
significantly from the peak attained 1 month after Td vaccina-
tion, the end-point GMT of the primaquine group remained
significantly higher than its baseline (P  .004) or that of the
unvaccinated control group (P  .02). End-point GMTs for
vaccinated placebo and chloroquine groups fell to levels com-
parable with their baselines (P  .10) and that of the control
(P  .22). There was no significant difference between anti-
tetanus GMTs calculated for the unvaccinated control group at
any of the 5 time points (ANOVA, P  .42).
Post-Td vaccination anti-diphtheria IgG responses (figure
2B). Anti-diphtheria IgG titers 1 month after Td vaccination
ranged from 1.7- to 257-fold greater than at baseline. Highest
anti-diphtheria GMTs, measured 1 month after vaccination,
were 27.23, 24.38, and 19.95 IU/mL for the primaquine, chlo-
roquine, and placebo groups, respectively (ANOVA, P  .64),
and averaged 58-, 62-, and 46-fold higher than their respective
baseline GMTs. Anti-diphtheria GMTs of the primaquine, chlo-
roquine, and placebo groups were comparable to one another
(P  .26) but were significantly greater than their respective
baseline GMTs (P .0001) and those of unvaccinated controls
(P  .0001) at each post-Td vaccination sample point. Anti-
diphtheria GMTs declined over time in each vaccinated group.
A significant decline from the peak 1 month after Td vaccina-
tion was measured in the chloroquine group 7 months after
vaccination (P .04) and in the primaquine and placebo groups
14 months after vaccination (P  .02 and .03, respectively).
In all 3 vaccinated groups, subjects that attained the highest
anti-diphtheria titers 1 month after vaccination generally also
registered the highest end-point titers (r  0.69–0.84). There
was no correlation between anti-diphtheria and anti-tetanus an-
tibody levels following immunization (r  00.19 to 00.01).
There was no significant difference between anti-diphtheria
GMTs calculated for the unvaccinated control group at any ofFigure 2. Geometric mean (GM) anti-tetanus (A) and anti-diphthe-
the 5 time points (ANOVA, P  .53).ria (B) IgG titers (IU/mL) in control and prophylaxis groups at base-
line (0) and at 1, 3, 7, and 14 months after tetanus-diptheria (Td)
immunization. Placebo, primaquine, and chloroquine groups received
Td inoculation at time 0; control group received neither prophylaxis
Discussionnor Td. Sample size range by test group for time points: placebo
(n  16–21), primaquine (n  22–30), chloroquine (n  15–21),
The results show that the attainment of protective anti-teta-control (n  8–13).
nus antibody titers and the magnitude of anti-tetanus GMTs
were routinely highest in the vaccinated primaquine group. This
finding complements the strong in vitro lymphocyte responsesto levels comparable to their respective pre-Td vaccination
baseline levels (placebo, P  .11; chloroquine, P  .50), but against tetanus that were measured in this treatment group
[5]. Of interest, there was no correlation between cellular andthat of the primaquine group remained significantly above base-
line (82% vs. 47%, P  .03). At end point, the proportion humoral responses to tetanus: Men with the highest lympho-
proliferative responses were equally likely to have either highof primaquine subjects with protective titers was significantly
greater than that of the unvaccinated control group (82% vs. or low anti-tetanus IgG titers. The heightened cellular and hu-
moral responses observed in the primaquine group during the43%, P  .03), while proportions in placebo and chloroquine-
treated groups were similar to that of the control (P  .27). time of prophylaxis may relate more to the immunostimulatory
properties of the drug than to its ability to prevent malaria-Anti-tetanus GMTs in the primaquine group exceeded those
of the vaccinated placebo group at 3 (P  .03) and 14 months induced immune suppression. While it seems clear that long-
term primaquine use was not immunosuppressive, the mecha-(P  .002) after Td vaccination. There was no statistical differ-
ence between GMTs of the placebo and chloroquine groups at nisms underlying its effect on cellular and humoral immunity
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are unclear and may relate to drug-induced leukocytosis or and duration of humoral immune responses following Td vacci-
hematopoiesis [10]. nation. The initially high anti-tetanus and anti-diphtheria IgG
Since no association has been shown between asymptomatic titers observed in primaquine users complement their cellular
malaria infections and reduced primary or secondary responses responses against tetanus and may engender a more effective
to tetanus immunization [11], it is unlikely that undetected longer-lasting immunity. These results constitute an additional
or subpatent malaria infections could account for the large measure of safety assurance to support regulatory agency evalu-
differences in cellular and humoral response that we measured. ation of primaquine for malaria prophylaxis.
Unrecalled previous tetanus immunizations in our subjects and
their chance clustering may have accounted for the significant
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Risk Factors for Repeated Gonococcal Infections: San Francisco, 1990–1992
Jeffrey D. Klausner, Donald C. Barrett, Dwyn Dithmer, Epidemic Intelligence Service, Epidemiology Program Office—State
Branch, Centers for Disease Control and Prevention, Atlanta, Georgia;Cherrie B. Boyer, George F. Brooks, and Gail Bolan
Department of Sociology, California State University, San Marcos,
Division of Adolescent Medicine and Department of Laboratory
Medicine, University of California, San Francisco, and Sexually
Transmitted Disease Control, San Francisco Department of Public
Health; Sexually Transmitted Disease Clinic, Harborview Medical
Center, University of Washington, Seattle
Gonococcal (GC) infections are very common and are sustained by a core group of persons who
often have repeated GC infections. Identifying individual risk factors for repeated GC infection is
essential so that infection control programs can develop better strategies for decreasing the incidence
of GC infection. A case-control study among high-risk persons found that being African American,
having previous chlamydia infection, and having less than a high-school education were associated
with repeated GC infections. Remarkably, measures of sexual behavior and access to health care
were not associated with repeated GC infections. These findings suggest that among high-risk
persons, the community prevalence of GC infection is more important in predicting risk for repeated
GC infections than individual behavior. Interventions should include continued use of resources in
high-prevalence communities and better understanding of the roles social and economic discrimina-
tion play in the risk for GC infections.
In the absence of an effective vaccine, the prevention of ted disease (STD), and having other concomitant STDs. The
usefulness of some of these studies was limited in assessinggonococcal (GC) infections relies on identifying and treating
infected persons and in modifying behaviors that place individ- currently important behavioral factors, such as partner selec-
tion and coupling dynamics, and in determining the role ofuals at risk for GC infection. Despite existing prevention ef-
forts, GC infections remain a significant problem in the United access to health care because of study design or scope of
data collection.States and throughout the world [1, 2]. GC infections are among
the most common of bacterial diseases, are frequently reac- In 1990, during an increase in the number of cases of GC
infection in San Francisco, we undertook a case-controlquired, and are sustained by a core group of persons who
engage in high-risk behaviors and who have a high prevalence study to identify patterns that might be associated with re-
peated GC infections. We assessed demographic and newof infection [2–13]. Therefore, an increased understanding of
risk factors, particularly behavioral risk factors, within the core behavioral factors, such as frequency, duration, and types
of sexual partnerships; health-care utilization and perceivedgroup of persons with repeated GC infections is essential so
that infection control programs can develop better strategies access; and illicit substance use. This report describes the
results of that study.for decreasing the incidence of GC infection.
During the 1970s, studies defined the importance of re-
peated GC infections and described the demographic charac-
Methodsteristics of persons who have repeated GC infections [3 – 9].
Factors associated with repeated infections included younger
Patients. From August 1990 through June 1992, we prospec-
age, black race, being single, having less than a high school
tively examined the San Francisco City and County STD control
education, having a history of a previous sexually transmit- database each day to identify new records of case-patients with
repeated GC infections. A case of repeated GC infection was de-
fined as a heterosexual patient age 15–24 years who was identified
in the database with a current diagnosis of gonorrhea and either a
Received 13 August 1997; revised 23 December 1997. history of gonorrhea within the past 2 years or a history at any time
This study was approved by the University of California, San Francisco,
of pelvic inflammatory disease (PID) associated with gonococcalCommittee on Human Research. Informed consent was obtained from all study
infection. Control-patients were selected from persons who wereparticipants.
Grant support: NIH AI-21912. identified in the database with a current diagnosis of gonorrhea
Reprints and correspondence: Dr. Jeffrey D. Klausner, Center for AIDS and within 2 weeks of the date of diagnosis of the case-patient and
STD, 1001 Broadway, Suite 215, Seattle, WA 98122 (klausner@u.washing-
who had no known history of gonorrhea. Recruiters were blinded toton.edu).
the case-control status of the patient. A disease-control investigator
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made up to three attempts to recruit patients into the study byq 1998 by The University of Chicago. All rights reserved.
0022–1899/98/7706–0051$02.00 letter, telephone, and field visits. Case-patient and control-patient
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histories were confirmed by questioning the patient and examining been exposed to an STD, smoking, douching, number of years
individual patient medical records. Patients unable to be located of sexual activity, number of lifetime sex partners, number of
or ineligible were replaced with the next available patient in the sex partners in the previous 2 months, frequency of having a
database. The demographic characteristics of case- and control- new sex partner in the previous 2 months, frequency of condom
patients enrolled in the study were compared with the demographic use in the previous 2 months, frequency of condom use by any
characteristics of all cases from the STD control database during
partner type (main or non-main partner) in their most recent
the same time period.
sexual encounter, reporting intoxication during sex by any part-Data collection. Information about patient demographics,
ner type in the previous 2 months, or receiving money for sexhealth, sexual behavior, and illicit substance use patterns was re-
in the previous 2 months.corded during a private face-to-face interview by trained interview-
Patients with repeated GC infections were more likely to beers using a structured questionnaire. Questions about health-care
access included frequency of medical visits, setting of provider, African American but less likely to be employed or have a
and medication usage. Data on sexual and drug use behavior were high school education (table 1). Patients with repeated GC
collected for patient and sex partners for the 2 months before the infections were also more likely to report a history of chlamydia
interview and for the patient’s lifetime. Patients were asked to infection or another STD, including syphilis, chancroid, PID,
categorize their sex partners as (1) main or regular partners and nonspecific urethritis, mucopurulent cervicitis, trichomoniasis,
(2) non-main or casual partners. Information about sex partner venereal warts, and herpes, and were more likely to have re-
demographics, health, sexual behavior, and illicit substance use
ceived drugs for sex. Subanalysis revealed that of the 9 personspatterns was collected for each category of sex partner.
who reported receiving drugs for sex, 7 recalled that the drugStatistical methods. Comparisons of cases and controls were
was crack cocaine.done by t and x2 tests for association. Variables that were not
Cases and controls did not differ by age of their partnernormally distributed were also examined by the Mann-Whitney U
when the data were stratified by patient’s sex. Cases and con-test. Fisher’s exact test was used for contingency tables with cells
smaller than 5 cases. P  .05 was considered statistically signifi- trols differed significantly, however, regarding the race of their
cant for bivariate comparisons. partner, particularly a non-main partner. Patients who had re-
Multivariate analysis involved the selection of all variables iden- peated GC infections were more likely to identify their most
tified in the bivariate analysis as significantly distinguishing be- recent partner as being of their own race than were patients
tween groups at P  .10. To facilitate comparison between odds with first-time GC infection (P  .04). Patients who had re-
ratios, patients were classified by age as to whether they were
peated GC infections were more likely to have African Ameri-
older than the median of 20 years. Logistic stepwise regression
can partners (odds ratio  2.3; 95% confidence interval, 1.1–with backward elimination was used to identify variables uniquely
4.7). However, when race of partner was stratified by patient’srelated to group membership at P  .10.
race, this was no longer statistically significant.
Results
Table 1. Selected characteristics of study patients with and without
During the study period, 185 persons with newly diagnosed repeated gonococcal (GC) infections, San Francisco, 1990–1992.
GC infection were enrolled: 94 had a history of previous GC
Gonococcal infection %infections and 91 had no prior history of GC infection. The
mean age ({SD) of the study population was 20 ({2) years;
First-time Repeated65% were male, 80% were African American, 7% were His-
Patient characteristic (n  91) (n  94) P
panic, 5% were white, 1% were Asian, and 7% were classified
as other. Most repeat cases (76%) had 1 previous infection; Demographics
African American 71 88 .004the maximum was 26. Demographic comparisons of study en-
Currently employed 37 24 .04rollees with all reported cases of GC infection in San Francisco
⁄High school education 65 50 .04County during this same period demonstrated that the demo-
Sexually transmitted disease (STD)
graphics of the study population were similar. During the en- history
rollment period, 2634 cases of GC infection were reported in Ever having sex partner inform
patient of STD 22 33 .09San Francisco residents ages 15–24 years. Of these, 57% were
Report of prior chlamydiamale, 64% were African American, 11% were Hispanic, 11%
infection 15 37 .03were white, 3% were Asian, and 11% were other. Mean age
Report of prior STD other than
({SD) was 20 ({2.5) years. GC infection 35 57 .001
Patients with repeated GC infections did not differ from Reported receiving drugs for sex 2 10 .03
Racepatients with first-time GC infection with respect to any of the
Any partner African American 36 56 .01following variables: number of medical visits in the past year
Non-main partner who isor 5 years, ability to identify a regular doctor, having a partner
same as patient 67 (n  57) 82 (n  68) .04
with an STD, being told by the health department they had
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Table 2. Adjusted odds ratios (ORs) in the multivariate logistic creased prevalence of infection, it follows that a person who
regression model for repeat gonococcal infections, San Francisco, has sex within this community will have an increased risk
1990–1992. of infection and, in this study, increased risk of repeated GC
infections.Factor Adjusted OR (95% confidence interval)
The association of lack of high school education with re-
African American 2.96 (1.29–6.77) peated GC infections may suggest factors relating to sexual
Completed high school 0.47 (0.23–0.95) mixing, but it also could suggest economic and social limits
Previous chlamydia infection 2.94 (1.38–6.26) that affect partner selection. Further study is needed to clarify
this association. The association with previous chlamydia infec-
tion and repeated GC infections might be explained by sexual
mixing within a group at high risk for STDs. In addition,Multivariate analysis was used to identify factors associated
previous chlamydia infection might be a marker for biologicwith patients with repeated GC infections. Logistic regression
susceptibility for GC infection.analysis (table 2) indicated that patients with repeated GC in-
This study was limited by several factors. The classificationfections were more likely to be African American and have
of case or control status relied on retrospective data obtainedhad a previous chlamydia infection but were less likely to have
from self-report, provider records, and the STD control morbid-completed high school.
ity database. It is unlikely that cases were misidentified since
case status depended on documented GC infection, but control
status may have been misidentified by absence of documented
GC infection or by a patient’s unawareness of previous GCDiscussion
infection. This could have led to differential misclassification
in which controls were more similar to cases and could haveThe results of this study suggest that among high-risk per-
sons, measures of sexual behavior, such as number of partners, resulted in underestimates of the observed associations or an
inability to find true associations. A second limitation was thenumber of new partners, years sexually active, and condom
use, are not associated with repeated GC infections. In addition, relative homogeneity of the study population, which could have
prevented the detection of other factors associated with re-no associations were found between measures of health care
access (e.g., number of medical visits within the past year or peated GC infections.
These findings add to those of previous studies showingpast 5 years and being able to identify a regular provider) and
having repeated GC infections. On the other hand, patients that certain minority populations and those with less formal
education are at increased risk for repeated GC infections [4–with repeated GC infections were more likely to be African
American, to have a history of chlamydia infection, and to 6, 9]. Our study indicates that areas for intervention should
include continued targeting of prevention and control resourceshave not completed high school.
The lack of findings related to individual sexual behavior to African Americans in San Francisco and increased efforts
to understand the roles that social and economic discriminationand the persistent association of African American race and
lack of high school education with repeated GC infections in play in partner selection and individual risk for STDs.
this study and others [4–6, 9, 11] underline the importance
of community prevalence in a person’s risk for repeated GC
infections. The majority of subjects in this study were African
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